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Abstract
Prostate cancer is the most frequently diagnosed cancer in men in Western countries. 
Clinically localized disease can be cured with surgery or radiotherapy, but once the 
disease has advanced or spread, there are no curative treatments. The aim of this 
thesis is to compare protein expression in a pair of normal epithelial and prostate 
cancer cells derived from the same patient and to determine the effect of interferon y 
on this expression pattern. Proteins that are differentially expressed or change in 
expression in response to y interferon might be of clinical value as biomarkers or 
therapeutic targets.
Biotin labelling followed by avidin chromatography was used to obtain membrane 
protein enriched lysates ffom a pair of cell lines derived from normal epithelium 
(1542 NPX) and prostate cancer (1542 CP3TX) from the same patient. These proteins 
were resolved and identified using SDS PAGE, coomassie staining and mass 
spectrometry. The same protocol was used to identify proteins differentially expressed 
on stimulation with interferon y.
The proteins identified were subject to further analysis, particularly annexin II (All), 
which was interferon-regulated. The expression of this protein was down regulated in 
the cancer cell line within four hours of interferon y stimulation. This expression 
pattern was found to be cell surface specific as the total cellular expression of All 
remained unchanged, as confirmed by immunofluorescence. All down regulation also 
reduced the invasive potential of the cancer cells. Re-introduction of All into LNCaP 
cells, which do not express the protein, led to an increase in their invasive capacity.
The mechanism regulating this cell surface specific effect was explored. It was 
discovered that inhibition of the ATP binding cassette transporter ABCA1 prevented 
surface All expression. Protection of ABCA1 from calpain mediated degradation, 
maintained All expression even in the presence of interferon y. These findings led to 
the development of a model of interferon y action on All involving phosphorylation 
of ABCA1 as a signal for targeted degradation by calpain II.
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Chapter 1 
Introduction
1.1 Cancer biology
Cancer, no other word in the English language has such an instant impact on our 
psyche. The actual definition of the word is “uncontrolled division of cells” (Soanes,
2003) with no reference to disease, which has led to many misunderstandings in 
clinical use of the term. Taken literally the word actually gives some indication of the 
origins of cancer, the normal process of cell proliferation. This realization indicates 
why cancers are so difficult to treat. Due to their common origin, the differences 
between normal and neoplastic cells are often so minimal that they are almost 
impossible to detect, monitor and exploit therapeutically. This has resulted in the 
treatment situation at present, where the majority of cancer therapeutics cause damage 
to normal tissue as well as the target cancerous tissue. A wealth of research activity is 
focussed on defining and exploiting these minimal differences between normal and 
cancerous cells to create discriminating therapeutics for clinical use.
To date medical science has achieved much in combating human morbidity in terms 
of communicable diseases, however, cancer remains one of the major causes of death 
in the developed world, affecting one in three people (Lewin 2000). Despite the 
prevalence of cancer, a concrete definition of what the disease actually constitutes 
remains elusive. The importance of clearly delineating such a definition cannot be 
underestimated, as substantial progress in the treatment or prevention of cancer cannot 
occur until researchers have identified the nature of the disease.
The potential for uncontrolled growth is a key feature of the diseases encompassed 
under the heading cancer (King, 2000). In normal tissue there is a harmonic balance 
between cell death and proliferation, with balanced regulatory interactions between 
stroma and cells and little to no competition between neighbouring cells (Bronchud,
2002). Genetic changes, however, can lead to inequalities in this balance subsequently 
resulting in uncontrolled growth. Such growth resulting in an expansion of cells 
without invasion into surrounding tissues occurs in both malignant and non-malignant
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states such as benign prostate hyperplasia (BPH). Clinically, uncontrolled cell 
proliferation in solid tissue is classified in a number of ways (See Figure l.l).
In addition to uncontrolled growth, cells must possess further attributes to be 
determined malignant and thus set apart from the other forms of tissue growth. One of 
the key attributes of cancerous lesions is the ability to invade and metastasize to other 
tissue. This is thought to be due to further genetic damage leading to a breakdown in 
the regulation of territoriality. In this situation the cancer cells are no longer in 
harmonic balance with neighbouring cells and begin to compete for space and 
nutritional resources (Bronchud, 2002). Clinically, cancer can be defined therefore, as 
a set of diseases characterized by unregulated growth leading to the invasion of 
surrounding tissues and potentially metastasis to other parts of the body (King, 2000). 
This definition is by no means all encompassing, but aids in the delineation of the 
prognosis expected with the clinical diagnosis of cancer. There is, however an 
obvious problem with using the clinical definition of cancer as a basis for scientific 
research into the origin of the disease, in that it defines the cancerous state by its end 
point. To define what makes a cell cancerous at a much earlier stage, where the widest 
treatment options are available, it is important to identify the processes that occur 
within the cancer cell which lead to a malignant end point.
Increase in the number of cells in a tissue or organ 
without gross morphological changes.
Disordered growth, changes in size, shape and 
differentiation.
Ordinarily benign neoplasm of epithelial tissue in 
which tumours form gland like structures.
A malignant neoplasm of epithelial cells 
Figure 1.1 Classification o f tissue growth (King, 2000).
Hyperplasia
Dysplasia
i
Adenoma
i
Carcinoma
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Despite a lack of concrete definition, over the last 50 years a wealth of research has 
examined the molecular basis of what makes a cancer cell different from its normal 
neighbour. Epidemiological studies examining the association between cancer 
susceptibility and age have indicated that between 4 and 7 mutations are needed for 
the development of malignant disease (Hanahan and Weinberg, 2000). This research 
began with the observation that with many solid tumours, disease incidence is 
proportional to age and that the slope of such a graph could be used to quantify how 
many mutations were required for carcinogenesis to occur. An example of this can be 
seen in an epidemiological study by Armitage and Doll where a graph of death rate 
versus age suggested that six mutations were required before carcinogenesis of the 
large intestine occurred (Armitage and Doll, 2004). Vogelstein and Fearon attributed 
this to sequential genetic events leading from colorectal adenoma to carcinoma and 
indicated that 5-7 mutations were required for such a transition (Fearon and 
Vogelstein, 1990). The results of these epidemiological and molecular studies were 
further verified by research into chemical carcinogens, which identified a long lag 
phase between exposure to a carcinogen and the appearance of a tumour. This lag 
phase can be observed clinically in epidemiological studies into human exposure to 
carcinogens such as asbestos, where people exposed form birth to the carcinogen had 
a mean diffuse malignant pleural mesothelioma appearance time of 55 years (Metintas 
etal., 1999).
Genetic changes or mutations, such as those required to initiate carcinogenesis, are a 
natural occurrence, constituting the driving force behind evolution. They are the result 
of a number of factors, both environmental and endogenous, with every organism 
having its own background rate of mutation due to errors in cell replication and 
additional genetic changes due to exposure to environmental mutagens (King, 2000). 
The prevalence of mutation in natural history and the research cited above confirm 
that it is not single mutational events that prove to be lethal through malignancy, but 
that malignant tumour formation is the consequence of several cumulative changes in 
the genomic DNA sequence (Hanahan and Weinberg, 2000). The acquisition of 
multiple mutations, needed for a cell to become malignant would be difficult to 
acquire in the timescale of human life, if the process was truly random (Hanahan and 
Weinberg, 2000). So how do such multiple mutations occur in a reasonably short 
timescales? How do these mutations bypass rigorous cell cycle checkpoints? The
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answer to these questions is thought to lie in malfunctions of certain DNA caretaker 
pathways leading to increased genomic mutability.
Despite the many causative factors, genetic mutation remains a relatively rare event 
and it has long been argued that the high number of mutations seen in malignant cells 
cannot be accounted for by the low mutation rates of somatic cells (Bindra and 
Glazer, 2005). As early 1953 Slaughter et al proposed that the likelihood of the 
occurrence of mutations required to initiate carcinogenesis was greater in a clonal 
group of cells with a high rate of genetic alteration, than in a background of low 
somatic mutation, this was named the “field cancerization model” (Slaughter et al., 
1953). This research led to the development of the genetic instability theory, which 
proposed that early changes in “caretaker genes”, responsible for maintaining genetic 
integrity, initiated a level of genetic instability which increases the likelihood of 
further mutagenic events. Against this background of genetic instability it was 
proposed that mutations causing an increase in activity of certain promoters of 
carcinogenesis, so called “gate keeper genes” such as stimulators of proliferative 
activity, would lead to a cycle of unregulated proliferation and therefore the initiation 
of carcinogenesis (Bronchud, 2002).
1.1.1 Tumour suppressor genes
Tumour suppressor genes are key “caretaker genes” involved in malignant 
progression. These genes in their normal state halt the processes initiated by 
promoters of carcinogenesis (such as oncogenes), by suppressing cell growth and 
division and promoting programmed cell death. Commonly, both alleles of the tumour 
suppressor gene must be mutated to cause an effect, they are therefore, termed 
recessive loss of function mutations. An example of such a tumour suppressor is p53, 
identified in 1979 as a cellular protein which accumulated in the nuclei of cancer cells 
and was originally thought to be a transcription factor with weak oncogenic activity 
(Lane and Crawford, 1979). During the 1980’s however it transpired that researchers 
were observing a mutant form of the p53 gene extracted from neoplasms and not the 
wild type gene (Hofseth et al., 2004). The main function of wild type p53 as 
suggested in the “guardian of the genome model” was to act as a sensor for DNA 
damage (Lane, 1992). Wild type p53 was found to be activated on induction of DNA
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damage and once activated led to the transcription of G1 cell cycle arrest factors, 
halting cell cycle progression at G1 if DNA damage was present (Hofseth et al., 2004, 
Lewin 2000). Following cell cycle arrest wild type p53 was found to mediate DNA 
repair or apoptosis depending on the cellular microenvironment (Lane and Hupp,
2003). However since the conception of the guardian of the genome model, wild type 
p53 activation has been demonstrated in response to a number of cellular stressors 
including hypoxia, oncogene activation, spindle damage, temperature change and 
ribonucleotide depletion (Lane and Hupp, 2003, Hofseth et al., 2004). Wild type p53 
has been found to perform a variety of functions including regulation of transition into 
S phase and of the spindle checkpoint, G2-M phase transition, apoptosis and 
angiogenesis (Quinn et al., 2005). In many tumours however, p53 is functionally 
inactivated therefore the sentinel for the monitoring of DNA damage, hypoxia and 
oncogene over expression is lost (Hanahan and Weinberg, 2000).
The gene for p53 is mutated in around 50% of human cancer cases worldwide 
(Hollstein et al., 1991). However these mutations tend to be misssense and not 
truncations or deletions, as seen in other tumour suppressor genes, indicating that 
selective pressures during the clonal evolution of the cancer cells have maintained a 
full length mutant form of p53 (Lane and Hupp, 2003). This conservation indicates 
that full-length mutant p53 may confer a selective advantage to cancer cells. Studies 
have indicated that misssense mutants of p53 gain oncogenic activity conferring a 
selective advantage to the expanding cancer cell population and explaining the initial 
mistaken identity of p53 as an oncogene (Blandino et al., 1999).
Mutation and functional loss of the caretaker protein p53, leads to genetic instability 
and may lead to oncogenic activity. The gene for this protein and others in the DNA 
damage repair pathway have been found to be mutated in many cancers (Hanahan and 
Weinberg, 2000, O’Byme et al., 2000, Moul et al., 2002, Hobeika et al., 1998). Wild 
type p53 is not required for normal cell division, however the instability induced by 
the functional loss of p53 enables increased variability in daughter cells and hence 
increases the chance of creating new cells with a selective advantage. This explains 
the experimental findings observed with p53 knock out mice, which develop normally 
but have an inherited predisposition to a wide range of tumour types displaying 
aneuploidy and other genetic changes (Malkin et al., 1990). A lack of functional p53
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may also explain the genetic instability seen in cells from patients with Li-Fraumeni 
syndrome or Blooms disease (BischofFet al., 1990, Lu and Lane, 1993).
Genetic instability enables cells to acquire the six attributes required for the transition 
to a cancer phenotype at a much higher rate than would be expected via random 
chance (Hanahan and Weinberg, 2000). The functional inactivation of p53 is an 
obvious survival advantage for the tumour cell and it is unsurprising, therefore, that 
nuclear accumulation of mutant p53 is a common feature in human cancers including 
breast (Honkoop et al. ,1998), colon (Manne et al., 1998, Aprikian et al., 1994), lung 
(Mitsudomi et al., 1995) and prostate (Aprikian et al., 1994). Nuclear accumulation of 
mutant p53 has also been correlated with a poor prognosis in these cancers. In 
prostate cancer, comparison of cells from the primary site with those derived from 
metastases, suggest that cells with mutant p53 are clonally expanded in metastatic foci 
(Borre et al., 2000). Studies have demonstrated that an increased level of p53 nuclear 
accumulation is observed in more advanced stages of prostate cancer and has been 
found to be predictive of prostate cancer related death (Borre et al., 2000). This 
research supports recent findings that p53 not only has a role in early carcinogenesis 
but also in later, more advanced stages of the disease (Lane and Crawford, 1979).
In addition to p53 several other tumour suppressor genes have been associated with 
prostate carcinogenesis in both mouse and human models, including the 
retinoblastoma gene (Rb) and PTEN (phosphatase and tensin homologue deleted on 
chromosome 10) (Maddison et al., 2004). Rb was the first human tumour suppressor 
gene to be discovered, its tumour suppressor activity was first demonstrated in the 
rare paediatric eye tumour from which it derives its name (Friend et al., 1986). The 
cloning of the Rb gene was first achieved by Knudson, who following analysis of 
incidence rates in hereditary and non-hereditary retinoblastoma suggested that the 
disease was caused by mutation of both alleles (two-hit hypothesis) of an anti­
oncogene (tumour suppressor gene) (Knudson, 1986). Rb encodes a 110 kD 
phoshoprotein which, like p53, regulates the cellular transition between G1 and S 
(Zhao and Day, 2001). The role of Rb at this stage is the transduction of growth 
inhibitory signals that regulate differentiation and growth, which is achieved through 
complex formation with transcriptional regulatory factors involved in the suppression 
or activation of transcription. This process is carefully regulated by cyclin dependant
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kinases, through modulation of the phosphorylation state of the Rb protein (pRb) 
(Zhao et al., 1997). Inactivation of Rb either by genetic mutations, deletions or 
hypermethylation leads to the avoidance of senescence and therefore the expansion of 
the cellular lifespan (Jarrard et al., 2002). Inactivation of pRb extends the proliferative 
capacity of the cell, leading to uncontrolled cell growth. This avoidance of senescence 
via the inactivation of pRb by viral oncoproteins e.g. human papilloma or adeno 
viruses, has been exploited to immortalise cell lines for scientific research (Jarrard et 
al., 1999).
Loss of pRb expression has been found to be an indicator of poor prognosis in a 
number of cancers including non small cell carcinoma of the lung and bladder 
carcinoma (Quinn et al., 2005). In prostate cancer loss of pRb expression is seen in 
approximately 30% of tumours, however reports of loss of heterozygosity at the Rb 
locus in prostate cancer extend to 60% of clinical cases (Maddison et al., 2004, Quinn 
et al., 2005, Jarrard et al., 2002). Increased loss of Rb expression is correlated with 
increasing stage and grade in prostate cancer, in early disease 1 -45% cases show loss 
of pRb, rising to 20-60% in later more advanced disease (Quinn et al., 2005). A recent 
study explored the role of pRb in prostate carcinogenesis and found that a single 
somatic allelic deletion of Rb in epithelial cells within a mouse model led to the 
development of focal hyperplasia, indicating that loss of Rb initiated proliferative 
prostatic disease (Maddison et al., 2004). The increase in loss of pRb with advancing 
stage in prostate cancer suggests that inactivation of Rb, like that of p53, has a role 
not only in carcinogenesis but also in later stages of the disease. A potential role for 
Rb in the regulation of apoptosis has been described in prostate cancer, although the 
mechanism is unclear (Zhao et al., 1997). It is proposed that a loss of pRb would 
allow prostate cancer cells to avoid apoptosis and as tumourigenesis is regulated in 
part by the balance of cell growth and death, this would lead to further unchecked 
proliferation (Zhao and Day, 2001). In metastatic disease a four-fold increase in 
proliferation is observed, when compared to the primary prostate tumour, which 
coincides with a loss of pRb expression in 34% cases. This suggests that loss of pRb 
expression is advantageous in the selection for aggressive clonal phenotypes that 
occurs in metastatic disease (Jarrard et al., 2002).
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In addition to the loss of Rb expression, loss of PTEN (MMAC1) expression in 
prostate cancer is also correlated with advancing disease. The tumour suppressor 
activity of PTEN was indicated following genetic analysis of a section of 
chromosome 10 commonly found to be deleted in 90% human glioblastomas, in this 
study 60% of glioma and 33% prostate cancer cell lines possessed mutations in the 
PTEN gene (Steck et al., 1997). Subsequently PTEN deletion has been observed in a 
number of solid tumours such as those of the breast (Li et al., 1997) and endometrium 
(Tashiro et al., 1997). Confirmation of the functional tumour suppressor role of PTEN 
came from the in vitro observation that over expression suppresses tumour colony 
formation and the in vivo observation that over expression suppresses tumour 
formation in nude mice (Di Cristofano et al., 1998). In addition, it was discovered that 
patients with cancer predisposition syndromes such as Cowden’s disease or 
Bannayan-Zonana syndrome had germ line mutations of PTEN (McMenamin et al., 
1999). The consequences of germ line inactivation of PTEN were analysed using 
PTEN knock out mice which develop tumours similar to those found in Cowden’s 
disease including breast, thyroid and prostate tumours (Di Cristofano et al., 1998). 
PTEN is thought act as a tumour suppressor by inhibiting cell cycle progression and 
inducing arrest at G1 through negative regulation of the P-I-3 kinase/Akt signalling 
pathway (Fumari et al., 1998). The loss of PTEN expression, like many other tumour 
suppressors is associated with mutation, deletion or hypermethylation of the gene 
(McMenamin et al., 1999).
Although much is now known of the tumour suppressor role of PTEN, little is known 
of the role in metastasis suppression it appears to display in prostate cancer. Recently 
PTEN was found to interact with Drg-1, the product of which has been found to have 
a metastasis suppressor activity in colon and prostate cancers (Bandyopadhyay et al.,
2004). Both molecular and immunohistological findings suggest that PTEN and Drg-1 
expression are inversely correlated with prostate and breast cancer progression and 
that in combination these markers are a significant predictor of patient survival 
(Bandyopadhyay et al., 2004). Traditionally loss of expression of a tumour suppressor 
protein is considered an early event in carcinogenesis, however in contrast with the 
findings of germ line PTEN mutation in mouse models, loss of PTEN appears to be a 
relatively late event in prostate cancer. Immunohistological studies discovered that 
PTEN was expressed in all prostate intraepithelial neoplasias (the alleged precursor of
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prostate cancer). In addition 64.2% of prostate cancer specimens showed 
heterogeneous staining and loss of PTEN expression was found to correlate 
significantly with the presence of high-stage disease (Gleason score >7) 
(McMenamin et al., 1999). Loss of PTEN expression has also been correlated with 
other indicators such as PSA and Gleason grade, to assess the suitability of PTEN loss 
as a prognostic indicator. In this study, 86% of advanced cases displayed a loss of 
PTEN expression, compared to 61% of cases with localised disease and 58% of cases 
with benign prostate hyperplasia. Statistical analysis of these results suggested that 
loss of PTEN could be utilised as an independent marker to follow the progression of 
prostate cancer (Koksal et al., 2004).
1.1.2 Oncogenes
Certain key “gate keeper genes” involved in controlling cell division have been 
isolated that when mutated, promote malignant progression. Proto-oncogenes (called 
oncogenes in their altered state) code for proteins associated with the promotion of 
regulated growth in their normal state, this group includes cell division, growth 
receptor and cell cycle regulatory proteins. Mutations within these genes often confer 
on the cell the ability to initiate growth without the appropriate stimulus leading to a 
cycle of deregulated growth. Such changes need only occur within one copy of the 
gene to have effect and are therefore, called dominant gain of function mutations. 
There are four main functional groups of oncogenes, protein kinases (src, erbB), 
nuclear signal transducers (myc, fos), regulators of cell growth (sis, fms) and guanine 
nucleotide binding proteins (ras gene family) (Shih et al., 1986).
The ras family of oncogenes were among the first to be discovered, found following 
research into the cellular homologues of the transforming genes of Harvey and 
Kirsten retroviruses (Bar-Sagi, 1989). The ras gene family encodes a group of closely 
related 21kD proteins with an affinity for guanine nucleotides and are therefore part 
of a larger family of guanine binding proteins (G proteins). G proteins are commonly 
involved in signal transduction, Ras proteins are thought to have a functional role in 
the transduction and mediation of growth control signals (Shih et al., 1986). The first 
mutationally activated, oncogenic versions of the ras genes were identified in human 
tumours in 1982 (Goldfarb et al., 1982, Pulciani et al., 1982, Shih and Weinberg,
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1982). Subsequently, members of the ras gene family have since been found to be 
mutated in many cancers (Lewin 2000, Hanahan and Weinberg, 2000). The three 
most commonly mutated ras genes are HRAS, KRAS and NRAS with almost 50% of 
cancers showing mutation of one or more of these genes (Cox and Der, 2002, Steams 
et al., 2005). ras genes are highly conserved, the amino acid sequence of human 
HRAS is identical to is murine homologue and similar to the form found in yeast 
(Shih et al., 1986). This high degree of sequence conservation suggests a critical 
cellular role for the ras family of proteins, this has been confirmed by analysis of 
single point mutations at key amino acid residues which decrease the oncogenic 
activity of ras in a number of human tumours (Shih et al., 1986).
Mutations of HRAS, KRAS and NRAS are observed in 10% of prostate cancers 
(Steams et al., 2005). The functional significance of attenuation of ras expression in 
prostate cancer has been explored in the androgen receptor positive cell line LNCaP. 
In this cell line expression of mutationally activated Ras increased the proliferative 
response of the cells to androgens, thus decreasing their androgen dependence (Bakin 
et al., 2003b, Bakin et al., 2003a). In xenografts of LNCaP cells carrying a non- 
oncogenic mutant of ras, androgen sensitivity was restored and complete regression of 
the tumour could be achieved through castration of the animal in 80% of cases with 
the remaining 20% exhibiting stasis in tumour growth (Bakin et al., 2003a). Androgen 
independence is an almost inevitable consequence following treatment of prostate 
cancer with castration or anti-androgens. Increases in autocrine and paracrine growth 
factors such as EGF, TGF-a and IGF-1 are among the most commonly reported 
changes in the progression of localized prostate cancer to androgen insensitive and/or 
metastatic disease (Culig et al., 2002). ras activation is a component of the signalling 
cascade for virtually all the growth factors found to be up regulated in prostate cancer. 
It is thought that ras acts as an intersection point for the diverse receptors and ligands 
involved in growth signal transduction (Weber and Gioeli, 2004). In agreement with 
the view that as prostate cancer advances, growth signalling increases, a recent study 
found that an increase in expression of growth factor receptors and indicators of ras 
activity correlated with increasing stage and grade of tumour (Weber and Gioeli,
2004). The indication from this and other studies is that mutationally activated Ras 
proteins heighten both growth factor and androgen receptor activity decreasing the 
dependence of prostate epithelial cells on androgen for proliferative growth. This is
18
confirmed by clinical observations of androgen dependent tumours with little to no 
indication of ras activity, becoming positive for ras activity following disease 
recurrence after hormonal treatment (Weber and Gioeli, 2004, Bakin et al., 2003a).
In addition to its proposed role in androgen independence in prostate cancer, 
mutationally activated ras has also been implicated in the enhancement of the pro- 
angiogenic response to VEGF. In a recent study activated HRAS has been found to 
enhance VEGF production in response to IGF-1 in sufficient amounts to significantly 
increase endothelial migration (Steams et al., 2005). The above studies suggest that 
molecular cooperation between mutationally activated ras proteins and various 
cellular receptors mediates a hypersensitivity to both pro-growth and pro-angiogenic 
signals, both of which are selectively advantageous in tumourigenesis.
1.1.3 The multifactoral nature of cancer
Oncogenes and those genes involved in tumour suppression have an important role in 
malignant progression, there are, however, other changes which must occur for a cell 
to obtain tumourigenic potential. Research into the genetic changes required for a cell 
to become cancerous, has led to the characterisation of key attributes acquired by cells 
during this progression to a malignant status. It has been indicated that a complex 
collection of cancer genotypes can be characterised by six common alterations that 
collectively dictate malignant growth. The progression of pre-malignant cells to 
possession of all six traits is not the same in all cancers but they share a common end 
point (Hanahan and Weinberg, 2000) see Figure 1.2.
The first of these traits characterised is the ability of cancer cells to obtain self- 
sufficiency growth signalling (Hanahan and Weinberg, 2000). For a cell to progress 
from a quiescent state to an active state (Gl) where growth and division can occur 
mitogenic growth signals (GS) are required. Tumour cells, by gaining autonomy in 
GS, decrease their dependence on the extra cellular environment, this can be achieved 
in a number of ways. In sarcomas and some glioblastomas, for instance, the extra 
cellular environment is altered by secretion of their own growth signals (Tysnes and 
Mahesparan, 2001). A more common strategy in malignant cells is the deregulation of 
membrane receptors that bind extra cellular GS. This is exemplified in breast tumours
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where the epidermal growth factor receptor (EGFR) is up regulated increasing the 
cell’s sensitivity to ambient levels o f this growth factor (Morris, 2002). Another 
common autonomous growth signalling strategy observed in cancer cells is the 
alteration o f extra cellular matrix (ECM) attachment proteins favouring those that 
transmit pro-growth signals e.g. integrins (Stewart et al., 2004). Alterations in the 
growth signalling can also occur within the cell, proteins responsible for changes in 
gene expression following the detection o f cellular abnormalities (e.g. SOS-Ras-Raf- 
MAPK cascade), are mutated in many types o f cancer. The main targets for alteration 
in this pathway are members o f the ras gene family which when mutationally 
activated can transmit pro-growth signals without upstream stimulus. The alteration o f 
this intracellular signalling cascade has multiple effects the main advantage o f which 
is to promote survival o f the cell (Hanahan and Weinberg, 2000).
Self-sufficiency in 
growth signals
Evading
apoptosis
Insensitivity to 
anti-growth signals
Sustained
angiogenesis
Tissue invasion 
& metastasis
Limitless replicative 
potential
Figure 1.2. Acquired capabilities o f cancer (Hanahan and Weinberg, 2000).
Autonomy in growth signalling is not the only attribute cells require to begin a cycle 
o f deregulated growth as there are opposing forces to such behaviour in the form of 
anti-growth factors. To achieve deregulated growth, the malignant cell requires
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desensitisation to such anti-growth signals. Anti-growth factors are present as soluble 
factors in the extra cellular fluid and bound to the ECM. These factors act by forcing 
cells into quiescence or differentiation. In inducing the quiescence anti-growth factors 
act through the Rb protein, the phosphorylation state o f which decides the fate o f the 
cell in the G1 phase o f the cell cycle (Hanahan and Weinberg, 2000). Anti-growth 
signals induce cells to differentiate by signalling throughout the Myc-Max-Mad 
pathway. Association o f the Myc and Max proteins drives the cell into growth, 
association of Myc with Mad leads to differentiation of the cell and thus apposes 
growth (see Figure 1.3).
Myc + Max ---------------------------------------Max +Mad
Favours Growth Favours differentiation
Figure 1.3. The balance o f  growth and differentiation.
Tumour cells however, avoid terminal differentiation by up regulation o f c-myc which 
causes Myc to remain associated with Max, a situation conducive to growth and 
opposed differentiation (Lewin 2000). Transforming growth factor beta (TGFP) is an 
example o f an anti-growth factor often deregulated in human tumours such as prostate 
(Tu et al., 2003), breast (Lebrecht et al., 2004) and colon (Biswas et al., 2004). 
Tumours often become insensitive to TGFP signalling by the down regulation or 
alteration o f intracellular transducers o f this signal such as TbetaR-I and TbetaR-II 
(Evangelou et al., 2000), or by the deregulation o f proteins downstream of the 
receptor such as Smad3 (Chipuk et al., 2002).
The pre-malignant cell with its loss o f sensitivity to pro and anti-growth signals is 
able to initiate deregulated proliferation. There are. however, further hurdles in the 
path to malignant progression. To achieve neoplastic growth, the pre-malignant cell 
has to overcome the finite replicative potential o f normal cells. This limitation is due 
to the shortening o f chromosomes with every round o f replication. This shortening o f 
the chromosome ends, or telomeres, means that human cells can undergo only around 
50 to 70 doublings, before senescence occurs. Telomeres are created initially by the 
enzyme telomerase that is switched off in later development o f the cell. In 85 to 90 
per cent o f cancer cells, however, telomerase is up regulated giving the cells increased 
replicative potential (King, 2000).
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Cells undergoing deregulated proliferation will eventually form large cell masses. 
Without sufficient vascularisation, the cells and the centre o f such structures would 
therefore depend on diffusion to receive all the essential nutrients. This form of 
nutrient transport via diffusion would not sustain large cell population, as cells need to 
be within 100pm o f a capillary (Strohmeyer, 1999). Neoplastic growth therefore, 
requires the formation o f new blood vessels (angiogenesis). As with any regulatory 
system, there are pro and anti-angiogenic signals. The induction of angiogenesis is 
present at an early stage in cancer and is initiated by a change in the balance o f pro 
and anti-angiogenic factors at transcription level (King, 2000). Vascular endothelial 
growth factor (VEGF) is an example o f a pro angiogenic protein and has been isolated 
as a target for inhibition in clinical drug trials. The regulation o f angiogenesis is an 
obvious therapeutic target, as limiting angiogenic potential causes nutrient starvation 
leading to large-scale apoptosis within the tumour (Ziche et al., 2004).
1.1.4 Invasion and metastasis
Invasion and metastasis are the result o f a co-ordinated balance between cell adhesion 
and detachment through CAM proteins, which occurs simultaneously with tumour 
cell-induced remodelling o f the basement membrane by endopeptidases (Stewart et 
al., 2004). This is a multi-step process (See Figure 1.4) and in accordance with the 
heterotypic model, involves both cancerous and normal cells within the tumour 
microenvironment.
Tissue invasion and metastasis are the attributes that make cancers malignant and 
ultimately fatal, contributing to 90 per cent o f human cancer deaths (Quaranta and 
Giannelli, 2003, Hanahan and Weinberg, 2000). Invasion into surrounding tissue 
alone, decreases treatment options and can be lethal as seen in astrocytomas and head 
and neck small cell carcinoma (HNSCC). The term invasion suggests the penetration 
and occupation o f neighbouring tissue, this tissue contains nerves and blood vessels, 
leading to complications such as pain and internal bleeding. Tumours are often 
surgically staged using the TNM system, which takes into account the spread o f the 
disease in terms o f invasion and metastasis (see Appendix 1). The extent of invasion 
into surrounding tissue can vastly affect the prognosis, in patients with stage I disease 
where there is no spread to the lymph nodes there is a 92% 5 year relapse free
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probability following treatment with irradiation. In comparison patients with stage III 
or IV disease where there is spread outside the prostate to lymph nodes or outside the 
pelvis the 5 year relapse free probability is 24% (Pisansky et al., 1997).
Angiogenesis
1
Degradation/ remodelling of basement membrane
i
Detachment from primary
I
Intravasation
1
Vascular transportation 
1
Evasion of host mechanisms 
1
Attachment at new site 
1
Extravasation
1
Proliferation in target organ
Figure 1.4. The multi-step process o f invasion and metastasis. Adapted from (Stewart et al., 2004).
The process of invasion generally involves the uncoupling o f cells from their 
surrounding microenvironment and the activation o f extra cellular proteases. These 
enzymes are resident in the transmembrane region of the cell, associated with 
integrins or bound to receptors. Some proteases are thought to be transported into the 
tumour area from normal tissue and promote carcinogenesis and invasion by 
degrading tissues, initiating angiogenesis and pro-growth signalling (Hanahan and 
Weinberg, 2000). The recruitment o f proteases from normal tissue to aid malignant 
growth is an example o f the heterotypic signalling seen in tumour cell masses (De 
Wever and Mareel, 2003). Certain host elements are present in all cancers; these
23
include lymphocytes, macrophages, dendritic cells and angiogenic factors. In 
pancreatic cancers greater than 50% o f tumours contain a majority o f host cells 
(Mareel and Leroy, 2003). The idea that other cell types contribute to the growth, 
proliferation and spread o f malignant cells, was proposed in the first edition o f the 
Lancet, termed “the soil and seed model.” This model suggests that the 
microenvironment o f each organ (soil) influences the survival and growth o f the 
cancer cell (seed) (Paget, 1889). Recently this model has been termed the heterotypic 
model o f tumour growth and suggests that tumour cells gain an advantage by being 
able to co-opt the neighbouring cells (Hanahan and Weinberg, 2000).
Uncoupling o f cells from their surrounding microenvironment occurs due to the 
deregulation o f cell-cell adhesion molecules (CAMs). The adherence o f cells via 
CAMs also acts to regulate growth, for example, E-cadherin bridges transmit anti­
growth signals. The expression o f E-cadherin is down regulated in a number of 
epithelial cell cancers including prostate (Jaggi et al., 2005), head and neck (Bosch et 
al., 2005) and melanoma (Ikoma et al., 2005) and has also been found to correlate 
with poor prognosis in these diseases. Reduced E-cadherin expression in mouse 
cancer models increases metastasis and invasion (Perl et al., 1998, Gingrich et al., 
1996). These results indicate that E-cadherin has an important role in metastatic 
progression. Invasion and metastasis into new microenvironments requires 
recognition o f new ECM proteins by the CAM proteins. In cancer cells this can be 
achieved through alteration o f alpha and beta subunits o f integrin molecules (Stewart 
et al., 2004). Different combinations o f these subunits results in greater than 20 
subtypes of integrins (Fomaro et al., 2001). Cancer cells are thought to have a 
selective advantage by switching expression to novel integrin subtypes that recognise 
the degraded stromal components produced by protease action, allowing the cell to 
associate with ECM proteins in new microenvironments (Stewart et al., 2004).
Invasion can be regarded as a normal developmental process, most markedly seen at 
gastrulation where a spatiotemporal balance o f promoters and suppressors o f invasion 
participate to form the different cellular layers (Mareel and Leroy, 2003). Invasion is 
a normal phenomenon occurring in terminally differentiated cells such as endothelial 
cells, for example leucocytes and macrophages which are extremely invasive (Falcone 
et al., 2001, Mareel and Leroy, 2003). It is possible that normal cells are affected in a
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paracrine fashion by soluble factors secreted by the cancer cells, which could then 
lead to the induction of pro-invasive factors by the normal cells. The understanding 
that cancer is not a discrete foreign collection of cells, but derived from an isogenic 
source and dependent on normal endogenous processes, may explain why curative 
treatments are so damaging to normal tissue and cause detrimental side effects. 
However achieving a better understanding of the microenvironment of the tumour 
should uncover new ways to exploit endogenous mechanisms to limit the spread of 
the disease, perhaps by restoring the normal restriction of invasion.
Metastasis, or the development of secondary cancer sites distal to the original tumour 
constitutes the final and often lethal phase of the disease (Quaranta and Giannelli,
2003). Metastasis to a novel tissue environment is advantageous to cancer cells 
because it allows them to escape space and nutrient limitations. The process of 
metastasis is distinct from that of invasion in that not only must the cells invade 
through surrounding tissue, but also detach from the primary tumour, enter a transport 
vessel (either lymph or blood vessel), be transported to a distal site whilst evading the 
immune systems defences, attach at a new site, leave the blood vessel and finally 
proliferate in the target organ (Stewart et al., 2004). This process requires many 
changes in the surface composition of the cells, which will be discussed further in 
section 1.3.2.
1.1.5 Stem cell theory of carcinogenesis
In normal tissue, cell growth is opposed by differentiation, with a small subset of stem 
cells dividing to produce transit-amplifying cells that in turn produce the 
differentiated cell types of the tissue (Lajtha, 1979, Leblond, 1981). As these cells 
progress to a more differentiated phenotype their ability to replicate is lost, this is in 
part due to a loss of telomerase, the enzyme responsible for maintaining chromosome 
length and integrity through rounds of replication. In most normal somatic tissues 
telomerase is present at undetectable levels, it is however readily detectable in germ 
line tissues and cancers (Kim et al., 1994). In certain tumors, including those of breast 
and prostate tissue, a loss of differentiation occurs concurrently with re-activation of 
telomerase and this is considered a marker of advanced disease (Baykal et al., 2004, 
Tricoli et al., 2004).
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One model of cancer progression proposes that the negative effect of differentiation 
on proliferative capacity is overcome by the acquisition or maintenance of a more 
stem cell like phenotype, including reactivation of telomerase (De Marzo et al., 1998). 
Theoretically this can be achieved in one of two ways i) de-differentiation of mature 
cells to a more stem cell like phenotype ii) genetic alteration of a stem or transit 
amplifying cell (Al-Hajj et al., 2004). Both of these situations give rise to a small 
population of cells (possible tumour stem cells) capable of not only forming a 
heterogeneous tumour but also maintaining self-renewal. In acute myeloid leukaemia 
(AML), breast and prostate cancer, a small fraction of cells (1:100 to 1:10000) has 
been isolated that is capable of colony formation (Bonnet and Dick, 1997, Al-Hajj et 
al., 2004). It has been suggested that mutational events in stem cell colonies create a 
background of genetic instability in the daughter cells that is maintained by self­
renewal of the cancer stem cell. This genetic instability is proposed to act as a field 
for the cancerization process (Braakhuis et al., 2003). The cancer stem cell model 
suggests that longevity of stem cells allows them to accumulate the 5-7 mutations 
required for a cancer to develop (Reya et al., 2001). Once genetically altered this stem 
cell could go on to transmit these alterations to a population of daughter cells, creating 
a patch of mutant cells. This patch would in turn undergo expansion creating a field of 
genetically altered cells in which further mutational events may occur leading to 
carcinoma (Braakhuis et al., 2003). See Figure 1.5.
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Figure 1.5. The cancer stem cell model o f  field cancerization (Braakhuis et al., 2003).
Evidence for this field cancerization model can be derived from studies in several 
cancers such as lung (Wiencke and Kelsey, 2002), HNSCC (van Oijen and Slootweg, 
2000, Hafiier et al., 2001)), bladder (57) and skin (Carlson et al., 2001), where pre­
neoplastic changes are present at multiple sites before the occurrence of a carcinoma 
(Braakhuis et al., 2003). The above theory suggests a single genetic origin of the
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neoplastic process, which indicates that the same mutation should be present 
throughout the lineage of cells if they are all derived from a single cancer stem cell 
ancestor. Confirmation of this was seen in HNSCC where patches of cells >200 cells 
in diameter were found to share a common genotype displaying p53 mutations 
(Garcia et al., 1999). Cells displaying a common clonal identity have also been noted 
in bladder carcinoma, even for lesions >7cm apart (Simon et al., 2001). Further 
evidence of a common clonal origin can be observed in the results of a number of 
studies comparing genetic alterations in apparently normal tissue surrounding areas of 
tumour resection, to those observed in the tumour specimen. In HNSCC for example, 
tumour associated genetic alterations in neighbouring normal mucosa were discovered 
in 33% of cases whose surgical margins were declared tumour free by histopathology 
(Tabor et al., 2002).
A stem cell model for prostate cancer, proposed originally by Isaacs et al, suggests 
that an increase in the total prostatic stem cell number and/or an increase in the clonal 
expansion of the stem cells into transit-amplifying cells may lead to neoplasia (Isaacs 
and Coffey, 1989). Subsequently, researchers have attempted to identify the stem cell 
fraction of normal and cancerous prostate tissue. In normal prostate tissue 80% of cell 
proliferation occurs within the basal cell layer and this layer is consequently thought 
to contain the stem cell fraction (Bonkhoff et al., 1994). As yet, no marker exists that 
identifies the prostate stem cell fraction, however through observation of the colony 
forming ability of epithelial cells cloned directly from areas of benign prostate 
hyperplasia a subset of cells with a high proliferative capacity which display 
pluripotency in three dimensional culture can be isolated (Hudson et al., 2000). It is 
postulated that these putative prostate stem cells possess decreased androgen 
dependence and are thus capable of the re-growth of the prostate gland following 
ablation of the prostate by castration. In the male rat 90% of prostate epithelial cells 
are lost following castration, the remaining 10%, possibly containing the stem cell 
fraction are androgen independent but remain androgen sensitive as restoration of 
androgens leads to regeneration of the prostate gland (Kyprianou and Isaacs, 1988). 
The androgen independent nature of these putative prostate stem cells has led to the 
suggestion that these cells are responsible for tumour reoccurrence and androgen 
insensitivity seen following hormonal treatment of prostate cancer (Bui M, 1998-99, 
Isaacs, 1999). This model suggests that there a subset of genetically altered (cancer)
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stem cells which aberrantly mimic the normal process of tissue renewal. These 
genetic alterations may consist of early carcinogenic events such as mutation of 
tumour suppressor genes leading to genomic instability and/or mutational activation 
of oncogenes, leading to over proliferation of the daughter or clonally derived cells in 
which further mutations may lead to carcinoma. The cells, under the selective 
pressure of hormonal therapy, may retain the capacity for androgen independence 
seen in the progenitor cells. The origin of these cancer stem cells remains unclear, 
they may result from a genetically altered normal stem cell or a de-differentiated cell 
from another part of the population. Elucidation of prostate stem cell markers will 
assist in the clarification of this issue.
1.2 Prostate cancer
Prostate cancer is the second most common cause of cancer death in men in Western 
countries and the incidence has increased in recent years. In England and Wales, for 
example, death rates have trebled in the last 30 yrs (Cussenot et al., 1998). There are 
several possible explanations for the increased incidence of prostate cancer (PCa), the 
most apparent of which is the increasing age of the population. Age is the most 
important risk factor in PCa, with a median age at diagnosis of 72 (Cussenot et al.,
1998). A heightened awareness of PCa amongst the public and the use of prostate 
specific antigen screening (PSA) have added to the rise in PCa diagnosis.
Globally there is wide racial variation in PCa incidence ranging from 0.1:100 000 
Thailand- 30:100 000 West Indies (Gao et al., 1997). There is also variation in 
severity of disease with African Americans suffering more aggressive cancers, which 
may be due to their higher testosterone levels (Gao et al., 1997). Racial differences 
may be enhanced by environmental factors such as diet. A high saturated fat and low 
selenium, Vitamin E and D, containing diet confers the greatest risk (Chan et al.,
2005). Proximity to radiation may also be a risk factor, as PCa was found to be one of 
the cancers inducible by exposure to atomic radiation (Beral et al., 1985). It is 
possible that environmental effects have a greater bearing on the incidence of prostate 
cancer than hereditary factors, as it has been inferred that less than 5% of PCa are 
inherited (Cussenot et al., 1998).
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There are however, several genetic factors associated with increased prostate cancer 
risk. These include alteration of members of the BRCA gene family and those 
involved in insulin-like growth factor (IGF) signalling. BRCA mutations have been 
studied extensively in relation to familial female cancers such as those of the ovaries 
and breast where mutation of BRCA1 is associated with a significant increase in 
cancer risk (Robson et al., 1998). It has been alleged that prostate cancer is over­
represented in familial groups with a history of BRCA associated female cancers 
(Sigurdsson et al., 1997). BRCA1 and BRCA2 have been studied extensively in 
Ashkenazi Jews due to the high frequency of three founder mutations in these genes. 
Studies of prostate cancer incidence in this population have found that mutations in 
BRCA2 confer a significantly increased risk of prostate cancer (Kirchhoff et al.,
2004). The association between BRCA1 mutation and prostate cancer has been widely 
debated, studies have reported a lower (Brose et al., 2004) and increased risk (Ford et 
al., 1994) of prostate cancer in family groups with a BRCA1 mutation. BRCA1 has a 
putative role as a tumour suppressor involved in the maintenance of genomic integrity 
(Bradbury, 2002). This function, however may not be restricted to the BRCA1 gene 
itself, as genetic analysis of the area surrounding the BRCA1 locus (17q21) has 
indicated a distal genomic region that is deleted in 70% of prostate tumour cells, 
which may contain one or more tumour suppressor genes (Williams et al., 1996, 
Newman and Liu, 1998). As germ line mutations of BRCA 1 and BRCA2 genes have 
been found at a relatively low frequency in prostate cancer cells, 0-2.3% and 0-3.2% 
respectively (Kirchhoff et al., 2004), it is possible that alterations in regions 
surrounding these genes may have a greater significance in terms of prostate cancer 
risk. The link between prostate cancer and BRCA mutations is the focus of an 
ongoing study into the identification of men with a genetic predisposition to prostate 
cancer and their clinical treatment (IMPACT)(Bonn, 2002), which should give further 
insight into the inherited aspects of prostate cancer.
Defects in the IGF-1/IGFR (Insulin-like growth factor receptor) axis are indicated as 
predisposing factors to prostate cancer. An increase in IGF-1 induced cellular activity, 
either through high circulating IGF-1 levels, increased availability of free IGF, or 
IGF-1R over expression has been associated with many cancers including prostate, 
ovarian, melanoma, colon and rhabdomyosarcoma (Hellawell et al., 2002, Playford et 
al., 2000, Renehan and Howell, 2005). At the cellular level IGF-1 has been implicated
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in carcinogenesis through autocrine and paracrine regulation of both mitogenic and 
anti-apoptotic effects, in tumour progression through ligand independent activation of 
other receptor tyrosine kinases and enhancement of matrix-metalloprotease (MMP) 
expression (Papatsoris et al., 2005). Both high circulating levels of IGF-1 and over 
expression of IGF-1R have been associated with increased risk of prostate cancer. 
High levels of circulating IGF-1 are associated with prostate cancer risk most strongly 
in men under 59, where there is a four fold higher risk with elevated IGF-1 serum 
levels (Papatsoris et al., 2005). High IGF-1 levels appear to be an early finding in 
prostate cancer, sometimes detected up to 5 years before prostate cancer is diagnosed 
(Papatsoris et al., 2005). This and the recent finding that circulating IGF-1 levels are 
high in individuals with high grade prostate intraepithelial neoplasia (HGPIN), a 
possible precursor of prostate cancer, has led to the conclusion that IGF-1 has an 
important role in early carcinogenesis (Nam et al., 2005). In the transgenic 
adenocarcinoma of the mouse prostate model (TRAMP) germ line mutations which 
decrease the level of circulating IGF-1, delayed neoplastic changes to the prostate and 
improved survival, providing further evidence of a role for IGF-1 in early 
carcinogenesis (Majeed et al., 2005). It has been proposed that small foci of prostate 
cancer cells secreting high levels of IGF-1 could have a paracrine neoplastic effect on 
surrounding cells leading to field cancerization (Papatsoris et al., 2005). Increased 
levels of IGF-1 are thought to be due to a polymorphism in a cytosineiadenosine 
repeat (CA19) upstream of the IGF-1 gene transcription site. CA19 homozygotes have 
a decreased risk of prostate cancer, interestingly this genotype is found more 
frequently in Caucasians than those of African descent (Friedrichsen et al., 2005, 
Schildkraut et al., 2005).
In addition to increased secretion of IGF-1, increased bioavailability of the compound 
has also been associated with increased risk of prostate cancer (Hellawell et al., 2002). 
In serum, 90% of IGF is associated with insulin like growth factor binding protein 3 
(IGFBP3) (Papatsoris et al., 2005). IGFBP3 modulates the activity of IGF and shows 
an inverse correlation with prostate cancer risk. IGFBP3 levels are highest in healthy 
individuals, intermediate in those with localised prostate cancer and lowest in 
individuals with metastatic disease (Kehinde et al., 2005). Differences in the ratio of 
IGF-1 :IGFBP3 correlates with prostate cancer risk in global populations, the ratio is 
lowest in African Americans who have a high risk of prostate cancer (Papatsoris et al.,
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2005). Low levels of both proteins are seen in Arab and Chinese populations who 
have a low risk of prostate cancer, further implicating the IGF-1 axis in global 
variation in prostate cancer incidence (Kehinde et al., 2005).
Over expression of the cellular transducer of IGF-1, IGF-1R, has been observed in 
primary prostate tumours when compared to benign prostate epithelium (Hellawell et 
al., 2002). Activation of this receptor appears to have a strong proliferative effect on 
prostate cells (Friedrichsen et al., 2005) which may in part be due to a transactivating 
effect on the androgen receptor (Papatsoris et al., 2005). This cross regulation is 
reciprocal, as androgens can cause a six fold increase in IGF-1R expression, an effect 
which is not negated by conventional anti-androgen treatment such as Casodex 
(Pandini et al., 2005). The cross talk between androgen and IGF pathways has been 
postulated as a possible explanation for androgen insensitive tumour re-growth seen 
in late stage prostate cancer (Papatsoris et al., 2005), (Pandini et al., 2005). However, 
IGF-1R expression appears to be inversely proportional to tumour stage, with 
expression reduced or lost in metastatic disease. This is observed in the TRAMP 
model, where IGF-1R expression is absent from metastasis and androgen independent 
disease (Kaplan et al., 1999). The significance of this finding for human prostate 
cancer appears somewhat limited as a recent study found that only 25% of cases over 
expressing IGF-1R in the primary tumour displayed reduced expression on 
progression to a androgen insensitive/metastatic phenotype (Hellawell et al., 2002).
1.2.1 Diagnosis
The majority of prostate cancers occur within the peripheral zone of the gland. Due to 
the anatomical position of this zone early disease is often asymptomatic, although in 
some cases there may be problems with urination due to overgrowth of the tissue 
surrounding the urethra (Mazhar and Waxman, 2002). Of presenting cases, 95% are 
identified as adenocarcinoma histologically based on the architecture of the tissue and 
the cell cytology. Prostate cancers are diagnosed using these features and graded 
using the Gleason scale (Mazhar and Waxman, 2002). Due to its asymptomatic and 
insidious onset, the need for effective screening for prostate cancer has become a 
research priority. At present, in the UK only 10% PCa cases are diagnosed in 
screening via digital examination, most are symptomatic and the diagnosis has to be
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confirmed by transrectal biopsy. Digital examination screening has poor predictive 
value, however, as the cancers are often not detectable by palpation until an advanced 
stage (Mazhar and Waxman, 2002). Transrectal ultrasound has been used to identify 
cases of PCa this technique has proved as ineffective in determining the spread of the 
tumour as digital examination (Mazhar and Waxman, 2002).
Both digital examination and ultrasound screening require the cancer to be well 
established, for screening to be effective the cancer needs to be detectable at an early 
stage. Pre-malignant changes called prostatic intraepithelial neoplasia (PIN) have 
been discovered that occur in 70% of prostates containing high-grade cancer. Their 
value as a prognostic marker however remains undecided, as PIN is seen in 40% of 
non-cancerous prostate tissue (Mazhar and Waxman, 2002). Screening for changes 
such as PIN would involve invasive procedures such as biopsies, which in turn carry 
risks of infection. There is, therefore a need for non-invasive screening technique that 
has the following characteristics:
Measurable in serum or from tissue specimens
Useful in screening, diagnosis, prognosis, monitoring therapy, or can be 
followed for early indication of relapse.
High sensitivity, specificity, reproducibility,
Practical cost efficient test 
Organ specific 
Cancer specific 
(Gao et al., 1997)
Prostate specific antigen (PSA) is a potential serum marker of PCa first described in 
1971 when it was found to be elevated in 96% of patients with newly diagnosed 
untreated prostate cancer (Stamey et al., 1987). The PSA gene is located on 
chromosome 19 and the 34 kD single chain glycoprotein product is a serine protease 
with trypsin like activity. PSA is synthesized by epithelial cells of prostatic acini and 
ducts where it liquefies seminal coagulum, PSA is also found in large amounts in the 
cytoplasm of cancerous prostate cells (Charrier et al., 2001). The use of PSA as a 
prognostic marker followed the finding that the serum level increases with clinical 
stage and tumour volume, falls following radical prostatectomy and then rises with
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tumour reoccurrence (Stamey et al., 1987). PSA held promise as a prostate cancer 
marker in diagnosis and prognosis; however, its clinical use is limited. PSA, despite 
its name, is not organ or disease specific, as it has been found in other tissues and is 
present at varying levels in female serum (Yu and Berkel, 1999). PSA has also been 
found to be elevated in 65% of patients with non-malignant prostate disease i.e. 
benign prostate hyperplasia and prostatitis (Charrier et al., 2001, Gao et al., 1997). 
Differentiation between the malignant and non-malignant state using PSA levels has 
been the subject of much research. It has been shown that calculating the serum ratio 
of free versus total PSA (free PSA plus that bound to protease inhibitor) increases the 
sensitivity of PSA screening and decreases the number of unnecessary biopsies by 
20% (Charrier et al., 2001). Despite such improvements it appears that the marker 
property of PSA seems related more to changes in gland architecture than malignant 
status (Stenman et al., 1991, Charrier et al., 2001). As a marker PSA, therefore, is not 
tissue specific and does not distinguish between malignant and benign disease, it also 
exhibits a poor correlation with cure rates (Charrier et al., 2001). Another 
complication with the clinical use of this marker is that in rare cases, aggressive 
cancers are PSA negative (Pryor and Schellhammer, 2002). Considering these 
limitations it is apparent that PSA is not an ideal marker of prostate cancer, however, 
it is the only molecular marker in widespread clinical use for the monitoring of this 
disease (Gao et al., 1997). There is obviously a need for further research into markers 
that fulfil more of the criteria listed above and are able to diagnose cancers with a 
high level of confidence.
1.2.2 Treatment
The current treatment of prostate cancer largely depends on the stage at which the 
cancer is diagnosed.
Prostate cancer progression commonly involves:
1. Asymptomatic early disease, possible problems with urination
2. Invasion of seminal vesicles, ureters, bladder base and external urethral 
sphincter erosion often causing haematuria.
3. Lymphatic spread into the iliac chain and para-aortic lymph nodes
4. Metastasis, vascular spread to bone in 80% of cases, also to liver, lung and 
adrenal glands. Perineal pain, weight loss, cachexia, bone pain and
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neurological complications usually related to metastases (Denmeade and 
Isaacs, 2002).
The treatment of clinically localized disease currently includes active surveillance for 
many cases especially those with other medical complications. Other more invasive 
management strategies are used which carry associated risk factors. Radical 
prostatectomy is a surgical solution for those with organ confined disease but carries 
a mortality risk of up to 5%, an impotence risk of 70% and incontinence risk of 5% 
(Mazhar and Waxman, 2002). Prostate cancer is relatively insensitive to radiotherapy 
due to the slow growth of the tumour; this treatment gives similar survival and 
incontinence rates as surgery, however, the impotence risk decreases to 10-40% 
(Mazhar and Waxman, 2002, Denmeade and Isaacs, 2002). A form of radiotherapy, 
called brachytherapy, has increased sexual potency but led to a higher risk of urinary 
problems (Denmeade and Isaacs, 2002). Radiotherapy is most effective as a palliative 
treatment in advanced prostate cancer as studies have shown that 90% of patients 
with metastatic disease undergoing radiotherapy were relieved of bone pain (Tong et 
al., 1982).
Hormonal therapy is often used in conjunction with radiotherapy or alone in 
advanced disease as it reduces the size of the tumour by 30-40% (Mazhar and 
Waxman, 2002). The treatments used in advanced disease include anti-androgens and 
gonadotrophin releasing factors, oestrogens have also been used but these can lead to 
an increased risk of cardiac disease (Denmeade and Isaacs, 2002). Hormone therapy 
is commonly used to alleviate the symptoms of metastatic disease, but is not curative 
and leads to androgen insensitivity of the tumour after a median period of 18 months 
at which point the treatment becomes ineffective (Mazhar and Waxman, 2002). 
Hormonal treatment can also be used as an adjuvant to chemotherapy in a palliative 
capacity.
Due to the insidious onset of the disease, prostate cancer often presents at a late stage, 
where there may be extra capsular invasion and metastasis to surrounding tissue. By 
definition in low Gleason grade tumours (more differentiated cancers) stromal 
invasion is present and as the tumour becomes more undifferentiated (higher Gleason 
grade), the risk of metastasis increases. Clinicians use Partin’s tables, PSA level,
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Gleason grade and tumour stage to calculate the chance of the patient having localized 
or locally advanced cancer. In patients with PCa which has extended outside the 
prostate, initially to seminal vesicles or local lymph nodes, curative treatment 
becomes less feasible (Stamey et al., 1999). In late stage cancers the treatment is often 
palliative however, there has been an emergence of new therapeutic strategies and 
chemotherapeutic agents. These include second-line hormonal therapy (Wilkinson 
and Chodak, 2004), chemotherapy (Oh et al., 2005), immunotherapy (Lee, 2002), 
granulocyte macrophage-colony stimulating factor (GM-CSF) therapy (Pandha et al., 
2004, Small et al., 1999), dendritic cell therapy (Pandha et al., 2004), gene 
vaccination therapy (Gulley et al., 2002), inhibition and/or blockade of growth factor 
receptors or growth factor receptor pathways (Hudes, 2002) and inhibition of neo- 
angiogenesis (Sternberg, 2003).
Many of these treatments display anti-proliferative and anti-angiogenic properties in 
vitro and in mouse models and may decrease PSA levels in vivo, but none yet have 
produced significant prolonged survival in patients with late stage prostatic disease. 
This is exemplified in the case of immunotherapy with interferons. Stimulation of the 
body’s immune system by enhancement of endogenous processes or by exogenous 
administration of cytokines has been a popular approach to anti-cancer therapy. 
Enhanced cytokine signalling by either of these means has been shown to instigate 
anti-proliferative (Hobeika et al., 1997, Huang et al., 2002, Tsai et al., 2002), 
proapoptotic (Bauer et al., 2003, Huang et al., 2002, Harris et al., 1999, Kramer et al., 
2001, Selleck et al., 2003), anti-metastatic (Tsai et al., 2002, Street et al., 2001, Huang 
et al., 2002), immunostimulatory (Kuratsukuri et al., 2000) and anti-angiogenic (Cao 
et al., 2001, Bauer et al., 2003) effects. By virtue of these effects cytokines could be 
seen as the ideal tumor suppressors, however, it has been noted that many tumors 
display a lack of immunogenicity possibly due to a lack of MHC class 1 expression 
(Kuratsukuri et al., 2000). Prostate cancer is one such tumor, the prostate cancer cell 
line LNCaP is unresponsive to interferons due to epigenetic silencing of JAK1 
expression, a protein required for interferon signal transduction (Dunn et al., 2005). In 
addition, prostate cancer metastases, from which the LNCaP cell line is derived, 
express little or no MHC class 1 protein (Blades et al., 1995). It has been postulated 
that this lack of immunogenicity is an important event in tumourigenesis as it allows 
the cancer cells to evade host immune responses (Blades et al., 1995, Bronte et al.,
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2005). This tumor mediated immunosupression may also occur at the systemic level 
as elevated levels of cytokine receptors identified in cancer patient serum have been 
found to bind to and inhibit cytokine activity (Ambrus et al., 2003).
Several studies have examined the effects of cytokines, particularly interferons, on 
prostate cancer cells. These cytokines are known to have cytotoxic and 
immunomodulatory effects on cancer cells, not only at the primary site but also at a 
cellular level in disseminated cancer (Ronchese et al., 2002). Interferon alpha (IFNa) 
has been the most extensively studied of the interferons in relation to prostate cancer. 
IFNa is produced by lymphocytes, lymphoblasts and macrophages and is part of 
innate immunity, activating macrophages and monocytes, stimulating natural killer 
cells and enhancing antigen expression by MHC1 (Kuratsukuri et al., 2000). In vitro 
IFNa has been found to inhibit growth of the prostatic cell line DU 145 by limiting 
progression from G1 to S phase of the cell cycle in a p53 and pRb independent 
manner (Hobeika et al., 1997). In xenograft mouse models of prostate cancer, IFNa 
has been shown not only to have an anti-proliferative effect, mediating a 37% 
reduction in tumour volume, but also an anti-metastatic effect in decreasing lymph 
node metastases. This is possibly due to an increase in the ratio of E-cadherin to 
matrix metalloprotease 9, as the ratio of these proteins has been suggested to be an 
indicator of metastatic risk (Huang et al., 2002). Clinically, IFNa is in therapeutic use 
for renal cell carcinoma, melanoma, transitional cell carcinoma and has undergone 
phase I and II trials for use in prostate cancer (Kuratsukuri et al., 2000, Kramer et al., 
2001, Huang et al., 2002). In the largest of these trials IFNa treatment produced a 
response rate of 5% and a >50% reduction in PSA in 23% of patients (van Haelst- 
Pisani et al., 1992). This minimal beneficial effect was accompanied by high toxicity 
with patients experiencing weight loss, fatigue, malaise, central nervous system 
toxicity, leucopenia, nausea and vomiting. This study concluded that patients cannot 
tolerate the high doses of IFNa required to produce a beneficial effect in prostate 
cancer (Kuratsukuri et al., 2000). Subsequently, to limit the dose of IFNa required, 
many clinical trials have been conducted combining IFNa with various other 
treatments see Table 1.1 below.
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Table 1.1. Clinical trials o f IFNa combination therapy
Treatment No. of 
participants
Response
rate
>50% PSA 
reduction
Reference
IFNa, IL-2 and dendritic 
cells primed with prostate 
specific membrane antigen 
(PSMA)
13 31% 23% (Maffezzini et 
al., 1996)
IFN a, Retinoic acid 14 15.3% 7.7% (Thalasila et 
al., 2003)
IFNa, TNFa 10 38% 18-87% (Kramer et 
al., 2001)
IFNa, 5-fluorouracil 28 0 14% (Daliani et al., 
1995)
As Table 1.1 demonstrates, the greatest cytokine-based therapeutic effect in prostate 
cancer is achieved by combination of two cytokines and co-administration of primed 
dendritic cells able to further stimulate the host immune system. Patients within these 
trials however, did still experience varying levels of toxicity. Further investigation 
will be required to ensure the benefits of IFNa treatment outweigh the side effects.
The therapeutic potential of interferon beta and gamma (IFNp, IFNy) in prostate 
cancer has been studied far less than that of IFNa. IFNp is produced by fibroblasts 
and epithelial cells and like IFNa has an anti-tumour activity (Kuratsukuri et al., 
2000). In vitro, IFNp has been found to suppress the growth of JCA-1 cells by 15- 
30% and when combined with the anti-tumour agent Onconase, by 42-51% (Tsai et 
al., 2002). In mouse prostate cancer xenograft models IFNp suppressed tumour and 
metastasis formation by 80% and eradicated tumors in 20% of mice (Cao et al., 2001). 
This effect may be due to the anti-angiogenic properties of IFNp in decreasing the 
expression of MMP’s and proangiogenic factors (Huang et al., 2002), as prostate 
tumours from mice treated with IFNp contained fewer microvessels and a greater 
degree of apoptosis than untreated tumors (Cao et al., 2001). IFNp is in clinical use 
for renal cell carcinoma and has been used in clinical trials for advanced prostate 
cancer (Bulbul et al., 1986). However 65% of participants in this study could not 
complete due to disease progression and those who did continue showed no response
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in terms of tumour volume, spread or PSA level, they also suffered various side 
effects such as shivers and fever (Bulbul et al., 1986). It remains to be seen whether 
the anti-tumor effects of IFNp will be mirrored in clinical trials.
IFNy is a type II interferon produced predominantly from CD4+ lymphocytes and 
natural killer cells that affects cells by signalling through the IFNy receptor (IFNyR) 
and the Janus kinase-signal transducer and activators of transcription (JAK-STAT) 
pathway. Activation of this pathway by IFNy leads to the transcription, via the 
ISGF3y transcription complex, of interferon inducible genes containing gamma 
activated sequence (GAS) elements (Deb et al., 2003, Aboagye-Mathiesen et al.,
1999). In humans, the IFNy inducible genes thought to be involved in PCa 
progression are located on the lOq 23-26 and 17q 21 chromosomal loci, regions which 
are commonly deleted in PCa (Shou et al., 2002). Recent studies found this region to 
be deleted in 30% of 49 PCa samples and is thought to encode tumour and metastasis 
suppressor genes (Shou et al., 2002, Nagano et al., 2003).
The cell surface effects of IFNy treatment in PCa cells include increased adhesion via 
modulation of P-cadherin, a integrins and ICAM1, increased density of cell receptors, 
clustering of receptors into large lipid raft structures or “signalosomes” and an 
increase in the display of proteins signalling the status of the cell (e.g. MHC-1, 
tumour associated antigens) (Bacso et al., 2002). Through modulation of these various 
cell surface proteins including CAM’s and RTK’s, cytokine treatment can alter 
several PCa attributes closely associated with tumour invasion and the acquisition of a 
metastatic phenotype. In addition, interferon y has been found to decrease the binding 
affinity for bone matrix stroma in PCa cells, indicating that this cytokine may be 
effective in decreasing the secondary skeletal tumours common in PCa (Sokoloff et 
al., 1996). In the prostate cancer cell lines PC3 and LNCaP, in vitro exposure to IFNy 
enhanced Fas-mediated cell death, rising from 40% to 60%. In a mouse model of 
prostate cancer IFNy treatment lead to a three-fold increase in apoptosis in the 
primary tumor (Selleck et al., 2003). This study suggests that IFNy acts to sensitize 
prostate cancer cells to the effects of Fas inhibition. In mouse models of metastatic 
prostate cancer, PCa xenografts showed a distinctly smaller tumour volume than those 
left untreated, even at the lowest dose (Shou et al., 2002) and mice lacking IFNy 
progress to metastasis quicker than those expressing the cytokine. These IFNy
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negative mice are as susceptible to tumour metastasis as mice lacking NK cells (Street 
et al., 2001). IFNy may be of therapeutic use for prostate cancer where it could be 
beneficial in late stage and hormone refractory disease by retarding invasion and 
metastasis. The finding that mice lacking the IFNy receptor develop spontaneous 
tumours more rapidly than those with functional receptors, indicates that IFNy is 
involved in both immune surveillance and retardation of invasion and metastasis, 
making this cytokine a true candidate for tumour/metastasis suppressor status (Shou et 
al., 2002, Nagano et al., 2003).
13 The proteome
The term proteome was coined in 1994 to describe the linguistic analogue of the 
genome, being the entire protein complement expressed by a genome or a cell/tissue 
type (Naaby-Hansen et al., 2003, Cai et al., 2004). Proteomics can be defined as the 
study of all proteins at the subcellular, cellular, tissue or even organism level (Cai et 
al., 2004). Proteomics is the large scale study of proteins, ideally proteomic studies 
seek to characterise and quantitate all proteins within a sample at a particular time 
under a particular set of environmental conditions (Fey and Larsen, 2001). However, 
proteomics is not solely used to obtain a snapshot of proteins at a given time, it can 
also be used to identify protein interactions with other proteins, DNA, or RNA, 
allowing analysis of complex biochemical pathways (Emili and Cagney, 2000). 
Studies of protein expression and interaction are not mutually exclusive, as one gives 
functional significance to the other. In proteomics, however, these studies are split 
into two disciplines “Expression proteomics” and “Functional or Cell map 
proteomics” (Blackstock and Weir, 1999). The difference between the two disciplines 
lies mainly in the techniques used and the number of proteins studied.
The term “Expression proteomics” is associated with the description of the total 
proteome of the subject, the differential expression of proteins between subjects and 
under different treatment conditions. This is sometimes denoted “discovery 
proteomics” as the researcher is seeking to identify both known and unknown proteins 
(Cai et al., 2004). Global analyses such as these require the separation of thousands of 
proteins from the original sample. The proteome unlike the genome is in a constant 
state of dynamic flux producing a mixture of heterogeneous proteins with differing
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biochemical properties and expression levels. Considering the above, analysis of the 
prokaryote proteome with its genome complement of less than 3000 genes appears 
daunting and analysis of eukaryote proteome with greater than 10,000 proteins and 
the added complication of mRNA processing and complex post translational 
modification, impossible (Zuo and Speicher, 2000). There is however, a technique 
commonly used in the global expression analysis of complex genomes which is both 
sensitive enough to give single protein resolution and discrimination of post- 
translational modifications (PTM). Proteomic methods such as 2D electrophoresis are 
the only techniques available that allow the analysis of splice variants and post 
translational modifications, as well as more conventional expression level 
quantification (Naaby-Hansen et al., 2001). Such modifications may be functionally 
critical and determine a disease, i.e. phosphorylation, glycosylation, as is the case of 
the prion diseases CJD and Alzheimer’s respectively (Banks et al., 2000). Novel post 
translational modifications, mostly phosphorylation, of several oncogene products and 
cell cycle components (including p53) have been identified in transformed liver cells 
(Yan et al., 2004). In addition to this aberrant glycosylation of several cancer 
associated proteins has also been reported, proteomics based approaches are ideally 
placed to characterise such aberrations (Banks et al., 2000).
2DGE is a gel-based assay in which proteins are separated in two dimensions, firstly 
by their isoelectric charge and secondly by molecular weight, this method has 
therefore been termed two-dimensional gel electrophoresis (2DGE). 2DGE is a 
technique developed in the early 1970’s which due to its ability to separate thousands 
of proteins at a time has become synonymous with the term proteomics (Cai et al.,
2004). Although this technique has been available to researchers for 35 years its 
application to analysis of cellular proteomes has been limited by the detection 
sensitivity of mass spectroscopy (MS). Recent technological advances such as 
electrospray ionisation (ESI) and matrix-assisted laser desorption/ionisation (MALDI) 
have, however, improved the detection limit of MS allowing 2DGE when coupled to 
MS to characterise thousand of proteins from a single sample (Cai et al., 2004).
Ideally 2DGE results in proteins separated into discrete spots, with each spot 
representing one protein, a typical gel is able to resolve 2,000 protein spots whereas 
the best gel systems presently available can resolve up to 11,000 protein spots
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(Dalton, 1999, Zuo and Speicher, 2000). This level of resolution appears appropriate 
for the quantitative analysis of the eukaryote proteome, however due to PTM and 
mRNA splicing each protein species may have a number of isoforms, which may on a 
well-resolved gel all separate out as distinct spots. This complication means that each 
of the 10,000 protein species of the eukaryote genome may be present as multiple 
isoforms, leading some to suggest that 2DGE does not have the dynamic range 
suitable for the global expression analysis of eukaryote proteomes (Zuo and Speicher,
2000). 2DGE is also limited in its sample load capacity, as the amount of sample 
applied increases the resolution of 2DGE decreases, leading to spots containing more 
than one protein and at high sample loads streaking may occur (Zuo and Speicher,
2000, Fey and Larsen, 2001). In addition, there has traditionally been a poor 
representation of certain protein species on 2D gels including proteins with high 
molecular weight, low abundance, basic and hydrophobic properties (Fey and Larsen,
2001, Naaby-Hansen, 2004).
It is thought that proteins with low abundance may be masked by other “housekeeping 
proteins” present at high levels within the cell, this can be rectified by selective 
removal of abundant proteins. This as with all pre-fractionation techniques has the 
associated risk of protein loss (Zuo and Speicher, 2000). Basic and hydrophobic 
proteins are thought to be underrepresented due to differing solubility or interactions 
with support materials in the first dimension. Many pre-fractionation techniques have 
been employed to increase the sensitivity of 2DGE including sequential extraction 
with different solvents (Thoren et al., 2002), subcellular fractionation (Lehr et al.,
2005), chromatography (Nagano et al., 2003), removal of abundant proteins (Lollo et 
al., 1999) and preparative isoelectric focussing (PIEF) (Zuo and Speicher, 2000). The 
latter technique aims to reduce the diversity and complexity of the protein mixture so 
that subsets of proteins can be resolved over complementary narrow pH range second 
dimension gels, termed the “zoom” technique (Naaby-Hansen, 2004). PIEF allows a 
higher sample volume application, better solubility and better representation of low 
abundance proteins, with a resolution limit of proteins present at 1000 copies per cell. 
The zoom technique using on average 5 gels covering an overlapping pH range, 
allows the detection of 2000-3000 spots per gel giving a total of 10-15000 protein 
spots for MS analysis (Zuo and Speicher, 2000). Despite the increased level of 
resolution pre-fractionation does have certain disadvantages. Firstly due to increased
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sample handling and risk of proteolysis pre-fractionation can lead to protein loss of up 
to 20% and as such a larger sample volume is required (Dalton, 1999, Fey and Larsen,
2001). Secondly IEF resolution in the basic range (> pH 7) is not as good as in the 
acidic range. As it is thought that one third to a half of cellular proteins have an 
isoelectric point above pH 7, this could lead to a under-representation of basic 
proteins and therefore false interpretation of expression levels (Fey and Larsen, 2001). 
Finally, all 2DGE methods have the complication of poor reproducibility, this is 
because 2D gels require a high level of technical skill to run, have no standard 
running conditions and are time and resource intense and therefore not suited to high 
throughput applications. Fluorescence labelling techniques such as difference gel 
electrophoresis (DIGE) have attempted to increase the quantitative range of 2DGE. 
This technique allows two or three samples labelled with separate fluorescent dyes to 
be run on the same 2D gel allowing direct comparison of different samples and 
avoidance of problems due to poor gel reproducibility (Naaby-Hansen, 2004). This 
technique however is disadvantaged not only by limited sample volume application, 
but also by fluorophore labelling bias.
The high variability of 2DGE makes comparison of these data within the scientific 
community difficult, the Human Proteome Organisation (HUPO) has however 
released an initiative to standardise the representation of data from human studies 
involving techniques such as 2DGE in an effort to consolidate and improve 
dissemination of data pertaining to the human proteome (Hanash, 2004). Despite its 
disadvantages, 2DGE remains the only appropriate method for quantifying changes in 
the protein profiles of cells, tissues and organisms. There are however several 
emerging techniques which seek not only to match the level of protein separation 
obtained using 2DGE but also to improve the representation of proteins poorly studied 
due to the limitations of this technique. Several of these new techniques utilise 
technological advances in MS to obtain protein identification without the 
complications of a gel-based step. An example of this can be seen in Liquid 
chromatography followed by MS, or so-called “shotgun” proteomics. This technique 
isolates proteins based on their biochemical properties, sometimes using a two 
dimensional approach, followed by MALDI or ESI MS protein identification. The 
advantages of this technique are that speed, sensitivity and scope of protein 
characterisation is increased, making the technique more dynamically flexible than
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2DGE. The main disadvantage with this technique however is its lack of quantativity, 
although this may be overcome with the advent of isotope-coded affinity tagging 
(ICAT) (Cai et al., 2004).
Surface enhanced laser desorbption and ionisation (SELDI), is also becoming 
increasingly used in global high throughput analyses, where samples are applied to 
capture chips (capture is based on varied binding surfaces such as metal affinity or ion 
exchange). MS is then performed through ionisation of the proteins directly from the 
chip (Stevens et al., 2004). The advantages of this technique over 2DGE are that 
sensitivity is increased so that only 500-1000 cells are required for protein 
identification, there is better representation of high molecular weight and basic 
proteins and that reproducibility is enhanced (Cai et al., 2004). This technology, in 
conjunction with bioinformatics, has been used in the profiling of tumour biomarkers 
in ovarian cancer, where signature protein expression patterns were able to predict the 
presence of the disease with 99-100% specificity (Petricoin et al., 2002). Despite the 
potential use of this system in high throughput applications such as cancer 
diagnostics, there remain complications in that the signature patterns used to identify 
disease differ between research groups focussing on the same disease. This may be 
due to differences in technique, the age of the equipment, or may truly represent a 
number of signature patterns all with potential as diagnostic criteria, further research 
is required before such a clinical application can be made.
Expression proteomics is a commonly used technique in cancer research as it enables 
the comparison of protein expression in normal and cancerous cells from the same 
tissue and of cells at various stages of tumourigenesis. In a recent differential 
expression analysis of proteins derived from oesophageal squamous cell carcinoma 
(ESCC) tissue 15 proteins, including manganese-containing super oxide dismutase 
(MnSOD), were found to be up regulated and the expression of five proteins including 
squamous cell carcinoma antigen 1 (SCCA1), down-regulated in cancer tissues when 
compared to normal epithelium (Qi et al., 2005). Studies such as this have not only 
provided vital information regarding protein expression in carcinogenesis and 
tumourigenesis, but have also provided a wealth of biomarkers with a potential use in 
the diagnosis, prognosis or treatment of cancer.
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Functional proteomics is a system-based approach, which directly analyses a specific 
subset of proteins that may be related in terms of function, sequence or structure. The 
central aim of this research approach is to characterize biological functions of proteins 
through their interactions with other proteins, DNA and RNA (Cai et al., 2004). These 
function-based studies have different protein separation requirements to those based 
on global analyses. Due to the nature of these studies, being the analysis of small sub­
groups of proteins, there is no requirement for the resolution of large numbers of 
proteins and therefore 2DGE is seldom used apart from in the analysis of post- 
translational modifications (PTM). Functional studies often require the protein to be 
in its natural functional conformation, a condition difficult to maintain in gel based 
systems.
Peptide or protein arrays are best suited to studies of this nature, these can represent 
all the variants of a bioactive peptide, protein family or species, an array of 
antibodies, or in fact the whole proteome of a cell/tissue or organism. These arrays 
coupled to MS can then be used to answer specific questions concerning protein or 
nucleic acid interactions, or to examine differing protein expression following various 
treatments (Fey and Larsen, 2001). These ‘non-living’ arrays can provide detailed 
information on protein interactions in detailed pathways such as those involved in cell 
signalling or enzymatic processes, there are however problems concerning 
quantitation. The main limitation of a protein array is one shared with 2DGE, the 
purification and stabilisation of a heterogeneous protein mixture (Emili and Cagney, 
2000), which may cause misrepresentation of protein species in the array. An 
additional limitation with regard to protein arrays is that proteins often function as 
part of a complex with other proteins and may be falsely represented as inert proteins 
or peptides on an array. A solution to this would be the formation of living arrays of 
cells. These would be able to address functional questions regarding thousands of 
proteins in complex pathways such as cell signalling, in which there are many multi- 
component complexes (Emili and Cagney, 2000). At present, this technique is only 
useful in simple genomes such as yeast due to their relatively low protein complexity. 
Creating yeast living arrays, however has allowed large yeast two-hybrid screens to 
identify the protein-protein interactions of 1004 proteins, some of which were 
previously unclassified (Uetz et al., 2000).
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1.3.1 The plasma membrane proteome
The plasma membrane proteome can be defined as the entire complement of proteins 
present in the plasma membrane at a specific time. The process of carcinogenesis 
leads to changes in the array of proteins present in the plasma membrane proteome. 
Changes may be seen for example, in the number or activity of growth factor 
receptors heightening growth factor responsiveness, in the number or type of ceil 
adhesion molecules expressed e.g. integrins, or in the number/activity of proteases 
present on the cell surface. Analysis of differential expression of such proteins in 
cancer is extremely important, as due to their position on the cell surface they have 
potential for use as diagnostic and/or prognostic markers and therapeutic targets. In 
the latter capacity, it may be possible to tailor treatments more specifically to the 
cancer cells and reduce the harmful side effects of anti-cancer treatments. The plasma 
membrane proteome, therefore, could not only be an indicator of the malignant status 
of the cell but also a resource for targeted cancer therapy. Research has lead to the 
identification of a number of cancer associated plasma membrane proteins, which 
currently account for 70% of all known pharmaceutical drug targets, some of which 
are in clinical use (See Table 1.2 below) (Wu and Yates, 2003).
Table 1.2. Disease specific anti-cancer therapeutics and their plasma membrane targets, adapted from 
(Adam et al., 2003)
Product Name Drug Target Cancer Treated
Gleevec abl-kinase Chronic Myeloid Leukaemia, 
Gastrointestinal stromal
Herceptin her2neu Breast
Panorex Ep-CAM Colon
IRESSA EGF receptor Non small cell carcinoma
A common feature to all of the acquired capabilities leading to the cell acquiring a 
cancer phenotype is the involvement of the plasma membrane. This is unsurprising as 
the plasma membrane (PM) is the interface between the cell and its immediate 
environment acting both as a barrier and allowing the exchange of information
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between the segregated environments. The basic structure of the plasma membrane is 
a lipid bi-layer, studded with integrally and peripherally attached proteins. These 
membrane-associated proteins confer the majority of the plasma membrane’s unique 
functions. Within the plasma membrane, further complexity is present in the form of 
subdomains called lipid rafts, enriched in cholesterol, glycosphingolipids and 
signalling molecules. These structures appear small in size but can represent a 
relatively large proportion of the PM and are thought to be involved in the regulation 
of signal transduction (Pike, 2003). It has been suggested that these sub-domains 
represent areas of increased order, with a corresponding decrease in fluidity, likely to 
be due to the lipid/cholesterol composition and abundance of transmembrane proteins 
(Pike, 2003). Further plasma membrane complexity is conferred by the aggregation of 
these lipid rafts into membrane invaginations or calveolae. This process clusters 
proteins into a plasma membrane microenvironment conducive to the initialisation of 
signalling cascades (Simons and Toomre, 2000).
In addition to its therapeutic target potential, the potential of the cell membrane 
proteome as a resource of prognostic and/or diagnostic indicators is also under 
extensive research. In PCa, a number of proteins have been discovered, the aberrant 
expression of which in can be exploited to determine the nature and progression of the 
disease. Such markers may detect early malignancy, especially in diseases with 
insidious onset such as prostate cancer. The protein PSA held promise as a 
diagnostic/prognostic marker; however the shortcomings of this protein as an 
indicator of prostate cancer have been illustrated in that it is neither organ nor disease 
specific (Charrier et al., 2001, Gao et al., 1997). Other potential markers of this 
disease have been identified, i.e. prostate specific membrane antigen (PMSA), 
chromogranin A, glutathione S-transferase pi and prostate stem cell antigen. A 
multiple marker approach may be required to overcome the shortcomings of each of 
these markers (Tricoli et al., 2004, Gao et al., 1997).
Protein based approaches have been used in the discovery of tumour markers for 
many years, from the discovery of Bence Jones proteins in the 1800’s, to the 
generation of tumour specific antibodies in epithelial cancer (Banks et al., 2000). 
Recent technological advances in the field of proteomics have led to research into a 
comprehensive definition of cancer cell membrane associated proteins. This approach
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may reveal those proteins involved in cancer progression that could be used as new 
biomarkers or therapeutic targets. The application of proteomics to cancer research 
has already proved to be as successful as genomics in generating quantitative 
expression data in the study of tumours of the liver (Chignard and Beretta, 2004), 
breast (Zhang et al., 2005), oesophagus (Qi et al., 2005) and prostate (Meehan et al.,
2002). In addition to this proteomic mapping of the vasculature of normal and 
cancerous tissue have led to the identification of drug delivery targets on the 
endothelium (Jain, 2000).
In oncology, proteomics is fast becoming the most widespread clinical application of 
research, making the technique translatable from bench to bedside. Genetic markers 
are also entering clinical practice, however some important carcinogenic changes are 
multi-factorial and unlikely to stem solely from a genetic lesion. A successful 
application of proteomics to oncology can be observed in the example of squamous 
cell carcinoma of the bladder, where several proteins unique to metastatic lesions 
were discovered. From this study, psoriacin was highlighted as a potential marker of 
the primary bladder carcinoma. An ELISA assay is currently being developed for 
psoriacin allowing its potential as a diagnostic marker to be evaluated. These 
researchers have now set up a comprehensive proteomic database for bladder 
carcinoma including profiles for both transitional and squamous cell tumours 
(Chambers et al., 2000, Celis et al., 1999)
Despite the benefits of proteomic technologies, they have yet to fulfil their potential in 
the analysis of the plasma membrane proteome. Although 30% of the human genome 
is alleged to code for membrane proteins (though not all are expressed in every cell) 
these proteins are commonly under-represented in proteomic data sets and only 30 
membrane proteins have been fully structurally characterised (Wu and Yates, 2003, 
Werten et al., 2002). This deficit of characterised membrane proteins is thought to be 
due to their biochemical nature. Integral membrane proteins are amphipathic 
containing both hydrophobic and hydrophilic regions allowing them to be retained in 
both phases of the membrane. This amphiphillic nature makes membrane proteins 
notoriously difficult to study with proteomic technologies. The main issue with such 
proteins is their solubility, especially from highly water resistant tissues such as hair 
and skin (Wu and Yates, 2003). To conduct 2D electrophoresis the proteins must first
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be solubilised in a non-ionic sample buffer, as in the first dimension proteins are 
separated on their relative isoelectric charge. Membrane proteins do not solubilise 
well in such buffers and have a tendency to precipitate at their isoelectric point 
(Naaby-Hansen et al., 2001). There are additional problems in the analysis of 
membrane proteins caused by their relative rarity. It has been suggested that these 
proteins make up only 5-8% of the proteome and as such, their expression may be 
masked by more abundant soluble proteins (Naaby-Hansen et al., 2001). Due to the 
problems with using conventional 2D gel electrophoresis techniques to analyse the 
PM proteome, many investigators have eliminated the isoelectric focussing step and 
returned to “the ageless workhorse” the one-dimensional gel (Wu and Yates, 2003), or 
favoured other non gel-based methods.
1.3.2 Proteomics and the study of invasion
The plasma membrane proteome contains a wealth of potential therapeutic targets, 
diagnostic and prognostic indicators. In relation to the present management of prostate 
cancer, there is a need for biomarkers at either end of the treatment spectrum, as early 
indicators of disease and as therapeutic targets in advanced disease. Standard 
proteomic strategies have been applied in the search for early indicators of PCa and as 
mentioned previously there are several promising targets under investigation. In 
contrast, there has been little application of proteomics to the study of advanced 
disease, for example invasion and metastatic processes in PCa. Previous research has 
included protein-based analysis of the cancer cell membrane to discover changes, 
which could contribute to an invasive phenotype. Studies of this nature have yielded 
several classes of proteins that are implicated in cancer cell invasion. The most 
studied of these are cell adhesion molecules (CAMs), endopeptidases and receptor 
tyrosine kinases (RTK’s) (Hanahan and Weinberg, 2000).
In prostate cancer, the effects of local invasion are not fatal but may cause unpleasant 
side effects such as urinary retention. Prostate cancer becomes lethal when metastasis 
occurs (Quaranta and Giannelli, 2003). This stage can only be reached through 
invasion and intravasation, as metastasis cannot occur without invasion. In PCa 
invasion often involves spread to the seminal vesicles, followed by spread to local 
lymph nodes. Prostate cancers are prone to metastasis, especially to bone, in that 80%
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of patients with advanced disease have bone metastasis (Stewart et al., 2004). There is 
no effective long-term cure for such disease and the survival ranges between 9 months 
to a year (Mazhar and Waxman, 2002). Palliative hormonal treatments can decrease 
the size of primary and secondary tumour masses, but as reported previously the 
tumour cells become increasingly androgen refractory (Mazhar and Waxman, 2002). 
It has been suggested that androgen refractory cancers are actually more invasive, this 
is possibly due to the up regulation of MMP’s (MMP2) and the conversion of 
integrins subtypes to those favouring motility (Baldi et al., 2003). Various CAM 
proteins are implicated in PCa progression, primarily the integrins and cadherins. 
Integrins are heterodimeric cell adhesion receptors, with as many varied 
combinational subtypes. Increased expression of integrins increases their adhesion to 
the ECM and therefore limits movement. Certain integrin subtypes, however, favour 
motility and cells switching expression to such proteins can be come highly invasive. 
For example in prostate cancer, cells with increased expression of a6 pi integrin are 
found to invade the seminal vesicles (Stewart et al., 2004). There also appears to be a 
shift in integrin expression in more advanced PCa, as metastatic cell lines express 
integrins that interact with the bone matrix (Stewart et al., 2004).
Cadherins are classed as cell surface adhesion glycoproteins that contain highly 
conserved sections that interact with cytosolic proteins, loss of either of these 
functional partners leads to lack of adhesion and increase the potential for invasion. E- 
cadherin is an epithelial specific calcium binding protein, loss of which has been 
implicated in the invasive process of a number of cancers. This cadherin is lost with 
increasing grade and stage in PCa (Stewart et al., 2004). Conversely, N-Cadherin, 
which facilitates cell-cell contacts, is up regulated in the advanced stages of PCa. N- 
cadherin is alleged to facilitate tissue invasion by allowing the cell to interact with the 
stroma (Mareel and Leroy, 2003). This cadherin switch is not unique to PCa or to 
cancer states, as it occurs during gastrulation in normal embryonic development 
(Mareel and Leroy, 2003).
The endopeptidase proteins implicated in invasive progression include MMP’s, 
serine, aspartic, threonine and cysteine proteases (Hanahan and Weinberg, 2000). 
Local proteolysis is facilitated by proteases outside the cell and thus these proteins are 
either localised to the membrane in an integral fashion or peripherally attached. Some
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proteases are produced in precursor form, secreted and cleaved on the cell surface, a 
process which often requires a binding site on the extra cellular face of the plasma 
membrane. These protease-binding sites are often aberrantly expressed in carcinomas, 
as increasing the binding platforms for such proteins increases the cells invasive 
potential. Annexin II is an example of such a protease binding platform implicated in 
metastatic progression (Mai et al., 2000c).
1.4 Annexins
The annexins constitute a subgroup of structurally similar calcium dependent 
phospholipid binding proteins (Gerke and Moss, 2002, Huo and Zhang, 2005, Tumay 
et al., 2005). Over fifty annexins have been described in 65 different species, thirteen 
of which occur in vertebrates, including humans and are denoted Al-13 (Tumay et al., 
2005, Gerke and Moss, 2002). The structure of A5 was the first to be solved using 
crystallography in 1990, this revealed five alpha-helical repeats wound into a right- 
handed super helix, which formed a membrane-binding domain. All annexins possess 
at least four of these 70 amino acid residue repeats (Huber et al., 1990). In contrast to 
this conserved core region, annexins possess a highly variable amino terminus which 
in certain members of the family serves as a site for phosphorylation and protein- 
protein interaction (Rety et al., 2005). Several human annexins (Al, 2 and 12) interact 
with members of a second calcium binding protein family, the SI00 proteins. 
Interactions with the SI00 proteins have been associated with the function and 
localization of annexins in both cellular and extracellular environments. In the case of 
A2 (also known as All) for example, suppression of its heterotetrameric binding 
partner S100A10 via small interfering RNA (siRNA) significantly reduces the cell 
surface expression of All (Deora et al., 2004).
Although much is known regarding the structural attributes of annexins in their ability 
to bind negatively charged phospholipids in a calcium dependent fashion, their 
functional roles within the cell remain largely undocumented. GFP localization 
studies have indicated that annexins appear to be mostly intra-cellular proteins with 
possible roles in membrane trafficking and organization (Radke et al., 2004) as they 
have the ability to shuttle between membrane and cytoplasmic compartments
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regulated by intracellular calcium concentrations (Deora et al., 2004, Gerke and Moss, 
2002).
Annexin 1 (A 1) is the most functionally characterized member of the annexin family. 
Studies have discovered Al involvement in diverse cellular mechanisms such as cell 
signalling (Croxtall et al., 2000), regulation of cell growth and differentiation 
(Elbtaouri et al., 1994) and apoptosis (Huo and Zhang, 2005). These mechanisms are 
often deregulated in cancer cells, thus Al has been implicated in carcinogenesis. 
Suppression of Al by RNA interference was recently found to block differentiation of 
erythroid cells, whilst over expression of Al increased differentiation of these cells in 
vitro (Huo and Zhang, 2005). In vivo an increase in Al expression correlates with 
differentiation in embryonic development in both mouse (Chepenik et al., 1995) and 
human cell lines (Fava et al., 1993). A direct link between Al and differentiation in 
cancer cells has been observed in the lung adenocarcinoma cell line A549, where 
induction of differentiation of these cells with phorbol 12-myristate 13-acetate (PMA) 
treatment leads to an up regulation of Al expression (Solito et al., 1998). In clinical 
specimens Al mRNA and protein expression is reduced in 79% of poorly 
differentiated oesophageal squamous cell carcinomas (Hu et al., 2004) and shows a 5 
fold reduction in breast cancer samples when compared to normal tissue (Shen et al.,
2005). The latter study did however only include a small sample size, a total of 2 
normal and 7 cancer samples, therefore their findings require confirmation in a larger 
sample. Al over expression has also been associated with carcinogenesis in 
hepatocellular carcinoma, possibly through interactions with the EGFR-MAPK-ERK 
signalling pathway (Radke et al., 2004, Huo and Zhang, 2005). In addition to its role 
in differentiation, A 1 has also been found to serve a function in the protective process 
of the inflammatory response. In normal mice treated with sub-lethal doses of 
lipopolysaccharide (LPS), Al is up regulated in epithelial cells, neutrophils and 
macrophages that are all known to be involved in protection from endotoxemia. In the 
same study when Al knockout mice were administered a sub-lethal dose of LPS, a 
toxic response, characterised by organ injury and lethality, occurred within 48 hrs. 
This could be rescued by administration of exogenous Al (Damazo et al., 2005).
Annexin II (also known as A2 and All) is a 36kD calcium dependent phospholipid 
binding protein that has been shown to be a co-receptor for several proteins including
51
endopeptidases. The most characterised role of annexin II is in the generation of the 
serine protease plasmin, a key protein in fibrinolysis (Falcone et al., 2001). In this 
capacity All acts as a binding site for the precursor plasminogen and the activator, 
tissue plasminogen activator (tPA) (Fogg et al., 2002). Annexin II is over expressed in 
leucocytes of a subset of patients having the hemorrhagic form of acute promyelocytic 
leukaemia (APL) (Rand, 2000, Deora et al., 2004). Increased surface production of 
the fibrinolytic protein plasmin by annexin II up regulation may thus be associated 
with the haemorrhagic complications in these patients (Menell et al., 1999). Annexin 
II mediated plasmin generation has also been shown to facilitate matrix invasion and 
degradation by macrophages (Falcone et al., 2001) and neurite development in 
differentiating PC-12 cells (Jacovina et al., 2001). All knock out mice display 
inefficient clearance of injury induced thrombi due to the lack of plasmin generation, 
these All null mice also display reduced activation of MMP 9 and 13 (Ling et al., 
2004). This finding further implicates All in cell matrix invasion through the 
activation or stabilisation of certain MMP’s. All is predominantly found in a 
heterotetrameric complex with the S100A10 (pi 1) protein and is located, in vivo, on 
endosomal and plasma membranes (Zobiack et al., 2002). The protein, however has 
an independent ability to bind phospholipids and can do so in monomeric and dimeric 
conformations. See Figure 1.6.
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Figure 1.6. Schematic representation o f  the structure o f  A ll, indicating binding sites for various 
factors. Adapted from (Hajjar et al., 1996).
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The All heterotetrameric complex is formed of two All and two pi 1 subunits, which 
are connected by disulphide bonds making the complex highly stable (Mai et al., 
2000c). p ll  is an llkD  member of the S I00 calcium dependent binding family of 
proteins and has no other known function other than to bind All (MacLeod et al.,
2003). This AIIpll complex, when located on the plasma membrane, has several 
alternative functions in addition to its role in generating plasmin. All is also a binding 
platform for the precursor of the cysteine protease Cathepsin B (Mai et al., 2000b). 
Annexin II is found on the surface of many cell types including neuronal cells 
(Jacovina et al., 2001), leucocytes (Menell et al., 1999), monocytes, macrophages 
(Falcone et al., 2001), endothelial cells (Chung and Erickson, 1994, Hajjar et al., 
1994, Ma et al., 2000). All is over expressed in many tumour types and also shows a 
change in localisation becoming a cell surface protease in tumour cells (Mai et al., 
2000c). In addition to stimulating the activity and providing a structural support for 
endopeptidases cell surface All is thought to play a role in cell-cell and cell-matrix 
adhesion through interaction with collagen and high affinity binding of p2- 
Glycoprotein I to endothelial cells, immunoglobulin transport, endo and exocytosis 
and Tenascin C signal transduction (Ma et al., 2000). Tenascin C is expressed during 
normal development and at sites of tissue regeneration and invasion, namely tumours 
(Ma et al., 2000). Activation of Tenascin C by All leads to a loss of focal adhesions, 
enhanced cell division and increased invasive capacity. All has also been 
characterised as a binding platform for various pathogens, such as cytomegalovirus 
and E.coli, indicating that in addition to its role in facilitating extracellular 
degradation it also acts as a receptor for the transduction of signals to the intra-cellular 
phase (Depla, 2000).
All in acting as a binding platform for proteases and ECM components (collagen and 
Tenascin C), facilitates the remodelling of the basement membrane (Ma et al., 2000). 
All present on the outer leaflet of the cellular membrane may also contribute to the 
cells invasive potential by the plasmin-mediated activation of other metallo-proteases 
(Kim and Hajjar, 2002). The presence of annexins on the outer leaflet has historically 
been a contentious issue; however, following a number of localisation studies this is 
no longer in dispute (Falcone et al., 2001, Chung and Erickson, 1994, Mai et al., 
2000a, Brownstein et al., 2003, Kim and Hajjar, 2002, Mai et al., 2000c).
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In relation to metastatic progression, All over expression on the surface of cells has 
been reported in a number of cancers including acute promyelocytic leukaemia (APL) 
(Olwill et al., 2005), pancreas (Paciucci et al., 1998), breast (Schwartz-Albiez et al., 
1993), lung (Cole et al., 1992, Brichory et al., 2001b), brain (Nygaard et al., 1998), 
HNSCC (Wu et al., 2002) and colorectal carcinoma (Emoto et al., 2001). In such 
neoplasms, surface annexin II over expression has been linked to a more aggressive 
tumour phenotype and concurrent poor prognosis (Emoto et al., 2001, Wu et al.,
2002). The potential role of All in basement membrane remodelling and its 
prevalence in aggressive tumours suggests that it is an important protein in the 
invasive potential of tumour cells. The link between All over expression and an 
aggressive phenotype was recently explored in macrophages where it was found to be 
correlated with an invasive and degradative phenotype (Falcone et al., 2001). All 
expression has been explored in a number of cancers where it has also been found to 
promote metastatic growth via the evasion of host-derived and chemo-therapeutic 
agents (Falcone et al., 2001). This research indicates that All secreted at high levels in 
sera from patients with renal carcinoma, may have an immunosuppressive effect (Mai 
et al., 2000c). This immunosuppressive effect may be necessary for the maintenance 
of surface All and therefore invasive potential, as auto antibodies to surface exposed 
All are frequently observed in patients with lung cancer (Brichory et al., 2001a). In 
addition, it has been shown that All and Activated Leukocyte Cell Adhesion 
Molecules (ALCAM) are involved in the metastatic progression of tumour cells 
following chemotherapy with adriamycin (Choi et al., 2000). All has a potential role 
in several of the stages in the multi-step process of metastatic progression, see Figure 
1.4, as due to its role in plasmin production it facilitates angiogenesis and in addition 
potentiates the invasive capabilities of this and other endopeptidases in remodelling of 
the basement membrane. The activation of Tenascin C by All aids the separation of 
the cell from the primary tumour and the presence of All in sera may assist in the 
evasion of host responses (Murphy-Ullrich, 2001). It appears that All has a 
remarkable effect on invasive capacity, this protein therefore, has a potential 
therapeutic use as a target for the restriction of invasion and therefore the treatment of 
advanced cancer.
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1.4.1 Annexin II in prostate cancer
All is over expressed in cancer cell lines and in vivo where it is commonly localized 
to areas of basement membrane invasion and metastatic foci (Liu et al., 2003a). In 
contrast, research suggests that in prostate cancer All expression is lost during the 
progression to a cancerous phenotype. The loss of All expression in prostate cancer 
cell lines has been widely documented (Smitherman et al., 2004, Baneijee et al., 2003, 
Kirshner et al., 2003, Liu et al., 2003a, Liu et al., 2003b, Fakih et al., 2002, Kumi- 
Diaka, 2002, Tekur and Ho, 2002, Chetcuti et al., 2001b). A comprehensive study of 
five normal prostate cell lines and seven cancer cell lines found that All was 
expressed strongly in the cytoplasm and nucleus of normal cells, with cancer cells 
exhibiting a reduced and altered pattern of expression. The same study found that a 
reintroduction of All to LNCaP cells, known to lack All, inhibited the migratory 
capacity of these cells (Liu et al., 2003b). This result is contrary to many studies 
indicating that over expression of All in cancer cells increases their invasive potential 
(Podgorski and Sloane, 2003, Mai et al., 2000b, Diaz et al., 2004). The expression 
pattern of All in prostate cancer cell lines is unclear, as several studies have suggested 
that reduced expression of All is observed in PC3 and DU 145 in comparison to 
normal prostate cell lines (Liu et al., 2003b). However, there is evidence to suggest 
that these two cell lines do express high levels of All (Baneijee et al., 2003). The only 
cell line consistently reported as lacking All expression is LNCaP. A recent study 
employing subtractive hybridization and Northern blot analysis of LNCaP cells 
suggests that Annexin II heavy and light chains are frequently lost in prostate cancer 
and in its precursor, prostatic intraepithelial neoplasia, due to hyper-methylation of 
the p36 gene (Chetcuti et al., 2001a). Further research however has indicated that 
hyper-methylation is not the only cause of All suppression as treatment with 5-aza- 
deoxycytidine failed to promote re-expression of All (Baneijee et al., 2003).
There have been several reports of loss of All expression in clinical tissue from 
primary prostate carcinoma. A reduction in All expression was observed in a panel of 
prostate tumour samples with Gleason grades ranging from 6-10. However, 25% of 
the samples with a Gleason score of >8 displayed focal All expression on the cell
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surface (Baneijee et al., 2003). In this study, it was alleged that All is lost in early 
stages of PCa and re-expressed at the later undifferentiated cancer stage (Baneijee et 
al., 2003). However, a subsequent study into All expression in various stages of PCa 
found that All expression decreased by 71% from BPH to androgen stimulated 
prostate cancer (AS-CaP) and declined a further 31% from AS-CaP to recurrent 
(androgen insensitive) prostate cancer (R-CaP). No evidence of All re-expression in 
advanced cancer was observed in this study (Smitherman et al., 2004). Consideration 
of the literature indicates that further research is required to explain the deregulation 
of All expression and its importance in prostate carcinogenesis and progression.
1.5 Rationale
This PhD project originated from a 2D gel-based proteomic analysis of a matched pair 
of isogenic prostate cell lines. This study consisted of global protein analysis of the 
cell lines which resulted in the identification of 22 proteins differentially expressed 
between the normal and cancer cell lines. Nine proteins were found to be down 
regulated in the cancer cell line including HSP70, Bip and MxA. Thirteen proteins 
were up regulated in the cancer cell line including Cathepsin D, gp96, HnRNP-K and 
PSMA5 (Nagano et al., 2003). This PhD project extended the characterisation of the 
isogenic cell lines through comparative analysis of the plasma membrane proteome.
The central aim of this PhD project was to analyze proteins differentially expressed 
on the surface of normal and neoplastic prostate epithelial cells using a proteomic 
approach, with a view to identifying proteins with potential value as diagnostic or 
therapeutic protein markers. The hypothesis to be tested was that there are differences 
in the plasma membrane proteome between normal and cancer cells that confer a 
determinative phenotype and are instrumental in the carcinogenic process.
The initial objective was to develop a reproducible and efficient method for extracting 
and analyzing cell surface proteins. This was required due to the poor representation 
of plasma membrane proteins commonly encountered with standard proteomic 
methods which include hydrophobic, high molecular weight and basic proteins 
(Naaby-Hansen, 2004, Fey and Larsen, 2001). The optimized cell surface analysis 
technique was then applied to the comparative analysis of the cell surface proteome of
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1542 NPTX and CP3TX cells. The 1542 NPTX and CP3TX cell lines were the 
chosen model for this analysis because due to their isogenic nature and their 
commonality in transformation, any differences in their protein expression profile are 
likely to be a result of the carcinogenic process (Bright et al., 1997). The cell surface 
proteome of these isogenic cell lines was chosen for comparative analysis because it 
not only contains factors and receptors involved in many of the signal transduction 
pathways altered in cancer cells, but also due to its accessibility in terms of providing 
diagnostic, prognostic or therapeutic targets for the management of the disease.
In addition to global analysis of protein expression in the isogenic prostate cell lines, 
the earlier work investigated the effect of stimulation with interferon a and y on 
protein expression in the isogenic cell lines. Stimulation with IFNy caused a decrease 
in protein synthesis which was 2-fold greater in the cancer cells (Nagano et al., 2003). 
Several proteins displayed differential expression in normal and cancer cell lines 
when stimulated with IFNy, these included MxA, Nmi and HnRNP-K. Approximately 
one third of the proteins in this study showing differential regulation between normal 
and cancer cells in response to IFNy had some role in endoplasmic protein processing 
and many represented the products of interferon inducible genes. This indicated that 
IFN-induced signalling pathways were possibly altered in the prostate cancer cell line 
1542CPTX (Nagano et al., 2003).
As an extension of this work, IFN signalling was studied through application of the 
optimized cell surface analysis technique to 1542 NPTX and CP3TX cells in the 
presence or absence of stimulation with IFNy. IFNy induced signalling was chosen for 
analysis due to the previous findings that this cytokine induced differential protein 
expression in cancer cells and in light of its reported potential use as a tumor and 
metastasis suppressor, in the retardation of tumourigenesis and metastatic progression 
(Shou et al., 2002, Nagano et al., 2003, Selleck et al., 2003).
The analysis of IFNy signalling identified several cell surface proteins with patterns of 
expression modulated by IFNy. One of these proteins, identified as Annexin II, was 
chosen for further characterization due to its reported role in ECM invasion and 
basement membrane remodelling, processes integral to the spread of prostate cancer 
to surrounding tissues (Falcone et al., 2001, Ma et al., 2000).
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In summary the aims of this PhD project were;
> To optimize a biochemical method for specifically extracting and separating 
membrane proteins.
> To identify the differences in expression of membrane associated proteins 
between normal and cancerous prostate cells.
> To identify any differences in the expression of cell surface proteins and those 
in the IFN signalling pathway between normal and cancer prostate cells, that 
may contribute to the difference in IFN-induced membrane protein expression.
> To investigate the functional role of key identified proteins and confirm 
differential expression using several cell lines.
Completion of these objectives should result in greater knowledge of differences in 
the cell surface proteome of these isogenic cell lines and as they share a single 
genomic origin and indicate the cell surface proteins involved in carcinogenesis or 
metastatic progression. This study should also increase the knowledge of IFNy 
signalling in these cell lines and indicate whether this cytokine could be of potential 
therapeutic use in prostate cancer.
58
2.1 Materials
Chapter 2 
Materials and Method
The following section details the materials used within this study and their source. 
The cell lines, solutions, antibodies and buffers used are also outlined.
2.1.1 Cell lines
The cell lines used in this study were primarily adherent epithelial cells derived from 
normal prostate tissue, prostate tumour or metastasis, see table 2.1.
Table 2.1. Human prostate cell lines used in this study, their origin and growth media.
CELL
LINE
ORIGIN MEDIA
1542
CP3TX
Primary adenocarcinoma (Bright 
et aL, 1997)
Keratinocyte serum free (KSFM), 5% foetal bovine 
serum (FBS), Bovine pituitary extract (BPE) 1.5ml, 0.2 
ng/ml Epidermal Growth Factor (EGF), 100 U/ml 
penicillin, 100 pg/ml streptomycin (PS).
1542
NPX
Benign Prostate epithelium 
(Bright et aL, 1997)
KSFM, 10% FBS, BPE, EGF, PS
1532 CPT Primary adenocarcinoma (Bright 
et al., 1997)
KSFM, 10% FBS, BPE, EGF, PS
1532 NP Benign Prostate epithelium 
(Bright et al., 1997)
KSFM, 10% FBS, BPE, EGF, PS
1535 CPT Primary adenocarcinoma (Bright 
et al., 1997)
KSFM, 10% FBS, BPE, EGF, PS
1535 NP Benign Prostate epithelium 
(Bright et al., 1997)
KSFM, 10% FBS, BPE, EGF, PS
PC3 Prostate cancer bone metastasis 
(Kaighn et al., 1979)
RPMI 1640, 20% FBS, PS, L-Glutamine
Pre 2.8 Normal prostate epithelium 
(Alam et al., 2004)
RPMI 1640, 20% FBS, PS, L-Glutamine PrEGM at
33°C
LNCaP Prostatic cancer lymph node 
metastasis (Horoszewicz et al., 
1980)
RPMI 1640, 20% FBS, PS, L-Glutamine
DU145 Prostate cancer brain metastasis 
(Mickey et al., 1980)
RPMI 1640, 20% FBS, PS, L-Glutamine
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The cell lines used most extensively within this study were 1542 NPX and CP3TX, a 
pair of isogenic cell lines derived from a radical prostatectomy specimen. These cell 
lines were immortalized by transduction at the third passage with a recombinant 
retrovirus encoding the E6 and E7 transforming proteins of the human papilloma virus 
(See Figure 2.1) (Bright et al., 1997). The epithelial and prostatic origin of these cell 
lines was confirmed by immunocytochemical analysis of cytokeratin and prostate 
specific marker (PSA, PAP) expression. Due to the heterogeneous nature of prostate 
cancer, primary cultures derived from fresh tumours often contain a mixture of benign 
and malignant cells. To confirm the identity of the 1542 CP3TX cell line a panel of 
eight microsatellite markers were examined for loss of heterozygosity (LOH) by PCR. 
These markers are located on chromosome 8p, a chromosomal region displaying a 
high degree of allelic loss in primary prostate tumours and thus postulated to be the 
sites of putative tumour suppressor genes (Bergerheim et al., 1991, Vocke et al., 
1996). This panel of microsatellite markers has been previously shown to detect LOH 
in microdissected prostate cancer specimens with a high degree of reliability (Vocke 
et al., 1996). 1542 CP3TX displayed LOH at four of the loci examined whilst in 1542 
NPX LOH was not detected. No LOH was detected in seminal vesicles or fibroblasts 
from the same patient indicating that the LOH was specific to the prostate cancer 
cells. 1542 CP3TX was subsequently characterised as representing a prostate cancer 
cell line (Bright et al., 1997). These 1542 cell lines therefore represent a unique 
opportunity to study the origin of cancer from a single genome perspective, where 
differences between the cell lines may be solely carcinogenic.
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Primary adenocarcinomas of the prostate resected from six patients
i
Transformed by E6 and E7 papilloma virus protein
i
Variable mixture of benign and malignant epithelium
i
Single cell cloning
i
Examine LOH to characterize and select tumour cells
i
Benign and malignant tumour cell line from same patient 
1542-NPTX(normal) and 1542-CP3TX(cancer)
Figure 2.1 A schematic representation o f  the formation o f  1542 NPTX(normal) and 1542 CP3TX 
(cancer) cell lines, adapted from (Bright et al., 1997).
The media in which the various cell lines were cultured were obtained from 
Invitrogen; all additives were available from central services in the Ludwig Institute 
for Cancer Research (LICR) except for those needed to complete KSFM, which were 
also purchased from Invitrogen. In certain experiments, it was necessary to exclude 
one or more components of the media and/or to add IFNy at a concentration of 500 
units/ml (Sigma). All cell lines were obtained from Prof. J Masters at the Prostate 
Cancer Research Centre, UCL.
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2.1.2 Source companies
This section includes the source companies for the materials and reagents used in this 
study, see table 2.2.
Table 2.2. The source companies for the materials used in this study and their location.
Amersham Biosciences Little Chalfont, Buckinghamshire, UK.
BD biosciences Oxford, UK.
Bio-Rad Hemel Hempstead, Hertfordshire, UK.
Calbiochem Nottingham, UK.
Cambrex Nottingham, UK.
GRI Braintree, Essex, UK.
Invitrogen Paisley, UK.
Merck Biosciences, Calbiochem, Novagen Nottingham, UK.
Molecular probes Paisley, UK.
New England Biolabs Hitchin, Hertfordshire, UK.
Novus Biologicals Littleton, USA.
Nunc Hereford, UK.
Perbio Tattenhall, Cheshire, UK.
Qiagen Crawley, West Sussex, UK.
Santa Cruz Biotechnology Heidelberg, Germany.
Sigma-Aldrich Ltd Poole, Dorset, UK.
Upstate Milton Keynes, UK.
VWR Poole, Dorset, UK.
Watson Marlow Falmouth, Cornwall, UK.
Zymed Cambridge, UK.
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2.1.3 Antibodies and fluorophore conjugates
This section includes the antibodies and fluorophore conjugates used in this study and 
details their source and optimised concentrations for use in various immunoassays, 
see Table 2.3.
Table 2.3. Detailing the concentrations o f  antibodies and fluorescent conjugates used for various 
experimental techniques in this study including immunodetection on Western blot (WB), 
immunofluorescence (IF) and immunoprecipitation (IP).
Antibody/ fluorophore conjugate Company Dilution 
used in 
WB
Dilution 
used in 
IF
Dilution 
used in IP
AntkABCAl rabbit polyclonal Novus Biologicals 1:100
Anti-annexin II Zymed - - 1:50
Anti-GRP 94 (gp96). Santa Cruz Biotechnology 1:3000 1:100 -
Anti-pro-cathepsin B Upstate 1:1000 - -
Anti-plasminogen Abeam 1:1000 - -
Anti-P actin Sigma 1:1000 - -
Anti-annexin II BD Biosciences 1:5000 1:100 -
Anti-annexin 11 light chain (pi 1). BD Biosciences 1:200 1:100 -
Anti-Rabbit IgG Amersham Biosciences 1:3000 - -
Calpain II (C-19). antibody Santa Cruz 
Biotechnology
1:100
Cholera toxin p subunit Molecular probes “ 1:100 -
Fluorocein goat anti-mouse IgG Molecular probes - 1:100 -
Goat anti-rabbit IgG Texas Red Molecular probes 1:100 -
Mouse IgG Amersham Biosciences
Mouse IgG, HRP-Linked Whole Ab Amersham Biosciences 1:5000
Phalloidin Molecular probes - 1:100 -
Phospho-Threonine-Proline 
Monoclonal Ab
New England 
Biolabs
1: 100
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2.1.4 Buffers
This section details the recipes for the various buffers used in this study and the 
source company of the reagents used.
Lysis Buffers
1 % Octylglucopyranoside (OGP)
1% OGP (Sigma) in 1 X PBS (Invitrogen)
1 complete protease inhibitor tablet (Amersham) per 50ml 
2D Lysis buffer
4% Chaps (Sigma)
8M Urea (Sigma)
2% NP40 (Sigma)
Complete protease inhibitor tablet, as above 
Phosphatase inhibitors (Amersham)
Leupeptin lpg/ml 
Aprotinin lpg/ml 
Pepstatin lpg/ml
Labelling Buffers
Blocking buffer
50mM NHC1 (Sigma) in lx PBS
Biotin
5mg/ml EZ-Link Sulfo-NHS-LC-Biotin (Perbio) in 1 x PBS 
5mg/ml EZ-Link Sulfo-NHS-SS-Biotin (Perbio) in 1 x PBS
Sample Buffer
62.5mM Tris-HCl, pH 6.8 (Sigma) 
20% Glycerol (Sigma)
2% SDS (Sigma)
5% P- Mercaptoethanol (Sigma)
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Running Buffer (lx)
25mM Tris
192mM Glycine (Sigma)
0.1% SDS 
pH 8.3
Live ceil immunofluorescence buffer
9.9g Hanks BSS (Cambrex)
5ml 10% sodium azide (Sigma)
50ml heat inactivated donor calf serum (Invitrogen)
4.76g Hepes free acid (Sigma)
5.2g Hepes sodium salt (Sigma)
Double distilled water (dd^O ) to 11
Western Transfer Buffer
20mM Tris 
192mM Glycine 
0.1% SDS 
20% MeOH (VWR)
Equilibration buffer
6M Urea 
2 % SDS 
1% DTT (Sigma)
30% Glycerol 
50mM Tris pH 6.8 
Agarose
0.5% Agarose (Sigma)
In lx running buffer with 0.03 % Bromophenol Blue (Sigma), added
Storage buffer
0.2% sodium azide in 1 x PBS
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Affinity chromatography buffers
Binding
1% OGP lysis buffer
Elution
lOOmM DTT 
8M Guanine HC1 (Sigma) 
Regeneration
8M Guanine HC1 
Wash buffers
1% OGP 
1% NP40
TBST
25mM Tris-HCl, pH 8.0
125mM NaCl
0.1% Tween 20 (Sigma)
Coomassie staining solution
0.2% R250 (Sigma)
40% MeOH
10% Acetic acid (VWR)
Coomassie destain
10%MeOH 
5% Acetic acid
66
2.2 Methods
The practices and procedures used throughout this thesis are described in the 
following methods section.
2.2.1 Cell Culture
All cell lines were obtained from Prof. Masters in either T-80 or T-25 cell culture 
flasks (Nunc) and detached using 0.25% trypsin (Invitrogen). The cells were split 
from one into three new flasks containing the appropriate media (see table 2.1 above). 
These cells were then incubated at 37 °C, in an atmosphere of 5% CO2 in air and fed 
twice weekly until reaching 80% confluence at which point they were either split 
again or used for experimental study. Cells were kept in continuous culture for no 
longer than 3 months or 10 passages, whichever was the sooner, to avoid potential 
phenotypic or genotypic changes associated with long-term culture. Cells were 
observed for signs of infection, overcrowding or starvation with the aid of an inverted 
microscope. All cell handling was performed in a cell culture hood with a laminar 
airflow system and aseptic technique was used to prevent IFNection. This protocol 
was adapted from (Hudson et al., 2000)
2.2.2 Counting cells
When using cells in experimental procedures it became necessary to accurately 
measure the number of cells present within a given solution. The general protocol for 
this procedure is as follows, although time to detachment differed within each cell 
line.
Spent medium was removed and trypsin added at a volume of 1ml per 25cm2. The 
trypsin was distributed over the growing surface and the excess was removed. Cells 
were then incubated for approximately 5 minutes at 37°C and observed for signs of 
detachment. When all cells were floating in the trypsin solution 10ml of medium was 
used to wash the cells from the growing surface, this solution was then transferred to a 
universal container (Nunc). The cell solution was mixed thoroughly and a 200pl 
aliquot was removed to an eppendorf tube (VWR). This aliquot was then diluted with 
200pl Trypan Blue (Sigma) and mixed thoroughly. A small drop of the diluted cell 
solution was added to both edges of the cover slip on a haemocytometer and the cells
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counted with an inverted microscope at xlO magnification. At least 100 cells were 
counted for an accurate representation of the cell population; dead cells (stained blue 
with trypan blue) were not counted. The number of cells present within the original 
solution was estimated using the following calculation.
Volume of a square = 0.1mm3 = lxlO^ml
Therefore, multiply by 10000 to get number of cells per ml
The sample was originally diluted with an equal volume of Trypan blue so to 
calculate the cells per ml the above figure was multiplied by 2, which equals 28 x 104
28 x 104 = 280,000 cells per ml
The original solution was 10ml hence;
280,000 x 10 = 2,800,000 cells in the original solution (10ml).
This protocol was adapted from (Caprette, 2000).
2.2.3 Freezing cells
To maintain long term cellular integrity it was necessary to transfer the cells to long­
term frozen storage (except the isogenic cell lines 1542, 1535 and 1532, frozen stocks 
of which were retained by Prof. Masters). The protocol for this was as follows.
The cells were cultured and counted as above, then spun down in a universal 
container and re-suspended in freezing medium consisting of RPMI + 30% FBS + 
10% DMSO. 1ml aliquots of this solution containing the cells were put into 1ml 
cryotubes (VWR) and placed in a box containing isopropanol. This box was then 
placed immediately into a -80°C freezer for 24 hrs. The final step was to transfer the 
cryotubes containing the cells into liquid nitrogen, noting the position of the aliquots.
It was necessary, when frozen cells were required, to defrost them quickly in a water 
bath to avoid formation of ice crystals that may affect the integrity and viability of the
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cells. Once defrosted the cells were transferred to a centrifuge tube, spun down, re­
suspended in the appropriate medium and transferred to a tissue culture flask. The 
cells were then cultured following the standard protocol (see section 2.2.1). Protocol 
adapted from (Wamasuriya, 2001).
2.2.4 Cell Lysis
Although several lysis buffers were used in this study, depending on the different 
requirements of the experimental procedure, the basic protocol for lysis was identical. 
The cells were observed for their degree of confluence and providing they were at 
least 70% confluent, were selected for lysis and put on ice. The old medium was 
removed and the cells were washed three times with cold lx PBS. Following the final 
wash, all traces of PBS were removed by aspiration and a volume of lysis buffer was 
added. The amount of lysis buffer added was dependent on the area of the growing 
surface and the requirement for sample concentration. The lysis buffer was run over 
the growing surface several times within 1 minute, following which the cells were 
removed from the growing surface into the buffer using a rubber scraper (VWR). 
Subsequently the lysis buffer containing the cells was aliquotted into an eppendorf 
and spun down for 1 min at 13000rpm. The supernatant was transferred to a clean 
eppendorf, labelled and then stored frozen or used immediately. The pellet, containing 
nuclear components and cell debris was also retained. This protocol was adapted from 
(Nagano et al., 2003).
2.2.5 Protein concentration assay
Following cell lysis, it was necessary to measure the amount of protein within the 
sample. The protein concentration assay varied according to the lysis buffer. 
Commonly a Bradford protein concentration assay (Perbio) was used. However, lysis 
buffers such as 1 % OGP interfere with this assay and in this case, a Lowry assay was 
used (Bio-Rad). The protocols for these assays are described in Appendix 2.
2.2.6 Biotin Labelling
To selectively enrich the cell surface protein fraction of the sample it was necessary to 
label surface proteins so they could be purified by affinity chromatography. The label
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chosen was a biotin construct that binds to proteins at their lysine residues. Two 
different types of biotin tag were used in this study, a long chain Sulfo-NHS ester, 
EZ-Link Sulfo-NHS-LC-Biotin and a reducible form with a cleavable disulphide bond 
in the spacer arm, EZ-Link Sulfo-NHS-SS-Biotin (Perbio). The cell labelling protocol 
detailed below was used for both forms.
The required solutions, biotin, blocking buffer, 1% OGP and lx PBS, were chilled in 
advance. The cells were washed 3 times in PBS to minimise contamination from 
media and cell debris during labelling, during the final wash the cells were observed 
for any loss of adhesion. The wash solution was removed, 5ml of biotin solution 
added and incubated for 5 mins on ice. Excess biotin solution was removed, the 
quench solution added and incubated for 10 mins on ice, the cells were again checked 
for signs of detachment. Following this procedure, the cells were washed again in 
PBS and left in the final wash solution. The PBS was carefully removed to prevent 
dilution of the lysis buffer and the cells lysed using 500pl 1% OGP and the protein 
concentration assayed using the Lowry method. This protocol was adapted from 
(Naaby-Hansen et al., 1997).
2.2.7 Affinity Chromatography
Samples for affinity chromatography were prepared using three T-80 cell culture 
flasks of 1542 NPX and CP3TX each containing approximately 750,000 cells. These 
cells were labelled and pooled into 500pl 1% OGP lysis buffer to increase the protein 
concentration and assayed as above using the Lowry method (see Appendix 2). A 
control sample of 1542 NPX cell lysate was prepared following the same method, 
with the exception that the cells were unlabelled. Several methods of affinity 
chromatography were compared during this study including the use of various avidin 
columns. The protocol that follows is the optimised form of affinity chromatography 
used in the majority of experiments. The elution step varies depending on the type of 
biotin used. The two alternatives used are described.
All solutions (see above under affinity chromatography solutions), were allowed to 
equilibrate at room temperature. Meanwhile immobilised Neutravidin beads (Perbio) 
were packed into three 1ml columns following the protocol described in Appendix 3.
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These columns were then clamped upright and attached to a peristaltic pump (Watson 
Marlow) at a flow rate of 0.5ml/min and equilibrated by the addition of 10ml binding 
buffer. The sample was then applied to the column and the effluent collected. The 
sample was left to incubate in the column for 30mins. Following this the effluent was 
re-applied and run-through the column. This process was repeated and the final 
effluent collected. The column was then washed with 10ml binding buffer from which 
two 5ml aliquots of the wash buffer were retained. The sample was eluted from the 
column in one of two ways, described as follows:
1. For SS biotin labelled cells, 1ml of DTT elution buffer was added and left to 
incubate on the column for 15mins. This buffer was drawn off, reserved and a further 
lml of elution buffer applied. This process was repeated once more and finally 1ml of 
regeneration buffer was added and the flow through retained. The fractions were 
pooled giving a final elution fraction of 4ml. The column was regenerated with a 
further 9mls of regeneration buffer and then stored with the addition of 5mls of 
storage buffer, at 4°C.
2. For the LC biotin labelled samples, the elution protocol was the same as above 
except using 5mls of Guanine HC1 as the elution buffer.
The protein concentration in the elution fractions was found to be extremely dilute 
and it was necessary therefore to dialyse the fractions using 10,000 molecular weight 
dialysis cassettes (Perbio) followed by vacuum concentration overnight at a low heat 
setting. The fractions were then stored as a frozen pellet, or if used immediately 
reconstituted in ddF^O and subjected to a Bradford assay (as in Appendix 2).
2.2.8 Calcium Dependent Release
For the study of cell surface All and its response to IFNy, it was necessary to devise a 
simple way of enriching the cell surface fraction of this protein in the sample. 
Enrichment was achieved using two different approaches. The first method used 
CaCb solution at 0, 0.5, 1 and 1.5mM, to compete with the calcium binding of All to 
the cell surface. Following three washes with lx PBS, 5ml of the solution was applied 
to the cells and left to incubate for 5 mins. The solution was then removed, vacuum 
concentrated and the pellet treated as described for the eluate above.
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The EDTA based method of extraction followed the same protocol as above, but used 
EDTA concentrations of 0, 0.5, 1, 5 and 50mM. This experiment demonstrated that 
0.5 to ImM EDTA provides the highest yield of cell surface AIL Therefore, the 
optimised protocol for subsequent experiments was as follows. 750,000 cells were 
required for each condition or cell line under study, which were maintained on ice 
throughout the procedure. The growing surface of these flasks was washed with ice- 
cold lx PBS three times, aspirated thoroughly and 1ml 0.5mM EDTA added. The 
EDTA solution was run over the growing surface several times for lmin. The solution 
was then removed, vacuum dried or subjected to a Bradford protein assay (see 
Appendix 2).
2.2.9 ID SDS PAGE
To resolve, characterise and identify the proteins present within the various samples it 
was necessary to separate them on a resolving gel. ID SDS PAGE was the method of 
choice because of its suitability for membrane protein analysis. In this study, a range 
of acrylamide gels were used. The formulation of these gels is shown in Table 2.4. All 
gels were either cast using the Bio-Rad (commonly) or HoefTer (longer gels for 
greater resolution) casting systems (Amersham). Large format gels were used most 
often because of their increased resolution. However, in some cases where only one 
protein required identification the mini gel protean system was used (Bio-Rad). The 
amounts below apply only to gels cast on 16x20 cm Bio-Rad plates. Other systems 
required modifications to the amount, but not proportion of the constituents listed 
below.
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Table 2.4. A Recipes for ID SDS PAGE running gels o f varying acrylamide concentrations. All values 
are in ml. B Recipe for 4.5% stacking gel, all values in ml.
A B
10% 12.5% 15%
30% Bis-Acrylamide 
(Bio-Rad).
10 12.5 15
1.5M Tris HC1 pH 8.8 (Sigma). 7.5 7.5 7.5
10% SDS (Sigma). 0.3 0.3 0.3
ddH20 12.15 9.5 9
10% APS (Bio-Rad). 0.15 0.15 0.15
Temed (Sigma). 0.02 0.02 0.02
30% Bis-Acrylamide 1.35
0.5M Tris HC1 pH 6.8 2.25
10% SDS 0.09
ddH20 5.35
10% APS 0.038
Temed 0.011
The gel mixture was prepared using the proportions given above, leaving addition of 
Temed until last to prevent premature setting and mixing well at each step. The 
mixture was then added to clamped plates of the appropriate size, pre-c leaned with 
ddH20, set in the casting system. The gel was then overlaid with enough ddH20 to 
cover the exposed top of the gel and create a straight edge. The gel was then left to set 
for 1 hour. Each resolving gel required a stacking gel, the recipe for which is shown in 
Table 2.4. Again, these amounts apply only to the larger gel size quoted above. The 
water was removed from the top of the set resolving gel and the stacking gel applied. 
A sample comb of sufficient well number and size was then added and the gel left to 
set for 30mins.
Meanwhile the samples were prepared. Accurate determination of the protein 
concentrations allowed equal protein aliquots of each sample to be prepared. These 
aliquots were then diluted with a third of the volume of 3x sample buffer. The choice 
of sample buffer, with or without reductant, depended on whether the sample 
contained reducible biotin in which case the non-reducible form was used. The
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samples were then mixed and heated to 95°C for lmin. In some cases where there was 
a necessity to resolve large proteins the heating step was omitted. For ease of 
explanation, the following applies to the Bio-Rad protean II system and was modified 
for other electrophoresis systems. Once set the sample comb was removed, the gel 
was attached to the cooling unit of the electrophoresis system. The gel was then 
placed in the electrophoresis tank and 1 x tank buffer added so that both exposed ends 
of the gel were covered and the top reservoir full. The samples were then applied to 
the gel, taking care not to cause any overspill to neighbouring wells. A volume of 
broad range rainbow marker (Amersham) appropriate to the size of the gel was also 
loaded. The electrophoresis conditions were dependent on the size of gel and the 
system used. Generally, the Bio-Rad gels were run for lhr at 40mA per gel with 
cooling and then overnight at 7mA. Some gels were run quickly at 50mA for 4 hrs 
with cooling.
The preparation of samples, casting and running of gels for mass spectroscopy was 
done solely in a clean room environment to reduce the risk of contamination. This 
protocol was adapted from (Amersham, 2005b).
2.2.10 Western Blotting
To immobilise the resolved proteins in the gel onto a medium more suited to antibody 
detection, the proteins in the gels were transferred to nitrocellulose paper using the 
wet transfer western blotting technique. For this the Bio-Rad protean II system was 
used. The nitrocellulose and filter paper were cut to appropriate size (to cover the gel 
surface) and marked in one comer for orientation of the gel. All equipment, tray, 
sponges, frames and tank, were washed in ddFbO. The sponges and nitrocellulose 
were then soaked in a volume of transfer buffer large enough to submerge the frames 
and sponges in a tray or container. The frames were then submerged in transfer buffer. 
The gel was removed from the electrophoresis tank and from the plates and the 
stacking gel portion (or agarose and IEF strip in the case of 2D gel electrophoresis) 
was carefully removed. The western transfer materials were then compiled, 
submerged in transfer buffer in layers of the following:
- Frame
- Foam
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- Filter paper
- Gel
- Nitrocellulose (orientating the mark on the paper with a feature of the gel).
- Filter paper 
Foam 
Frame
Once the layers were assembled, a clamp was applied and the frame was taken out of 
the buffer and placed in the western transfer tank, ensuring that the gel side faced the 
negative electrode. The tank was then filled to the top with 1 x transfer buffer and run 
either for 3 hours with cooling at 300mA, or overnight at 60mA. Once transferred the 
gel was discarded, the membrane washed in TBS-T and stored in dry, protective 
conditions. This protocol was adapted from (Amersham, 2005d).
2.2.11 Coomassie staining
To visualise the proteins directly whilst still in the gel it was necessary to apply a 
general protein stain. Coomassie blue was chosen for its ease of use, there follows a 
description of the two main coomassie staining methods used in this study.
Standard Coomassie staining
The gel was removed from the electrophoresis apparatus and glass plates and the 
stacking gel removed. The gel was then put into a clean plastic tray, covered with 
100ml of filtered coomassie blue solution and left to incubate overnight on a rocking 
platform at slow speed. Following this the coomassie solution was carefully removed 
and the gel was washed in de-stain solution until the background appeared reasonably 
clear. The gel was then ready for scanning, quantitation of bands, or cutting of bands 
for mass spectroscopy. The latter required all preparation, running and staining of gels 
to be done in a clean room environment. This protocol was adapted from (Amersham, 
2005c).
Biosafe Coomassie staining
This method was used when more sensitive detection of proteins was required. It also 
has the added benefit of requiring less incubation time. The manufacturer’s protocol 
used in this study is described in Appendix 34.
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2.2.12 Silver Staining
When extremely sensitive protein detection was required, silver staining was 
performed. As the usual method is not compatible with mass spectroscopy, a modified 
form of staining was used. This protocol was based on the Shevchenko technique 
(Shevchenko et al., 1996) and is described in Appendix 5.
2.2.13 2 Dimensional Gel Electrophoresis (2DGE)
To analyse certain proteins more thoroughly, especially with regard to their post 
translational modifications, it was necessary to perform 2DGE to separate proteins 
depending on their isoelectric point and mass. The protocol for this is described 
below.
First dimension/ Isoelectric focussing (IEF)
The first step of 2DGE was performed on Immobiline dry strip gels (Amersham, Bio- 
Rad) of varying pH range. Those most frequently used in this study were pH 3-10 or 
3-6. The gels were thawed, labelled and left on a glass plate, while the other reagents, 
including mineral oil, IPG buffer (Amersham) or Ampholyte mix (Bio-Rad), 2D lysis 
buffer and bromophenol blue were brought to room temperature. The strips were re­
hydrated before use in a solution containing:
IPG buffer/ampholyte mix at 2% of the final volume 
Sample at a concentration of 150 pg/pl
2D lysis buffer* up to a final volume of 300-350pl (depending on strip size)
* = 2D lysis buffer with bromophenol blue added at a concentration of 2pl per 5ml
This solution was prepared, mixed and loaded into the sample groove of a re-swelling 
tray (Bio-Rad). The corresponding labelled strip was then removed from its protective 
covering and carefully placed gel side down in the re-swelling tray groove. 
Approximately 2mls mineral oil was then added on top of the strip to exclude all air. 
The strips were then allowed to re-hydrate overnight undisturbed.
76
Once re-hydrated the strips were ready for IEF using the Bio-Rad Multiphor system. 
Preparation for IEF involved cleaning all equipment with ddFhO and cutting filter 
paper wicks (Bio-Rad) for each end of the strip and moistening them with ddH20 . 
The electrophoresis platform was then made ready by the addition of 15ml mineral oil 
(Amersham) and positioning of the glass electrophoresis plate to exclude as much air 
as possible. Oil was added to the inside of the plate and the strip divider was applied, 
again excluding as much air as possible. The re-hydrated strips were then placed in 
the correct orientation gel side up in the grooves of the strip divider and the wicks 
added extending 3mm onto the surface of the gel. Electrodes were then attached on 
top of the wicks 2mm from the start of the gel. Mineral oil was added so that the 
wicks were submerged and IEF was performed as below using a gradient current 
increase:
300V 5mA 10W 1 hr
300V 5mA 10W 2 hrs
3500V 5mA 10W 3 hrs
3500V 5mA 10W 19 hrs
300V 5mA 10W 2 hrs
Second Dimension
The second dimension was similar to ID SDS PAGE with the exception that gradient 
gels were used and the sample was applied in the form of an IPG strip. The gels for 
the second dimension were cast using a gradient former and multiple casting tank 
(Bio-Rad). The recipe for casting the 18x20cm gradient gels used in this study is 
shown in Table 2.5 below.
Table 2.5. Recipe for 9-16% gradient gel, values are shown in ml.
9% Chamber 16% chamber
30% Bis-Aery lamide 8.9 15.8
1.5mM Tris HC1 pH 8.8 7.4 7.4
ddH20 13.3 6.4
10% SDS 0.3 0.3
Temed 0.0118 0.0118
10% APS 118.2 118.2
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The glass plates were placed into the multiple casting chamber separated by plastic 
films to allow ease of separation. The top of the chamber was added and attached to 
the gradient former. The gradient former was then placed on a stirring platform 5cm 
higher than the casting chamber, with the connecting tube clamped. The 9% and 16% 
solutions were prepared (excluding APS) and were added to separate chambers and 
whilst stirring the APS was added. Subsequently the communicating valve between 
the two solutions was opened and the connecting tube unclamped. The plates were 
filled to 1 inch below the top of the plate and overlaid with ddFhO as for ID SDS 
PAGE gels. These plates were labelled and left covered overnight in a cold room, to 
allow full polymerisation of the acrylamide. Before application to the gel, the IPG 
strips required treatment with equilibration buffer. The strips within the strip divider 
were placed in a plastic container and covered in 100ml equilibration buffer. Filter 
paper wicks were added to each end of the strip and clamped and the strips were then 
left on a rocker for 30 mins with a buffer change halfway through.
The gels for the second dimension were prepared by removal of the ddF^O overlay 
and addition of 0.5% agarose solution to the top of the plate. The strips were removed 
from equilibration buffer and blotted to remove excess fluid. Each strip was then 
added to a gel using forceps, noting the orientation, pushing the strip to the bottom of 
the agarose so that it sat on the top of the gradient gel. The agarose was then left to set 
and the Bio-Rad Protean II system was prepared as for 1D SDS PAGE. The gels were 
then applied to the electrophoresis apparatus and run using the same settings as 
mentioned previously for SDS PAGE. Following the completion of the second 
dimension, the gels were subjected to western transfer. This protocol was adapted 
from (Amersham, 2005a).
2.2.14 Immunodetection of proteins bound to nitrocellulose membrane
There follows the general scheme of immunoblotting used in this study. Primary 
antibodies were each used at their optimal dilutions (see table 2.3) and secondary 
antibodies were used at a dilution of 1:5000.
The nitrocellulose membrane was re-hydrated in TBST for 15 mins and then put into 
blocking buffer for 1 hour at room temperature or overnight at 4°C. The choice of 
blocking buffer was dependent on the primary antibody used, antibodies to phospho-
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proteins for example required blocking in BSA. Following blocking, the membrane 
was transferred to a solution containing the correct dilution of primary antibody, in 
TBST and left for 1 hr at room temperature or overnight at 4°C. Some antibodies 
required the addition of 2% blocking protein to the primary antibody to limit 
background interference. The membrane was then washed three times in TBST for 5- 
lOmins each wash. After washing, the secondary antibody was diluted in TBST, 
added to the membrane and incubated for 1 hr at 20°C. The membrane was washed as 
before and the antibody signal detected using enhanced chemiluminesence (ECL) 
detection reagent kit (Amersham). The membrane was incubated in ECL for 1 min 
following which excess fluid was removed and the membrane placed face down in a 
plastic folder excluding all air. The membrane was then placed right side facing into 
an x-ray film cassette and taken to a dark room where blue Fuji film (GRI) was 
exposed to the blot for 1, 5, 20 and 60mins. These exposure times were adjusted 
depending on the strength of signal. The films were processed automatically in the 
majority of cases.
Following immunodetection the membranes were either washed in TBST and stored, 
or placed in stripping buffer for 2 x 30mins to remove the antibodies, rejuvenating the 
membrane for subsequent immunodetection. This protocol was adapted from 
(Amersham, 2005d).
2.2.15 Immunofluorescence
In this study two main immunofluorescence techniques were performed, the choice of 
which depended on the protein localisation requirements of the experiment.
Paraformaldehyde fixation
The first technique used fixation of cells grown to 60% confluence on cover slips in a 
24 well plate, with 4% paraformaldehyde. These cells were initially washed three 
times in lx PBS and then fixed for lOmins. The cover slips were then washed three 
more times, put into 1ml of blocking buffer and incubated for 30mins at room 
temperature. The primary antibodies were prepared in lx PBS at the appropriate 
dilution (see table 2.3) and applied to the cells for 1 hr at 20°c. Subsequently the cells 
were washed three times, fluorophore-conjugated secondary antibody added and
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incubated for lhr at 20°C. The cover slips were then given a final three washes and 
mounted on a microscope slide with Mowiol mountant (Sigma). The slides were 
stored at in the dark at 4°C for no longer than 3 days before viewing. This protocol 
was adapted from (Wojciak-Stothard et al., 1998).
Live cell immunofluorescence
Live cell immunofluorescence was used when it was necessary to observe the cell 
surface localisation of All and pi 1 and their interaction with lipid rafts and the actin 
cortex. The cells were cultured on glass cover slips in a 24 well plate. After 24 hrs, 
IFNy was added to half the wells and the cells left to incubate for a further 24hrs. The 
cells were then washed three times with ice cold 1 x PBS and incubated with the 
correct dilution of primary antibody for 1 hr at 20°C. The cells were washed again 
three times in lxPBS and incubated at 4°C with FITC-conjugated cholera toxin B 
(Molecular probes) for 30mins. The wash procedure was repeated and the cells fixed 
with 4% paraformaldehyde (see above). A further 3 washes were performed and the 
cells were permeabilised with 0.2% TX100 (Sigma) for 6 mins. A further wash step 
was performed in triplicate after which blocking solution was added to the cells for 
30mins. Following this, the correct fluorophore-conjugated secondary antibody and 
phalloidin were added to the cells at the appropriate concentrations and incubated for 
1 hr at room temperature. A final wash step was performed, after which the cover 
slips containing the cells were mounted cell side down onto microscope slides using 
Mowiol mountant. The slides were stored in the dark at 4°C for no longer than 3 days 
before viewing. This protocol was adapted from (Groves, 1992).
2.2.16 Cell invasion assays
In this study a technique was required that would assay the invasive potential of 
cultured cells, for this the Biocoat matrigel invasion chamber system (BD 
biosciences) was used. 750,000 cells at 70% confluence in a T-80 tissue culture flask 
were incubated with or without IFNy for 24 hrs. The invasion chambers were thawed 
and a coating of fibronectin (50pl of fibronectin at a concentration of 0.01 mg/ml in 
1 % PBS) (Invitrogen) was applied to the base of the chamber and left to dry for 1 hr. 
The matrigel inside the chamber was then re-hydrated with the appropriate medium 
lacking serum, but including 0.1% BSA, with or without IFNy, for 1.5 hrs. The cells
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were detached from their growing surface by addition of 3ml of cell dissociation fluid 
(Sigma) and counted using the above protocol. Aliquots of 2 x 105 cells in 250pl were 
then prepared in the appropriate serum free medium plus or minus IFNy. Excess 
medium from the re-hydration of the matrigel was removed and the transwell 
chambers were placed into a 24 well plate. In this plate 500pl of the medium plus or 
minus IFNy, was added to the wells, underneath the chamber. The 250pl cell aliquot 
was then added to the top of the assay chamber, following which the plates were 
covered and incubated for 24 hrs at 37°C in 10% CO2 in air After this time period, the 
membranes at the bottom of the chambers were washed three times in media plus 
0.2% BSA. The cells remaining in the upper chamber were removed with a cotton 
swab. The membranes were fixed for lOmins in 4% paraformaldehyde and stained in 
haematoxylin solution for an additional lOmins. After rinsing in lx PBS the 
membranes were then either placed in storage buffer and kept at 4°C, or counted 
immediately. Quantitation of migrant cells was performed by counting 6 random 
fields on each membrane at x20 magnification. This protocol was adapted from 
(Falcone et al., 2001).
The invasion assay protocol was adapted for both an assay of invasive capacity with 
exposure to an anti-AII antibody and transfection of LNCaP with a GFP All 
construct. In the first case the alterations to the protocol included re-hydrating the 
matrigel with media plus or minus 25pg/ml Anti-AII antibody (Zymed) incubated at 
4°C. This medium was also used in the bottom of the wells, to incubate cells for 
15mins before detachment and in the suspension of cell aliquots. The control for this 
experiment involved the addition of anti-mouse IgG at 25pg/ml (Amersham) in place 
of the All antibody used above. In the GFP transfection study, the same protocol was 
used, with the exception that the cells were obtained ffom a 24 well plate, were not 
stained with haematoxylin and the migrant cells were counted using a fluorescence 
microscope. This protocol was adapted from (Falcone et al., 2001).
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2.2.17 Transfection of LNCaP cells with a green fluorescent protein All (GFPAll) 
construct
To examine the effect of All expression in LNCaP cells, the cells were transfected 
with an All GFP construct or with the GFP vector alone as a control. The cells were 
then observed for GFP expression and subjected to an invasion assay.
Bacterial transformation
A small aliquot of the wild type All construct was obtained from Dr S Moss 
(Merrifield et al., 2001). The GFP construct was based on the pEGFP-Cl plasmid 
vector, a diagram of which can be seen in Figure 2.2. This plasmid encodes a variant 
of wild type GFP and resistance to kanamycin and neomycin. The plasmid DNA was 
amplified by transformation into competent E. Coli JS4 cells, in the following 
manner. The bacteria were removed from storage at -80°C and defrosted on ice, lp l 
of GFPAII DNA was then added to a lOOpl aliquot of bacteria, left to incubate for 30 
mins on ice and the bacteria were transformed using a heat shock of 45 secs at 42°C. 
The samples were then left for 2 mins on ice, following which 500pl Luria Broth 
(LB) (Qiagen) was added. This mixture was incubated for lhr at 37°C, whilst pre­
prepared bacterial plates, containing agar, LB and 30pg/ml Kanamycin, were warmed 
in a 37°C oven. Following incubation a 150pl aliquot of transformed bacteria was 
spread onto the bacterial plate using a glass spreader. The plates were incubated 
inverted for 12-16 hrs. Colonies were then selected, placed in 2ml of LB medium and 
left to incubate overnight. Plasmid DNA extraction was performed by means of a 
maxi prep kit (Qiagen), the protocol for which is included in Appendix 6. DNA 
concentration and purity were quantified by reading absorbance at 260/280nm using 
UV spectrotrometry. The entire DNA used for transfection had a purity reading of 
over 98%. This protocol was adapted from (Qiagen, 2005a).
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Figure 2.2. A schematic diagram of the pEGFP-Cl vector (BDBiosciences, 2005).
LNCaP transfection
The transfection of LNCaP cells with the GFPAII construct and vector only (BD 
biosciences) followed the same protocol. The LNCaP cells were plated into a 24 well 
plate containing cover slips at a density of 71,250 cells per well, appropriate medium 
was then added and the cells were allowed to adhere overnight. The transfection was 
performed using FuGENE 6 reagent (Roche) the protocol for which is included in 
Appendix 7. A ratio of 9:1 FuGENE reagent to DNA was used, adding 1.8pl 
FuGENE to 0.4 pg DNA. The cells were observed 18 hrs following transfection and 
then either fixed in paraformaldehyde (see section 2.2.15), or re-transfected with 
either GFPAII or empty vector following the same protocol and subject to an invasion 
assay, (see notes at end of section 2.2.16). This protocol was adapted from (Roche, 
2005a).
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Chapter 3 
Characterisation of cell surface proteins differentially expressed by 
normal and neoplastic prostate epithelial cells
3.1 Introduction
The analysis of the plasma membrane proteome requires strategies optimised for the 
enrichment of rare, relatively insoluble proteins. Many strategies have been employed 
to analyse cell surface proteins from radio-labelling with I or H (Naaby-Hansen et 
al., 2003), to complex three-dimensional crystallisation analyses (Werten et al., 2002). 
Recently however, vectorial labelling with less hazardous compounds, such as 
fluorophores and biotin, followed by affinity chromatography has been employed in 
the enrichment of this protein fraction (Naaby-Hansen et al., 2003).
A long chain sulphonamide ester of biotin, called Sulfo-NHS-LC-Biotin, has been 
successfully used to study spermatozoa cell surface proteins. In this study, 98 sperm 
cell surface proteins were identified, 22 of which were phosphorylated, including 
several novel protein identifications (Naaby-Hansen et al., 1997). Tagging with biotin 
derivatives, as opposed to His, FLAG or HA tagging, is advantageous, as the addition 
of the sulpho group makes the biotin impermeable to the cell, thus limiting unwanted 
intracellular labelling. In one of the first studies to employ biotin labelling, it was 
found that this labelling technique minimised cytoplasmic contamination (Busch et 
al., 1989). The study of membrane proteins is commonly hampered by their insoluble 
nature, biotin labelling also increases the solubility of the compounds it is associated 
with, a quality which is a distinct advantage as success in purification of membrane 
proteins depends on solubility (Viard et al., 2002).
The use of the biotin tags such as Sulfo-NHS-LC-Biotin is however, of limited use in 
proteomics as the tag itself can lead to the generation of multiple isoforms due to the 
negative charge it carries. This can be avoided by the use of a reducible biotin 
derivative, such as Sulfo-NHS-SS-Biotin, which can be removed before protein 
separation (Werten et al., 2002, Naaby-Hansen et al., 2003). This reducible form of 
vectorial labelling has been successfully used to analyse cell surface protein
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composition, one of the first applications being the analysis of cell surface proteins on 
rat hepatocytes (Busch et al., 1989).
Biotin is a small co-enzyme synthesised by bacteria, plants and some fungi (Cronan, 
1990). Biotinylated proteins are rare in nature, it is estimated that there are only 4 
mammalian proteins with this modification (Cronan, 1990). These are acetyl coA 
carboxylase (Chandler and Ballard, 1988), pyruvate carboxlyase, methyl crotanyl- 
CoA carboxylase and propianyl CoA carboxylase (Robinson et al., 1983). The rarity 
of endogenous biotinylated proteins indicates that biotin labelling provides a specific 
way of tagging surface proteins with little to no background from endogenously 
biotinylated molecules (Cronan, 1990). Avidin has an extremely high affinity for 
biotin, therefore avidin-biotin affinity chromatography is an efficient, high yield 
method of cell surface protein purification (Werten et al., 2002).
Pre-fractionation steps, such as affinity chromatography, are often used in proteomics 
to decrease the diversity and complexity of a protein mixture, giving a sample 
enriched in the number and concentration of a desired subset of proteins (Naaby- 
Hansen et al., 2001). Biotin-avidin affinity chromatography has been improved by the 
engineering of monomeric avidin columns with a decreased affinity for biotin, 
allowing competitive elution with free biotin. These columns however, are prone to 
degradation by protease and reducing agents. Therefore a streptavidin tetrameric 
column has been developed which has superior stability (Cronan, 1990).
The aim of this study was to characterise the differential protein expression of an 
isogenic pair of prostate cell lines (1542 NPX and CP3TX), using biotin labelling and 
affinity chromatography. Each step including lysis, labelling and affinity 
chromatography, was optimised to find the most effective method of obtaining a 
sample enriched in cell surface proteins. These proteins were then characterised by 
mass spectroscopy.
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3.2 Methods and Results
3.2.1 Identification of surface proteins
Cell surface proteins differentially expressed between 1542 NPX and CP3TX cell 
lines were analysed by the use of biotin-avidin affinity chromatography. This was 
achieved through optimisation of the manufacturers affinity chromatography protocol 
(Perbio) to give an enriched cell surface protein yield in the sample. This enrichment 
was necessary due to the inefficient resolution of ID SDS PAGE as with this 
technique many protein species may be present in a single band. 1 dimensional SDS 
PAGE was the chosen technique for protein separation, as the increased resolution of 
2DGE systems is outweighed by the difficulty of resolving hydrophobic proteins 
(Thoren et al., 2002). Due to the protein complexity in ID SDS PAGE gel bands, to 
achieve a protein concentration appropriate for mass spectroscopy identification it 
was necessary to increase the biotinylated protein yield from pre-fractionation to a 
concentration that was easily observable with coomassie staining. Once this goal was 
achieved, bands were cut and sent for analysis by mass spectroscopy.
3.2.2 Biotin labelling
Two biotin derivatives were considered for use in this study, namely Sulfo-NHS-LC- 
Biotin (LC) and Sulfo-NHS-SS-Biotin (SS). These two labelling compounds were 
compared for efficiency and yield of putative cell surface proteins. Three T-80 cell 
culture flasks each containing approximately 750,000 cells for both 1542 NPX and 
CP3TX cell lines were labelled with either LC biotin or SS biotin and three flasks of 
each cell line were left unlabelled as a control. The cells were lysed in 1% OGP lysis 
buffer and the lysates fractionated over neutravidin columns, according to their 
elution conditions (see section 2.2.7). The samples were resolved on 12.5% gels, run 
in duplicate for coomassie blue staining or western transfer. This experiment was 
repeated in triplicate. Representative gel images are shown in Figure 3.1. The 
neutravidin columns were recycled for use in all three replicates.
The results of these studies indicate that in the gels containing SS biotin samples 
(Figure 3.1 A.), there are a large number of bands within the control lanes, which
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appear to increase in number and density in each replicate. These bands may represent 
unlabelled proteins binding to the neutravidin beads or support. There are however, 
bands present within the sample lanes which are absent in the control, which may 
represent cell surface proteins. The LC gels did not contain enough protein to be 
observed by coomassie staining. The biotin labelled proteins in these gels could only 
be visualised on immunoblotting with avidin. On the LC biotin labelled gels there 
were also bands within the control lanes, although far more bands were present in the 
labelled sample lanes (see Fig.3.1 B).
Labelling with SS biotin gave a yield of putative cell surface proteins high enough for 
detection by coomassie staining and this therefore was the labelling method of choice. 
Further optimisation was required, however, before this technique could be applied to 
the characterisation of cell surface proteins. Background contamination in the control 
samples made it extremely difficult to observe differentially expressed proteins 
between the normal and cancer samples. In the affinity chromatography protocol the 
wash step is required to remove any contaminating non-labelled material. To optimise 
this step of the protocol, the final elution product following application of several 
different wash solutions were compared. Eight T-80 cell culture flasks each 
containing 750,000 unlabelled 1542 NPX cells were lysed with 1% OGP and split into 
three aliquots. These samples were then run over three newly formed neutravidin 
columns, washed with each of the following made up in lx PBS;
8M urea+ SDS+ 1% OGP 
0.5% SDS 
0.1% OGP
The proteins present within the elution fraction following affinity chromatography of 
the unlabelled samples were resolved on a 12.5 % gel and visualised by coomassie 
staining. This experiment was repeated in duplicate and a representative gel is shown 
in Figure 3.2.
Unexpectedly, the wash buffer 1% OGP used in the original cell labelling 
experiments gave the elution fraction with the least background contamination. The 
most stringent wash containing 8M urea gave the most contaminated sample. It was
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therefore concluded that in the initial labelling experiments, recycling of the 
neutravidin columns led to a build up of contaminating proteins observed as bands in 
the control unlabelled sample. The results of the wash buffer study suggested that 
using a fresh column and washing with 1% OGP gave the cleanest elution fraction. 
The optimised features of SS labelling and 1% OGP wash buffer were therefore added 
to further improve the affinity chromatography protocol.
3.2.3 Lvsis conditions
The cell lysis conditions were optimised using 150,000 cells from each of the 1542 
NPX and CP3TX cell lines at 70% confluence labelled as per protocol with LC biotin 
(see section 2.2.6). The yield of biotinylated protein was examined using two different 
lysis buffers, 1% NP40 and 1% OGP. Both of these buffers provide a gentler method 
of membrane solubilisation than the more frequently used detergent SDS (Roche, 
2005b). Following labelling, the cells were lysed with 500pl of either detergent and 
the protein concentration analysed according to the Lowry protocol (see Appendix 2). 
Protein concentrations were higher in NP40 lysed cells at 2.0mg/ml, compared to 0.8 
mg/ml in OGP treated cells. The samples were then resolved on a 12.5% gel subject 
to SDS PAGE. The proteins were transferred from the gel to a nitrocellulose 
membrane by Western transfer. The membrane was then probed using IIRP- 
streptavidin and visualised with ECL. This experiment was repeated in triplicate. 
Figure 3.3 shows a representative result.
Although it appeared from the Lowry assay that NP40 gave a better protein yield, the 
avidin blotting showed that 1% OGP solubilised a greater number and range of 
biotinylated cell surface proteins. The NP40 lysis appeared to yield biotinylated 
proteins in the range of 75 to 160kD, whereas OGP lysis allowed resolution of 
biotinylated proteins from 15 to 160kD. Differences in the surface composition 
between 1542 NPX and CP3TX cells lysed with 1% OGP were also apparent on the 
avidin blot featured in Figure 3.3A. The greater yield in range and quantity of 
biotinylated proteins using OGP lysis buffer is probably attributable to its ability to 
solubilise membrane proteins sensitive to hydrophobic environments. This detergent 
was therefore chosen as the lysis buffer for solubilizing proteins for affinity 
chromatography.
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The results of the above experiments were used to create an optimised protocol (see 
sections 2.2.6 and 7) that could be employed for the pre-fractionation and cell surface 
enrichment of samples for 1D SDS PAGE analysis.
3.2.4 Surface protein identification
Once the labelling and affinity chromatography protocol had been optimised it was 
possible to apply this protocol to the pre-fractionation of 1542 NPX and CP3TX 
samples and run long Hoeffer 12.5% gels to obtain maximum resolution of the surface 
protein enriched sample. Samples from three T-80 tissue culture flasks each 
containing 750,000 1542 NPX or CP3TX cells were labelled with SS biotin and lysed 
with 1% OGP. 50pg of each 1542 NPX and CP3TX sample were run against the same 
quantity of unlabelled sample (lysate from 2,250,000 NP cells) as a control and 
duplicate gels were run for coomassie blue or silver staining. All running and staining 
of these gels was performed as per protocol, (see sections 2.2.9 and 2.2.11) with the 
exception that all preparation, running and staining was performed in a clean room 
environment. This location was necessary to minimise the protein contamination of 
bands cut from the gels so that any samples being sent for mass spectroscopy analysis 
would be as free from contaminating protein as possible. Representative gel images 
can be seen in Figure 3.4.
The stained gels were screened for bands absent from the control and showing 
apparent differential expression between 1542 NPX and CP3TX. Sample bands were 
cut from several gels representing replicates of the above experiment and the proteins 
were identified by Nano-HPLC-ESI-MS/MS by the Mass spectroscopy group at 
Ludwig Institute for Cancer Research (LICR). The results of the protein identification 
are shown in Tables 3.1 and 3.2.
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Table 3.1. Cell surface associated proteins identified via Nano-HPLC-ESI-MS/MS from 1542 NPX 
and CP3TX cell surface protein enriched lysates.
Protein MW (kD). Postion
in
Figure
3.4
Location Function
4F2 heavy chain antigen 58 4-7 Transmembrane Amino acid transport
A tyrosine kinase 110 T ransmembrane Cell signalling
Annexin III 36 11 Peripheral Signal transduction
Aminopeptidase 80-90 6 Peripheral ECM modulation, Signalling
BiP 70 Membrane Molecular chaperone
3-Galactosidase 4,6,7 Peripheral Lysosomal hydrolase
Calnexin 90 6 Plasma membrane, assoc 
lipid rafts
Molecular chaperone
CD9 26 14 Transmembrane Cell adhesion
CD 109 160 2 GPI anchored Cell-cell interactions
CD44 44 -  larger
splice
variants
2-4 Cell surface glycoprotein, 
lipid rafts
Cell adhesion
CTL2 80 6 Transmembrane Cell signalling
E-Cadherin 95 4 Transmembrane Cell adhesion
EGF receptor 138 1-2 Transmembrane Growth signalling
Emmprin 29 9 Peripheral Induction o f  MMP’s
Ephrin type A 110 4 Transmembrane Cell signalling
F ll receptor 33 10 Integral Cell signalling, adhesion
gp96 92 6 Peripheral Molecular chaperone
Glucosidase 11 60 6 Transmembrane Chaperone, glucose trimming
HSP 70 71 8 Peripheral Molecular chaperone
HSP27 27 Plasma membrane Cell adhesion
HSP60 60 9 Mostly mitochondrial, 
observed on plasma 
membrane
Expressed on cell surface in 
infection, autoimmune disease and 
in tissue culture
Integrin alpha 2 130 3 Transmembrane Cell adhesion
Integrin alpha 3 130 4 Transmembrane Adhesion, Migration, Signal
Integrin alpha 5 110 4 Transmembrane Cell adhesion
Integrin fll 91 1-5 Transmembrane Cell adhesion
Integrin 04 200 1 Transmembrane Cell adhesion
Integrin 06 89 4 Transmembrane Cell adhesion
LAR receptor 211 7 Transmembrane Signal Transduction
MEMD 65-100 4-5 Transmembrane Cell adhesion
Neuropilin like protein 85 4 Transmembrane Cell signalling
Porin 1 30 11 Transmembrane Voltage gated ion channel
Porin 2 33 11 Transmembrane Voltage gated ion channel
Prostagladin F2 receptor 99 4 Transmembrane Cell signalling
Scavenger receptor B1 62 7 Transmembrane Lipid and lipoprotein receptor
SCYLP 21 14 Peripheral Protein folding
Thioredoxin 13 Peripheral Formation o f S-S bridges
Transglutaminase 2 80 7 Plasma membrane 
localizes with HSP27 in 
keratinocytes.
Cell adhesion, spreading, cell- 
matrix interactions
VLA-3 alpha 115 4 Transmembrane Cell adhesion
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The cell surface analysis of 1542 NPX and CP3TX cells resulted in the identification 
of 69 proteins by Nano-HPLC-ESI-MS/MS, of which 35% were integral membrane 
proteins and 21% peripheral membrane proteins (see Table 3.1). However, MS 
analysis revealed a high level of complexity in several of the protein bands excised, 
with non-membrane proteins also present (see Table 3.2). These non-membrane 
proteins may represent proteins associated with membrane proteins, or artefacts due to 
sample contamination. The presence of various keratins indicates that the latter may 
be the main causative factor. Although the bands excised were selected on the basis 
that they appeared to show differential expression between the two cell lines, the 
complexity of these bands negates any inference regarding relative expression levels 
of individual proteins from the normal and cancer cells. To quantitate the relative 
expression of individual proteins, sensitive immunotechniques are required. These 
techniques are however, limited by the availability of discriminatory primary 
antibodies. Due to this limitation and time constraints, further analysis could only be 
conducted for two of the identified proteins.
Proteins identified from the cancer cell line included EGF-R, several integrins and 
molecular chaperones. The latter include proteins with the endoplasmic reticulum 
(ER) retention KDEL sequence, indicating as has been previously noted (Altmeyer et 
al., 1996), that the localisation of ER associated proteins is deregulated in the 1542 
CP3TX cell line. An 1 lkD band that appeared to contain more protein in the 1542 
CP3TX sample shown in Figure 3.4 C, was identified as containing three proteins 
including a fragment of the CD 9 antigen. The abundant expression of this band in the 
cancer cell line indicated that the proteins therein may have potential as tumour 
markers and therefore CD9 was selected for further analysis. Lysates obtained from 
affinity chromatography enriched samples of three T-80 cell culture flasks each 
containing 750,000 1542 NPX or CP3TX cells were subject to electrophoresis on 
15% gels and transferred as per protocol (see section 2.2.10). These membranes were 
then probed with the anti-CD9 antibody. This experiment was repeated on several 
occasions, however the only commercially available CD 9 antibody did not give a 
signal in the 1542 cell extracts even when used at a concentration of 1:50. The 
antibody did however, detect a protein at the correct molecular weight for CD9 in a 
control extract produced by the antibody manufacturer.
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Calnexin, a 90 kD molecular chaperone was also isolated from a protein band 
showing greater intensity of staining in the 1542 CP3TX cell line. As this band 
contained other proteins, further analysis of the relative expression level of calnexin 
was required. To explore the expression of this protein in several isogenic cell lines, 
the following study was performed. Three T-80 cell culture flasks containing 750,000 
cells, were set up for each of the 1532 NP/1542 CP3TX, 1535 NP/1535 CP3TX and 
1542 NP/1542 CP3TX cell lines. The cells were washed and lysed in 500pl 1% OGP. 
The samples were loaded onto a 12.5% gel at a concentration of 50pg per well and 
subject to electrophoresis and western transfer as per protocol. The membranes were 
then probed with anti-calnexin antibody; this was repeated in triplicate. 
Representative results are shown in Figure 3.5. The results from these triplicate 
experiments were analysed by densitometry. These readings were then normalised to 
those for (3 actin expression to compensate for any differences in loading. The 
normalised data were then used to calculate the fold difference in calnexin expression 
between the normal and cancer isogenic cell line pairs. The fold differences were as 
follows; 1532 CPT 1.4 fold higher expression than 1532 NP, 1542 CPTX 2.25 fold 
higher expression than 1542 NP and 1535 CPT 1.9 fold higher than 1535 NP. These 
data were also used in a student’s t-test to infer the significance of the fold 
differences. All fold differences in calnexin expression were found to be significant 
with P values of 0.04, 0.002 and 0.0005 for the 1532, 1542 and 1535 isogenic pairs 
respectively, indicating that it is highly unlikely that the differences in calnexin 
expression observed are due to random fluctuations in these data. These results 
indicate that calnexin expression is significantly up regulated in the 1542 CP3TX cell 
line and that the same pattern of up regulation is observed in the other cancer cell 
lines when compared to their normal counterparts. This pattern of over expression is 
most apparent in the 1535 and 1542 isogenic cell lines.
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Table 3.2. The non-membrane associated proteins identified from the gels in Figure 3.4. Fourteen 
additional proteins were isolated but were unidentifiable by database searches and de novo sequencing.
Protein MW (kD). Postion in Figure 3.4.
Pyruvate kinase 53 12
Phospholipase alpha 50.5 12
Alpha tubulin 45 9
Beta 5 tubulin 44 9
Beta actin 37.5 11
Keratin 10 58 9
Myosin heavy chain 196 3
Keratin 9 62 9
T-complex protein 1 55 9
Elongation factor 2 51 11
Enhancer protein 19 14
Pyruvate kinase (muscle isoform) 53 9
Keratin 17 43 12
Keratin 18 43 12
Keratin 6A 56 12
3.3 Discussion
The aim of this study was to develop an optimised strategy for membrane enrichment, 
so that the cell surface proteome of prostate epithelial cells could be compared. The 
rationale for this was that proteins exhibiting differential expression could possibly be 
involved in the progression to a cancerous phenotype. Proteins exhibiting differential 
expression patterns between normal and cancerous cells also have the potential to be 
exploited as markers of malignant disease or as targets for treatment of such disease. 
The advantage of using isogenic cell lines in a study of this nature is that any inter­
individual variation is removed and therefore any differences observed are more 
likely to be representative of the carcinogenic process. The cell surface protein 
analysis was performed using biotin vectorial labelling and avidin affinity 
chromatography to pre-fractionate the sample into a membrane enriched protein
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extract. Initially two biotin derivatives were compared for their efficiency in labelling 
cell surface proteins. This comparison was achieved through the observation of the 
range and quantity of proteins biotin labelled with each of the biotin derivatives. 
Irreducible forms of biotin such as the LC derivative require either competitive 
elution or elution under extremely acid conditions. Both of these elution methods 
require severance of the biotin-avidin association and consequently produce lower 
yields than the reducible biotin label. This elution method also interferes with the 
resolution of samples, as they must be dialysed prior to running. Sulfo-NHS-SS- 
Biotin gave the higher yield of cell surface proteins. The efficiency of this label 
probably lies in its ability to be dissociated from the protein of interest. The SS tag is 
cleavable by the use of a reductant, such as DTT or p mercaptoethanol, allowing 
elution of the target protein without interference with the biotin-avidin interaction. 
The interaction between these proteins is extremely strong, having an affinity constant 
of >1015 m 1 and therefore even when using the modified streptavidin compound the 
energy required to break the interaction is considerable.
In addition to the choice of protein label, the selection of wash buffer for use in 
affinity chromatography proved critical for obtaining a resolvable cell surface 
enriched protein fraction. The purpose of the washing stage of the pre-fractionation 
process is to remove any contaminating unlabelled cellular protein, which may be 
loosely bound to the avidin or support. In an attempt to preserve interactions between 
the intracellular domains of the biotinylated integral membrane proteins and their 
cytosolic binding partners during the isolation procedure, high-salt, alkaline buffers 
recently demonstrated to efficiently remove non-biotinylated cytoskeletal protein 
from Streptavidin beads (Zhao et al., 2004), were omitted from the washing procedure 
in this study. As a consequence five of the nine protein bands examined by mass 
spectrometry were found to contain contaminating cellular proteins such as, a-actinin 
4, p 5 tubulin, elongation factor 2 (EF2) and pyruvate kinase in addition to one or 
more surface proteins. Integrins, ALCAM and CD44 are strongly anchored to the 
cytoskeleton, which could explain the detection of actinin and tubulin molecules in 
the affinity enriched fractions. However, neither EF2 nor pyruvate kinase interact 
directly or indirectly with membrane proteins, suggesting that they represent 
procedural contaminants, rather than proteins co-purified in complex with a 
transmembrane partner.
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As biotinylated proteins are rare (Cronan, 1990), very few contaminating bands 
should be seen in the control lanes. The results shown in Figure 3.2 appear to suggest 
that use of a more stringent wash buffer results in more contaminating unlabelled 
protein bands following affinity chromatography. The highest level of contamination 
is seen with the use of 8M Urea in the wash buffer. This contamination may be due to 
the stringent nature of this chemical and its ability to degrade the avidin and column 
support. Once the column has been degraded there could be a variety of binding sites 
available for unlabelled cellular proteins, perhaps explaining the multitude of proteins 
observed in the elution fraction when the 8M Urea wash buffer was used. The results 
indicated that 1% OGP wash buffer gave the least background contamination when 
used with a fresh neutravidin column. The problems with protein build up on these 
columns when recycled may also be attributable to degradation as the regeneration 
solution contains low pH guanidine HC1, an agent that also may damage the columns.
The choice of lysis buffer was also crucial for obtaining a cell surface protein 
enriched sample. Two lysis buffers were compared in triplicate for their ability to 
solubilise a large range and quantity of labelled surface proteins. Avidin 
immunoblotting on whole cell lysates showed that 1% NP40 detergent gave higher 
protein concentrations, but solubilised a small range of labelled high molecular 
proteins. Despite appearing to yield less protein, 1% OGP lysis buffer solubilised a 
larger molecular weight range of proteins. The ability of the OGP lysis buffer to 
solubilise labelled cell surface proteins lies in its properties as a detergent. OGP is a 
non-ionic detergent capable of solubilizing membrane proteins in a gentler manner, 
often allowing retention of native structure (Roche, 2005b). Recently this detergent 
has been used to improve the yield of proteins in MS, where it was found to facilitate 
the recovery of hydrophobic peptides and increased the total number of peptides 
detected to 85% (van Montfort et al., 2002). A 1% OGP solution was therefore 
deemed the most appropriate lysis buffer for the cell surface analyses conducted in 
this study.
The experiments described above resulted in the formulation of an optimised protocol 
for cell surface protein analysis, which provided a high yield of cell surface proteins 
with minimal contamination from unlabelled proteins and containing a wide range of
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molecular weight proteins. The efficacy of this protocol was then tested by its 
application to the cell surface analysis of 1542 NPX and CP3TX cells.
The pre-fractionation, analysis and identification of labelled cell surface proteins from 
the two isogenic cell lines was conducted and these data pooled. This resulted in the 
mass spectroscopy identification of 69 proteins in total, 35% of which were integral 
and 21% peripheral membrane proteins. There were however, 16 known non- 
membrane proteins identified and a further 14 proteins of unknown identity. Despite 
the potential association of such proteins with true membrane proteins, the 
identification of non-membrane associated proteins is an indication that there is 
contamination at some level. This suggests that further improvements are required to 
optimise the membrane protein enrichment procedure to achieve a less contaminated 
sample for MS. This experiment would benefit from being conducted in a solely clean 
room environment to minimise the contact with exogenous proteins. Improvements 
could also be made in the labelling and affinity chromatography protocols to minimise 
endogenous and non-specific protein elution.
The results from this study indicate that the cell labelling/affinity chromatography 
protocol was capable of producing a cell surface protein enriched sample. It is 
assumed that 5-8% of cellular proteins are membrane proteins, compared to 56% of 
the protein mixture using this cell surface analysis technique. This represents a greater 
than 10 fold enrichment of cell surface proteins. This level of enrichment is 
comparable to several other recent studies employing various cell surface proteomic 
techniques. In the analysis of neural cells from the human brain a 60% enrichment of 
membrane proteins was observed using stepwise depletion of non-membrane proteins, 
density gradient fractionation and liquid chromatography followed by MS 
(LCMS)(Nielsen et al., 2005). A similar study examining cell surface protein 
expression in human keratinocytes via 2 dimensional LCMS achieved a 57.3% 
enrichment of such proteins (Blonder et al., 2004). Recently a 67.3% enrichment of 
membrane proteins from a lung cancer cell line was achieved using an approach 
similar to that used in this study (Zhao et al., 2004). The increased level of cell 
surface protein enrichment in this lung cancer study may be due to their utilisation of 
HPLC as an additional step following avidin chromatography. This strategy may be
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beneficial, although any further fractionation steps within the protocol do increase the 
risk of sample loss and therefore interfere with quantitation.
The bands excised were selected based on apparent differential expression between 
the 1542 NPX and CP3TX cell lines. However, on MS analysis several bands were 
found to be extremely complex. This degree of complexity is to be expected as ID 
SDS PAGE gels do not give the single protein degree of resolution of techniques such 
as 2DGE. The advantage of the ID SDS PAGE technique is the large range of 
hydrophobic proteins that can be resolved without problems with crystallization or 
interaction with gel supports. Due the band complexity it is impossible to define 
which proteins may be over expressed in the cancer cells without further analysis. It is 
interesting to note however that a large proportion of the proteins identified are 
involved in cell adhesion. These proteins include E-cadherin, CD44 and 6 integrin 
subtypes, cell adhesion molecules that have been implicated in malignant and 
metastatic progression (Stewart et al., 2004). E-cadherin, for example, has been 
shown to exhibit an anti-proliferative effect, the loss of which promotes cancerous 
growth and increases invasive potential. Integrins, like cadherins, are implicated in 
malignant and metastatic progression. Several integrins were identified in the 1542 
CP3TX cell line. Over expression of integrins is thought to limit movement of the 
cells therefore decreasing their invasive capacity. However, up regulation of several 
integrin subtypes favours motility and can lead to a more invasive phenotype. The 
integrin subtype a6 pi, is most commonly implicated in the invasion of prostate 
cancer cells into seminal vesicles (Stewart et al., 2004). pi integrin was identified in a 
band that from the cancer cell line. Further quantitative analysis by 
immunotechniques will be required to infer the relative expression of these cell 
adhesion molecules, before any assumptions can be made regarding their role in 
carcinogenesis.
The expression of two proteins identified from the cancer cell line, CD9 and calnexin, 
was examined in detail through immunodetection of proteins separated via ID SDS 
PAGE. The band found to contain the CD 9 fragment at approximately 8 kD was one 
of the least complex bands analysed, containing only two other proteins. CD9 was 
consistently detected in avidin purified biotinylated membrane fractions from the 
cancer cells. A ten amino acid peptide corresponding to amino acids 21-30 was
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sequenced by ESI-MS/MS, indicating that the fragment originates from the N- 
terminus of CD9. A band containing the 8kD CD9 form was strongly stained in Sulfo- 
NHS-LC-biotin labelled cancer cells, but not detected in the biotinylated fraction of 
normal prostate cell proteins. Both extraction and enrichment were performed in the 
presence of EDTA and under a broad umbrella of protease inhibitors, suggesting that 
the biotinylated CD9 fragment is generated prior to biotinylation and extraction. CD9 
is the most well-characterised member of the Transmembrane 4 subfamily and may be 
implicated in cell migration, proliferation and tumour cell metastasis (Mhawech et al., 
2003). Although the full length CD9 molecule is thought to inhibit motility in a range 
of cancers (Wang et al., 2002a), expression of the CD9 antigen fragment in acute 
lymphoma correlates with poor prognosis (Komada and Sakurai, 1994). Loss of the 
full length protein has been found to have prognostic value in several tumours 
including adenocarcinoma of the lung, colon, breast and pancreas (Wang et al., 2002a, 
Komada and Sakurai, 1994). It appears that loss of the full-length CD9 molecule 
promotes an invasive phenotype and leads to a poor prognosis. In the 1542 CP3TX 
cells the presence of the CD9 antigenic fragment, may indicate that the CD9 molecule 
is being degraded in the cancer cells thus giving them a selective advantage in tissue 
invasion. Immunoblotting studies could not confirm whether there is an up regulation 
of the CD9 fragment in cancer cells as the only commercial antibody available did not 
produce a recognisable band even at high concentrations despite its ability to detect 
CD9 in a positive control. This result may indicate that the CD9 fragment expressed 
in the 1542 cell lines is undetectable by an antibody raised against the full-length 
protein. To address this situation further study using an antibody specifically designed 
to recognise the CD9 fragment peptide sequence will be required. In addition to this 
quantitative PCR could be performed to examine expression of the CD9 mRNA 
transcript in the normal and cancer cells. Confirmation of the over expression of this 
motility associated protein fragment in the cancer cell line could possibly indicate its 
utility as a diagnostic marker of prostate cancer, with the added advantage that it may 
be present in the extracellular milieu (Komada and Sakurai, 1994).
Calnexin a type I transmembrane protein, was also identified from fractionated 1542 
CP3TX cell lysate. Due to its role as a molecular chaperone, this protein has an 
endoplasmic reticulum retention sequence however, despite the possession of such a 
sequence calnexin has been shown to be expressed on the cell surface associated with
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glycoproteins (Li et al., 2001). This protein has been implicated in cell adhesion via 
interactions with other CAM’s such as integrins pi and 6 and expression of calnexin 
has been found to increase in cancer cells on initial contact with substratum 
(Ruoslahti and Reed, 1994, Yeates and Powis, 1997). In a recent study of a small 
sample of breast tumour specimens, calnexin was found to be over expressed in 75% 
of samples compared to adjacent normal tissue. A correlation was also seen between 
over expression and increasing breast tumour grade (Li et al., 2001). This correlation 
between calnexin over expression and increasing tumour grade suggests that the over 
expression of calnexin, perhaps by its interaction with CAM’s, may play a role in 
metastatic progression. The expression of calnexin in several isogenic cell lines was 
analysed by immunoblotting. In all samples the cancer line was shown to express 
significantly higher levels than its normal isogenic pair. This over expression in 
cancer cells, suggests that calnexin plays some role in malignant progression, further 
studies are required to assess whether this role includes progression towards an 
invasive phenotype.
In summary the results of this study have lead to the optimisation of a protocol for cell 
surface protein analysis, which has been applied to the analysis of surface protein 
composition in 1542 NPX and CP3TX cells. This analysis has lead to the 
identification of cell surface proteins involved in cell adhesion, signalling and growth 
and that are already implicated in malignant progression. The cancer specific over 
expression of one of these proteins, calnexin, was confirmed in 1542 NPX, CP3TX 
and two other prostate isogenic cell lines. This protein with further study, may have 
potential as a diagnostic marker in prostate cancer.
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Figure 3.1. Cell surface fractionated NP and CPT cell lysate labelled with A SS biotin and B LC 
biotin. The SS biotin gave a labelled protein yield visible on staining with coomassie blue, whereas the 
LC required avidin blotting to visualise labelled proteins.
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Figure 3.2. Elution fractions from unlabelled lysate subject to affinity chromatography using different 
wash buffers. A 8M Urea, 0.5% SDS in 1% OGP B 0.5% SDS C 0.1% OGP.
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Figure 3.3 ID SDS PAGE avidin immunoblot o f  1542 NPX (N) and CP3TX (C) biotin labelled 
proteins lysed in A 1% OGP, B 1% NP40. Lysis with 1% OGP appears to give a better yield o f labelled 
proteins in both quantity and molecular weight range. Differences between 1542 NPX and CP3TX can 
be observed (See red arrows).
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Figure 3.4. Affinity purification and identification o f  biotinylated surface proteins. A NHS-SS-sulpho- 
biotin labelled surface proteins were solubilised with l%  Octyl-b-D-glucopyranoside in the presence o f 
protease and phosphatase inhibitors and purified by avidin affinity chromatography. Tfie excised 
protein bands are indicated by arrows and numbered to the right. ESI-LC-MS/MS analysis identified 24 
transmembrane proteins and 11 peripherally attached surface proteins in 15 excised protein bands. (B  
and C) A band containing the 8kD fragment of the 24kD tetraspanin protein CD9 was consistently 
detected in enriched surface fractions from the cancer cells (band 14, left images in b and c).
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Figure 3.5. A Calnexin and B p Actin expression in a panel o f prostate cell lines. All cancer cell lines from 
the three isogenic cell line pairs express more calnexin than their normal counterparts
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Chapter 4 
Comparative analysis of 1FN signalling and cell surface protein 
expression in 1542 NPTX and CP3TX cells
4.1 Introduction
Previous studies have suggested that interferons modulate the surface protein 
composition of cancer cells (Nagano et al., 2003, Shou et al., 2002), including changes in 
the expression of a number of cell adhesion molecules and cell surface receptors (Bacso 
et al., 2002). Cytokines cause a number of cellular effects including cell cycle arrest, 
growth suppression and inhibition of metastatic potential in prostate cancer (Nagano et 
al., 2003, Shou et al., 2002, Sokoloff et al., 1996). In addition, IFNs play an indirect role 
in immunosurveillance by upregulating antigen presenting molecules such as MHC 1 
(Shou et al., 2002). Interferon signalling is initiated by binding to receptors unique for 
each IFN (See Fig 4.1). The signalling pathways for both type I and II IFNs converge, 
however, at the level of signal transduction from these receptors. On stimulation by IFNy, 
Janus kinases (JAK) 1 and 2 activate the cytosolic domains of the IFNy receptor leading 
to the recruitment of STATI proteins. These STAT proteins consist of two subunits a and 
p, which are activated by phosphorylation and move into the cytoplasm. IFNy signalling 
leads to a homodimerisation of STAT1 proteins which travel to the nucleus and initiate 
the transcription of genes containing specific IFNy response elements (Sehgal et al., 
2002). IFNa signalling also leads to the activation of STAT1 and STAT2 that form a 
transcription complex with p48 called the IFNa-induced transcriptional activator (ISGF). 
This complex is responsible for the transcription of genes with IFN stimulated response 
elements (ISRE) (Clifford et al., 2002).
STAT1 in addition to its integral role in the cross talk between the type I and II IFN 
signalling pathways, can also be activated by mitogenic factors such as EGF and PDGF 
(Marra et al., 1996). IFNs and growth factors share a common signalling pathway, 
crosstalk between which amplifies the mitogenic effects of EGF and PDGF. Treatment of 
cells with IFNy potentiates the mitogenic activity of EGF. However, cells exposed to
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both agents or to IFNy alone exhibit an anti-mitogenic response (Marra et al., 1996). It is 
of note that regulation of one pathway can lead to two opposing outcomes.
Recent research demonstrated that IFN signalling is abnormally regulated in 1542 
CP3TX cells when compared to the 1542 NPTX cell line (Nagano et al., 2003). In 
prostate cancer cell lines, many interferon inducible genes are down regulated. In 
addition a key member of the transcription complex, p48, displays aberrant expression in 
comparison to normal prostate epithelial cells (Shou et al., 2002, Nagano et al., 2003). 
p48 has a critical role in IFN signalling and the action of cytokines on tumour cells, in 
that altered expression leads to IFN insensitivity. p48 was found to be down regulated in 
melanomas and it has been suggested that this down regulation is an early event in the 
development of melanoma, conferring a selective advantage through insensitivity to IFN 
signalling (Clifford et al., 2002).
The finding that IFN signalling is abnormal in cancer cells indicates that a diminished 
response to both type I and type II interferons may lead to avoidance of immune 
surveillance and confer a survival advantage to the tumour cell. This insensitivity to 
cytokines has been proposed to be the subversion of a natural process, in that altered p48 
expression can be observed in placental trophoblasts and is thought to promote feto­
placental survival (Cross et al., 1999). The expression of p48, STAT 1 and of the IFNy 
receptor (IFNyR) in 1542 NPTX and CP3TX cell lines is examined in the present study 
to observe the effect of IFN stimulation on these cells and any differences in signalling 
which may be responsible for modulation of IFN inducible proteins, especially those on 
the cell surface. Following on from the work of Nagano et al., 2003, this study focuses on 
IFNy signalling in 1542 NPTX and CP3TX cell lines, including a comparative analysis of 
the affect of IFNy on the expression of a cell surface protein gp96, a molecular chaperone 
identified in the previous chapter as expressed on the surface of 1542 NPTX and CP3TX 
cells. This protein was chosen for further analysis because previous studies have found 
gp96 to be down regulated by IFNy and has been implicated in the immune response 
through delivery of peptides to MHC I molecules (Nagano et al., 2003, Dai et al., 2003). 
gp96 is a 96kD glycoprotein normally resident in the endoplasmic reticulum (ER) having
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both a signal peptide and the tetrapeptide, Lys-Asp-Glu-Leu (KDEL), retention sequence 
for this location (Robert et al., 1999). gp96 has, however, also been localized to the cell 
surface of tumour cells (Yedavelli et al., 1999a, Manjili et al., 2002, Caudill and Li, 2001, 
Haverty et al., 1997a). The cell surface location of gp96 was confirmed through a series 
of immunofluorescence studies and found to be surface associated by biotin labelling in 
further research using methods similar to those used in the present study (Altmeyer et al., 
1996). The over expression of gp96 has been reported in oesophageal carcinoma and is 
thought to confer a selective advantage to cancer cells by inhibiting apoptosis (Chen et 
al., 2002). In addition, studies have shown that gp96 harvested from tumours can be re­
administered to the patient as an anti-tumour vaccine, due to its ability to elicit both a 
non-specific cytokine and a specific cytotoxic T cell response (Robert et al., 1999, 
Manjili et al., 2002). Cytokines have been reported to have a number of effects on gp96, 
however a recent study disclosed that not only was gp96 over expressed in the 1542 
CP3TX cell line, but that expression could be decreased by 24 hr exposure to IFNy 
(Nagano et al., 2003).
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Figure 4.1. The IFNy signalling pathway. Taken from (Newport, 2003).
107
4.2 Methods and Results
4.2.1 Differential response to IFN y in 1542 NPTX and CP3TX cells - p48
The expression of the IFN inducible transcription factor p48 was compared in the 
presence and absence of cytokines IFNa and y and EGF. EGF was included to examine 
the effect of crosstalk between the IFN and growth factor signalling pathways on p48 
expression.
Eight T-80 cell culture flasks each containing approximately 7 x 106 cells at 70% 
confluence for each of the 1542 NPTX and CP3TX cell lines were prepared and 
transferred into minimal medium (KSFM without supplements or serum added) for 24 
hours. It was necessary to transfer the cells to minimal medium as the normal growth 
media contains EGF and therefore would interfere with the analysis of the effect of EGF 
on IFN signalling.
Table 4.1 Cell culture conditions for analysis o f p48 expression in response to cytokines, with or without 
EGF stimulation in both 1542 NPTX and CP3TX cell lines.
Condition Media
EGF + Complete KSFM (cKSFM) (containing 0.2 ng/ml EGF)
EGF- KSFM w/o supplements or serum (KSFM)
EGF- IFNa KSFM, 500U/ml IFNa
EGF- IFNy KSFM, 500U/ml IFNy
EGF- IFNay KSFM 500U/ml IFNa, 500U/ml IFNy
EGF+ IFNa cKSFM, 500U/ml IFNa
EGF+ IFNa cKSFM, 500U/ml IFNa
EGF+ IFNy cKSFM 500U/ml IFNy
EGF+ IFNay cKSFM, 500U/ml IFNa, 500U/ml IFNy
The stimulation conditions applied to both 1542 NPTX and CP3TX cell lines can be 
observed above in Table 4.1. As p48 is an IFN inducible transcription factor, both IFNa 
and y were added alone or in conjunction. The influence of the mitogen EGF on p48
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expression in response to these cytokines was analysed by repeating the cytokine 
stimulation with or without EGF present in the media. Each of the conditions indicated 
above were applied for 24hrs. The cells were then labelled with LC biotin as per protocol 
(see section 2.2.6), lysed in 500pl 1% OGP lysis buffer and quantitated using the Lowry 
protein concentration assay. The samples were resolved on a 12.5% gel at a concentration 
of 30pg of protein per well and subject to western transfer. This experiment was repeated 
in triplicate. The membranes were then probed with avidin, anti-p48, anti-STAT 1 and P- 
actin antibodies, representative results of which can be seen in Figure 4.2.
Avidin blotting of the resolved cell lysates revealed a number of proteins, with differing 
patterns of expression in response to the cytokines IFNy and a in 1542 NPTX and 
CP3TX cell lines (See arrows Figure 4.2 A). These may represent cell surface proteins or 
a background signal from other non-labelled cellular proteins detected by the avidin 
probe. To examine the differences in IFN signalling further, the pattern of p48 expression 
was analysed, see 4. LB. The bands from three replicate gels were analyzed as digitized 
images by using a GS-700 Imaging Densitometer (Bio-Rad). The mean optical density 
(OD) of band images is expressed as volume (OD x area) and adjusted for background to 
give arbitrary units of adjusted volume, these values were then normalised to P-actin to 
adjust for loading differences. Densitometry analysis of the results of this study indicated 
the following; firstly that the expression of p48 in the absence of EGF is barely detectable 
in 1542 NPTX cells, with higher expression in 1542 CP3TX (8.6 ± 0.9 in NPX versus 15 
± 1.3 in CP3TX). The difference in p48 expression became more marked when EGF was 
present in the medium, 1542 NPTX cells maintain a barely detectable level of this 
protein, whereas in 1542 CP3TX cells there is an approximate 2 fold increase in p48 
expression (rising from 15 ± 1.3 to 33 ± 1.5).
The responses of 1542 NPTX and CP3TX cells to IFNy and a under normal conditions 
and in the absence of EGF, revealed differing expression patterns of p48. In the normal 
cell line, in the absence of EGF, stimulation with IFNa increases expression three fold 
(rising from 8.6 ± 0.9 to 27 ± 1.4), whereas in the cancer cell line there is a lesser 
increase in expression (rising from 15 ± 1.3 to 33 ± 1.1). However, with IFNy the
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converse is the case with 1542 CP3TX displaying a greater increase in expression in the 
absence of EGF (rising from 8.6 ± 0.9 to 27 ± 1.3 in 1542 NPTX cells and from 15 ± 1.3 
to 63 ± 1.8 in 1542 CP3TX cells). When both cytokines were added together to EGF 
starved cells the synergistic effect is the same as with the single cytokine showing highest 
expression, i.e. IFNa in 1542 NPTX cells, IFNy in 1542 CP3TX cells. When the 
cytokines were applied to cells in the presence of EGF, an enhanced expression of p48 
was observed that followed the same pattern as in the absence of EGF described above.
Statistical analysis using one-way analysis of variance (ANOVA) indicated that cell line 
has no significant effect on p48 expression, whereas the presence of EGF in the growth 
medium and stimulation by IFNa did elicit a significant effect on p48 expression in these 
cell lines (P=0.024 and PO.OOl for EGF and IFNa stimulation respectively). To examine 
interaction between factors a two-way ANOVA was applied to these data, which 
indicated that there was a significant interaction between the factors EGF and IFNa 
stimulation in terms of variation in p48 expression (P=0.003) and also between the 
factors cell line and IFNa stimulation (PO.OOl). This indicates that although no 
significant difference was observed in p48 expression between the cell lines in the 
absence of other factors, when IFNa is introduced a significant difference in p48 
expression occurs. The p48 expression data for IFNy stimulation produced no significant 
effects in either ANOVA analysis. The two cytokines were found to have no interactive 
effect, in agreement with the observations made above.
The membranes from the p48 expression analysis were re-probed with an antibody to 
STAT1, a transcription factor involved in IFN signalling. This revealed two bands 
detected by the STAT1 antibody, corresponding to the correct molecular weights of the 
STAT1 a and p subunit. In the normal unstimulated state, the predominant subunit 
expressed was the higher molecular weight STAT1 a form in both cell lines (See Figure
4.2 C). The expression of the a subunit remained at a constant level in all the culture 
conditions in both cell lines. The STAT1 p subunit appeared to be expressed at similar 
low levels in 1542 NPTX and CP3TX cells in both the normal unstimulated state and in 
the absence of EGF. On addition of either IFN, the STAT1 p sub-unit expression
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appeared to increase, indicating that the expression of this transcription factor subunit is 
induced by IFNs. In the 1542 NPTX cell line in the absence of EGF, expression of 
STAT1 p showed an apparent similar increase following the addition of either or both 
IFNs. When EGF was present, the effect of the two cytokines on STAT1 p expression 
was potentiated. In the 1542 CP3TX cell line under EGF starvation conditions, both IFNs 
increased STAT1 p expression. The greatest response however, followed treatment with 
IFNy. The combined effect of both cytokines resulted in a STAT1 P level comparable to 
that with IFNy alone. In the presence of EGF, this pattern of expression was enhanced but 
unchanged in the cancer cell line.
4.2.2 IFNyR
The IFNyR is up regulated by IFNy (Bacso et al., 2002). In this study, IFNyR expression 
was analysed in several prostate cell lines in the presence and absence of IFNy. Two T-80 
cell culture flasks each containing approximately 7 xlO6 cells at 70% confluence for each 
cell line (1542NPX, 1542 CP3TX, DU 145, LNCaP, PC3, Pre 2.8) were prepared and 
IFNy was added to one of each pair of flasks for 24 hrs. The cells were then washed x 3 
in lx PBS and lysed in 1% OGP. The protein content was measured using the Lowry 
protein concentration assay, following which 50pg of each sample was loaded on a 10% 
gel and subject to electrophoresis and subsequent western transfer. The membrane was 
then probed using an antibody to the IFNyR. This experiment was repeated in duplicate 
representative results of which can be observed in Figure 4.3, the results were normalised 
to p actin and analysed via densitometry.
The IFNyR antibody appears to detect several bands at the approximate molecular weight 
for IFNyR. This observation could be due to lack of specificity of this antibody or 
indicate that several isoforms of the protein are present in the lysate. In the unstimulated 
state, the band corresponding to the correct weight for the IFNyR protein appeared to be 
most highly expressed in the Pre 2.8, 1542 NPTX and CP3TX cell lines, with the other 
cancer cell lines showing a low level of expression. On stimulation, the expression of 
IFNyR in 1542 NPTX cells showed an apparent increase of approximately 3 fold (rising 
from 11 ± 1.8 to 35 ± 3). However, in the other normal cell line, Pre 2.8, expression did
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not appear to increase. PC3 and 1542 CP3TX cells displayed an increase in expression 
comparable to that of 1542 NPTX cells, whereas DU 145 appeared to show only a slight 
increase in expression on stimulation with IFNy. In contrast, LNCaP demonstrated an 
apparent marked decrease in expression of the IFNyR when exposed to IFNy. Analysis of 
these results was hampered by the lack of specificity of the IFNyR antibody and any 
result observed could be entirely attributable to non-specific interactions.
4.2.3 gp96, a cell surface glycoprotein differentially regulated by IFNy
gp96 is a glycoprotein found on the surface of certain cells where it may play a role in 
triggering an immune response (Robert et al., 1999, Manjili et al., 2002). Recent 
proteomic studies found this protein to be over expressed in the 1542 CP3TX cell line in 
comparison to 1542 NPTX and that this expression can be modulated by IFNy (Nagano et 
al., 2003). In the present study, the expression of gp96 was explored using samples from 
a panel of prostate cell lines. Two T-80 cell culture flasks each containing approximately 
7 xlO6cells at 70% confluence for each cell line (1542 NPTX, 1542 CP3TX , DU145, 
LNCaP, PC3, Pre 2.8) were prepared and one of each pair of flasks stimulated for 24 hrs 
with IFNy. The cells were then washed, lysed and quantitated as above. The samples 
were resolved on a 10% gel at a concentration of 30pg of protein per well and then 
subject to western transfer. The membrane was then probed using an antibody to gp96. 
This experiment was repeated in triplicate, a representative result of which can be 
observed in Figure 4.4.
The results of an anti-gp96 immunoblot on whole cell lysate from various prostate cell 
lines can be observed in Figure 4.4A. The results of this analysis on the panel of prostate 
cell lines in the presence and absence of IFNy suggests that in the unstimulated state, the 
cancer cell lines expressed more gp96 than the normal cell lines. However, after 
normalisation to p actin any differences observed are completely attributable to 
differences in loading. On stimulation with IFNy, there was also no difference in 
expression when the densitometry readings were normalised to p-actin.
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The expression of gp96 on the surface of the 1542 NPTX and CP3TX cell lines in the 
presence and absence of IFNy, was examined using the cell surface analysis protocol 
optimised in chapter 3 (See section 2.2.6-7). Six T-80 cell culture flasks each containing 
approximately 7 xlO6 cells at 70% confluence were prepared for both 1542 NPTX and 
CP3TX cell lines. Three flasks of cells were exposed to IFNy for 24 hours. The cells were 
then labelled with SS biotin, lysed in 1% OGP and subject to affinity chromatography as 
per protocol (see section 2.27). Following pre-fractionation, the samples were dialysed, 
vacuum concentrated and then quantified using a Bradford protein concentration assay. 
30|ig of each sample was loaded onto a 10% gel, subject to electrophoresis and western 
transfer. This experiment was repeated in triplicate. An immunoblot of a representative 
result using anti-gp96 antibody is shown in Figure 4.4B. These results were analysed via 
densitometry, normalisation to actin was not possible as the proteins present were derived 
solely from the cell membrane.
These results show that in the unstimulated state an approximately 2 fold higher level of 
gp96 cell surface expression can be observed in 1542 CP3TX when compared to 1542 
NPTX cells (17 ± 1.2 in NPTX cells compared to 34 ± 0.6 in CP3TX cells) a student’s t- 
test shows this is a significant result, with a probability value of PO.OOl. On stimulation 
with IFNy the expression of gp96 on the cell surface of 1542 CP3TX cells shows a 
significant decrease (P<0.001 using a student’s t-test) to almost undetectable levels, 
confirming previous findings (Nagano et al., 2003). The converse is true of the 1542 
NPTX cells, which on IFNy stimulation show a 2 fold increase in cell surface expression 
of gp96 (rising from 17 ± 1.2 to 37 ± 1.9, P<0.001). Surface gp96 expression in normal 
and cancer cell lines, in response to IFNy was confirmed as significantly different by the 
students t test, PO.OOl.
The gp96 expression patterns observed in 1542 NPTX and CP3TX cell lines were 
analyzed further by two dimensional gel electrophoresis (2DGE). Six T-80 cell culture 
flasks containing approximately 7xl06 cells were prepared for both 1542 NPTX and 
CP3TX cell lines. Three flasks of each cell line were stimulated for 24 hrs with IFNy, 
after which the flasks were lysed and pooled into 500pl 2DGE lysis buffer (see section
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2.1.4). The protein concentration of the samples was quantified by a Bradford protein 
assay and 300pg of protein applied to an Immobiline pH 3-6 IPG strip for each sample as 
per protocol (see section 2.2.13). The first and second dimensions of 2DGE were 
performed according to this protocol and the gels transferred to nitrocellulose. These 
membranes were then probed with anti-gp96 antibody.
Differences were observed between the cell lines in not only the level of expression, but 
also the number of isoforms induced on stimulation with IFNy (See Figure 4.5). The 2D 
analysis confirms that gp96 is expressed more highly in the 1542 CP3TX cell line than in 
its normal counterpart and that this expression decreases on stimulation with IFNy. In the 
1542 NPTX cell line, stimulation with IFNy causes an increase in the number of gp96 
isoforms present, whereas in the 1542 CP3TX line only one isoform continues to be 
expressed after 24 hrs in the presence of IFNy.
The effect of IFNy on cell surface expression of gp96 was also analysed using 
immunofluorescence. One 24 well plate containing cover slips was prepared for the cell 
lines DU 145, PC3, LNCaP, Pre 2.8 and seeded with 20,000 cells per well. The cells were 
cultured for 72 hours and then half the wells in each plate were stimulated with IFNy for 
24 hrs. The cells were washed and fixed in paraformaldehyde as per protocol (see section 
2.2.15). Immunofluorescence was performed using an anti-gp96 antibody (See Figure 
4.6). The amount of primary antibody required to achieve immunolocalisation of the 
gp96 protein was assessed through optimisation of the procedure using various 
concentrations of primary antibody. Dilutions of 1 in 50, 1 in 100, 1 in 200 and 1 in 500 
were used, although no improvement in signal was seen past 1 in 100. An additional 
attempt to improve the signal from immunofluorescence was made in the form of adding 
2% blocking buffer (BSA or Non-fat dried milk) to the primary antibody solution. This 
modification however appeared to weaken the signal and was therefore omitted from later 
experiments. Subsets of cells from each cell line, stained with secondary antibody only, 
were used as a control to assess the level of non-specific background staining. These 
controls lacked any perceivable immunofluorescent signal either with the naked eye or by 
cooled CCD camera detection, in all cell lines.
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The localization of gp96 in unstimulated cells appeared to be predominantly nuclear and 
cytosolic, although cell borders can be seen, suggesting membrane localisation of the 
protein. In the normal cell line Pre 2.8 the expression of gp96 increased, especially in the 
nuclear region. In the three other cancer cell lines there was an apparent reduction in 
gp96 expression, with staining becoming diffusely cytosolic. These results indicate that 
an increase in gp96 expression is seen in the normal cells and the converse is observed in 
the cancer cell lines on stimulation with IFNy.
4.2.4 Affinity chromatography of IFNy stimulated 1542 NPX and CP3TX cells
To further examine the effect of IFNy on the surface composition of 1542 NPX and 
CP3TX cells, vectorial labelling with SuIfo-NHS-SS-biotin of 2.25 x 104 cells was 
conducted for each cell line in the presence or absence of 24 hr stimulation with IFNy. 
This was followed by avidin affinity chromatography, to pre-fractionate cell surface 
proteins before electrophoresis and mass spectrometry identification. 50pg of each 
sample was loaded onto two 12.5% gels, in duplicate and subject to standard 
electrophoresis conditions. One set of gels was then subject to western blotting whilst the 
other was stained in coomassie blue. This process was repeated in triplicate, a 
representative coomassie stained gel can be observed in Fig.4.7A. The bands from three 
replicate gels were analyzed as digitized images by using a GS-700 Imaging 
Densitometer (Bio-Rad). The mean optical density (OD) of band images expressed as 
volume (OD x area) and adjusted for background to give arbitrary units of adjusted 
volume.
Several proteins were identified by densitometry that showed apparent differential 
expression on treatment with IFNy, two of these proteins appeared to be up regulated by 
the cytokine, but a 36 kD surface protein found in high density was significantly down 
regulated in response to IFNy stimulation (Fig 4.7A red asterisk). The three bands 
corresponding to these proteins showing the largest apparent change in expression on 
treatment with IFNy were cut and sent for MS analysis. The protein down regulated by 
IFNy was identified as All by MALDI-MS analysis of peptides generated by trypsin 
degradation of the excised Coomassie stained gel band. The other proteins of 66 and 46 
kD were identified as Selectin and IFN induced protein 53 and Selectin, respectively. As
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can be observed from Fig.4.7A these three proteins appear to be expressed at the same 
level on the surface of normal and cancer cells and show a similar pattern of regulation in 
response to IFNy stimulation in both cell lines. The expression of Selectin and IFN 
induced protein 53 is increased by approximately 2 (17 ± 2, increasing to 35 ± 4) and 4 
fold (20 ± 1 rising to 61 ± 2 )  respectively, following stimulation with IFNy. The 
significance of this data was confirmed statistically using two-way ANOVA analysis for 
both selectin and IFN induced protein 53. Cell line was found to be an insignificant factor 
in the expression of both proteins (P=0.41 and P=0.24 respectively), however IFNy 
treatment was shown to have a significant effect on expression (P=<0.0001 in both 
cases). There was no interaction between cell line and IFNy treatment in either case 
(P=0.41 and P=0.54 respectively).
All expression decreased by 3 fold (32 ± 2 to 9 ± 1.3) on stimulation with IFNy in both 
cell lines. This was confirmed by immunoblotting of the three replicate gels with an anti- 
AII antibody, a representative result and be seen in Fig.4.7B. Statistical analysis of these 
results using the students t-test indicates that not only is All expression significantly 
down regulated by IFNy, with a P value of 0.001 in 1542 NPX cells and 0.000 in 1542 
CP3TX cells, but also that the down regulation of surface expressed All in response to 
IFNy occurs to a greater degree in 1542 CP3TX cells (P=0.001).
4.3 Discussion
The aim of this study was to compare the effects of IFNs on protein expression in 1542 
NPTX and CP3TX cell lines. The initial section of this research focused on the 
comparison of proteins involved in the interferon signalling pathway. The rationale for 
this study was that identification of differing responses to IFNs may lead to a therapeutic 
use of these cytokines. The expression of various key proteins in IFNy signalling such as 
p48, STAT1 and the IFNyR, on exposure to various conditions (IFNy, a and EGF) was 
determined. These experiments also allowed examination of the cross talk between the 
IFN signalling pathway and that of the mitogen EGF. The second section focussed on the 
analysis of cell surface proteins differentially modulated by IFNy in 1542 NPTX and 
CP3TX cells.
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4.3.1 IFN signalling
Avidin blotting of lysates from cells exposed to various stimulation conditions revealed 
several proteins modulated by IFNs. It is possible that these represent cell surface 
proteins regulated by IFNs, confirming that these cytokines can modulate the cell surface 
composition of 1542 NPX and CP3TX cells. Additionally these results demonstrate that 
there are different patterns of protein expression in the 1542 NPX and CP3TX cell lines 
under different stimulation conditions. Before any protein identifications can be made, 
however, pre-fractionation using affinity chromatography should be employed to remove 
contaminating cellular proteins that may confound true cell surface patterns of 
expression.
The differences in IFN modulated protein expression in 1542 NPTX and CP3TX cells 
were examined by analysis of the transcription factor p48. This protein was chosen, as it 
is a part of a complex responsible for the transcription of interferon inducible genes, 
many of which have been found to be differentially expressed in these cell lines (Nagano 
et al., 2003). In this study, p48 was found to be over expressed in the cancer cell line. 
This finding is possibly indicative of the cancer cell being more sensitive to p48-inducing 
factors such as EGF, which is present in the complete KSFM. This sensitivity could result 
from over expression of the EGF receptor making the cell more responsive to normal 
circulating levels of EGF. The increased expression of p48 could be a downstream effect 
directly or indirectly due to the cancer cell acquiring a more mitogenic phenotype and 
thus a survival advantage. The induction of p48 expression by EGF and IFNs indicates 
that signalling from the EGFR may in some part follow a similar pathway to that of IFNs, 
suggesting the possibility of cross talk between these pathways.
Additional differences in the pattern of expression of p48 were observed between the 
isogenic pair of cell lines, indicating that there could be an alteration in crosstalk between 
the IFN and EGF signalling pathways in the cancer cells. In normal cells in the absence 
of EGF, more p48 is expressed on stimulation with IFNa than with IFNy, as would be 
expected if p48 was required for transcription of genes containing ISRE’s. The situation
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is the converse, however in the 1542 CP3TX cell line, where more p48 is expressed on 
stimulation with IFNy. Although the type I and II IFN pathways are similar, sharing a 
number of key proteins, p48 is not thought to be involved in IFNy inducible gene 
transcription. This converse expression of p48 in cancer cells could be advantageous, as it 
may lead to the avoidance of IFN signalling and the subsequent cell changes leading to 
heightened immune surveillance. Further studies would be needed however, to confirm 
this hypothesis. These studies could include quantitative analysis of other signalling 
factors associated with IFN signal transduction, such as STAT2.
In addition to the above, differences in IFN signalling between 1542 NPTX and CP3TX 
cells are also seen in the expression of the STAT1 p subunit. Unlike the a subunit which 
remains at a constant expression level in all conditions in both cell lines, the p subunit 
appears to be modulated by IFNs a and y. In the normal cell line the level of expression 
of the STAT1 p subunit increases by the same amount in response to a or y alone or in 
combination. In the cancer cell line this is not the case, as while both cytokines lead to 
increased expression of STAT1 p, a higher level of induction is seen with IFNy. The 
potentiation of p48 and STAT1 p expression patterns in both cell lines by EGF, suggest 
that there is some cross talk between the mitogenic and IFN signalling pathways. The 
aberrant expression patterns of IFN signalling molecules observed in the 1542 CP3TX 
cell line may also be attributable to convergence with the EGF or some other 
antagonising signalling pathway. Further exploration of the interactions between these 
pathways is required before their effects on each other can be clearly delineated.
As mentioned previously IFNy is capable of modulating cell surface proteins, including 
its own receptor IFNyR. In IFNy stimulated cells expression of IFNyR has been localised 
to lipid rafts, along with the signal transducer STAT1 molecules (Bacso et al., 2002, 
Sehgal et al., 2002). Expression of the IFNy receptor was examined in the presence and 
absence of IFNy in several prostate cell lines. The rationale for this study was that a lack 
of the upregulation of IFNyR seen in normal cells, could lead to a reduction in 
responsiveness to IFNy in the cancer cells and the avoidance of immunosurveillance.
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The IFNyR protein appeared to be most strongly in the unstimulated state in the normal 
cell line Pre 2.8, with 1542 NPTX and CP3TX also showing an apparent high level of 
expression. The other cancer cell lines, PC3, DU 145 and LNCaP expressed IFNyR at a 
lower level. On stimulation, the 1542 NPTX cell line appeared to show the increased 
expression of the IFNyR expected of a normal cell line. However, no increase in 
expression was seen in Pre 2.8 cells. Most of the cancer cell lines appeared to show 
upregulation of the IFNyR protein, there was however, a degree of variation in this 
increased expression of IFNyR in the cancer cells. The 1542 CP3TX and PC3 cell lines 
appear to express the greatest level of IFNyR induction, there then followed DU 145 with 
a lower level of induction by IFNy, then LNCaP which showed a reduction in IFNyR 
expression on exposure to IFNy. This may indicate that a loss of IFNyR regulation by 
IFNy represents a step towards a more metastatic phenotype. The reduction in IFNyR 
expression observed in LNCaP could be advantageous to a tumour cell as not only would 
it avoid immune detection but also the growth suppressive effects of IFNy. These 
observations however, should be taken as no more than inferences for further study, as 
the lack of specificity of the IFNyR antibody made assessment of the significance of the 
results impossible. Further replicates of this study are required, including both positive 
and negative controls to isolate the bands that represent the IFNyR. This could be further 
verified by protein/peptide competition for binding sites on the protein of interest 
followed by comparative immunodetection with pure lysate and both negative and 
positive controls. This protocol could be used for any immunoblot where unexpected 
multiple bands, suggesting non-specificity, are observed. In addition, 
immunohistochemical analyses of IFNyR expression in differing grades of prostate 
cancer clinical samples may provide a more conclusive link between IFNyR expression 
and malignant progression in prostate cancer.
4.3.2 Cell surface proteins
The glycoprotein gp96 was chosen for further analysis to examine the effect of IFNy on a 
cell surface protein involved in immune display that is upregulated in 1542 CP3TX cells. 
Studies of total cell lysate and immunofluorescence in a panel of prostate cell lines in the
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presence and absence of IFNy confirmed that gp96 expression levels were elevated in the 
cancer cell line. Cell surface analysis of gp96 was performed using the optimised 
protocol from chapter 3. This experiment resulted in confirmation that gp96 is over 
expressed in the 1542 CP3TX cell line and that expression can be reduced by exposure to 
IFNy. Stimulation with IFNy resulted in an increase in gp96 expression in 1542 NPTX 
cells, also confirming previous findings. Further confirmation of this effect resulted from 
2DGE where it appeared that the increase in gp96 expression in the normal cells was due 
in part to an increase in the number of isoforms of the protein, this reaction was not 
observed in the 1542 CP3TX cells. The appearance of these isoforms may have been due 
to non-specific staining of other proteins, however this effect was not seen any other 
applications of the antibody probe.
gp96 is a molecular chaperone responsible for the transport of peptides to the MHC 1 
proteins on the cell surface. In addition, gp96 has been reported to be a primitive antigen 
display molecule in its own right, able to elicit cytotoxic responses (Robert et al., 1999, 
Manjili et al., 2002). Consequently it is difficult to account for the over expression of this 
protein in cancer cells, as increased antigen display may be a selective disadvantage. 
However, studies have discovered that gp96 over expression in cancer cells is linked to 
inhibition of apoptosis (Chen et al., 2002). It is possible, therefore, that in the cancer cell 
line there is a trade-off in gp96 expression between the negative effects of antigen display 
and the advantage conferred by the inhibition of apoptosis. Further evidence for this 
could be seen in the fact that 1542 NPTX cells produce a number of gp96 isoforms on 
stimulation with IFNy, in contrast with the reduction seen in the single gp96 isoform in 
1542 CP3TX cells. These results may suggest that in the normal cells multiple isoforms 
of gp96 are produced to transport a number of different peptides for antigen display on 
stimulation with IFNy, possibly to facilitate the immune response. In the cancer cells this 
does not occur, the response being to down regulate gp96 and thus potentially avoid 
immune surveillance.
The application of the cell surface analysis protocol developed in chapter three allowed 
the identification of several proteins displaying apparent differential expression when
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stimulated with IFNy. The two isogenic cell lines had similar protein expression patterns 
when stimulated with IFNy, both displaying upregulated levels of interferon-induced 
protein 53 and selectin and exhibiting a down regulation in All following 24 hour 
treatment with IFNy. The down regulation of cell surface All in both 1542 NPX and 
CP3TX cell lines following 24 hour exposure to IFNy was confirmed by western blotting. 
The results of this experiment however, revealed a difference in response to IFNy 
between the two cell lines. In the 1542 CP3TX cell line a greater degree of All down 
regulation in response to IFNy was observed in comparison to that of normal cell line. 
This may suggest that, in vivo, IFNy could cause a greater down regulation of All and 
possibly invasive potential in the cancer cells. All was chosen for further study due to its 
potential role in cell invasion and therefore its possible therapeutic target value.
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Figure 4.2. A comparison of IFN signalling molecules in 1542 NPTX CP3TX cells on stimulation with 
various factors showing; A an avidin blot o f total cell lysate following cell surface labelling with LC biotin, 
B the expression of p48, C expression pattern of STAT1, D loading control ((3 actin). The table at the top of 
the figure denotes the position of each o f the samples conditions used in this study and relates to all four gel 
representations.
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Figure 4.3 A IGFR expression in several prostate epithelial cell lines plus or minus 24 hr stimulation with 
IFNy, B P actin expression as a loading control. IGFR expression is possibly higher in normal cell lines and 
appears to increase with IFNy treatment in the majority o f cancer cell lines. A decrease in expression o f this 
protein may be observed in LNCaP.
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Figure 4.4 Anti-gp96 immunoblot o f A panel o f prostate cell lines, B 1542 NPTX and CP3TX cell surface 
fraction, plus or minus stimulation with IFNy.
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Figure 4.5. Anti-gp96 immunoblot o f 2D analysis o f 1542 NPX and CP3TX cell lines with or without 24 
hour stimulation with IFN gamma. On stimulation NP cells appear to produce a multitude of gp96 isoforms 
leading to a higher expression level, this is not seen in CPT cells.
Pre 2.8 DU145
0 72 0 72
PC3 LNCaP
0 72 0 72
Figure 4.6 gp96 immunofluorescence in a selection of prostate cell lines in the absence or presence of 
IFNy treatment, at a magnification of x60. These results suggest that gp96 is down regulated in cancer and 
upregulated in normal prostate epithelial cells.
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Figure 4.7. A SDS PAGE coomassie stained gel showing total and cell surface fractions o f 1542 NPX (N) 
and CP3TX (C) cell lysate plus or minus IFN gamma stimulation. Proteins showing apparent differential 
expression on stimulation with IFNy are indicated by arrows. IFN induced protein 53 and Selectin both 
increase in expression on stimulation, whereas the level of All decreases. B A duplicate gel probed with 
anti-AII. This replicate experiment confirms All is down regulated by IFNy on the cell surface, this effect 
is most apparent in the 1542 CP3TX cell line.
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Chapter 5
The modulation of cell surface All by IFNy
5.1 Introduction
The 36kD calcium dependent phospholipid binding protein All, identified in chapter 4, 
was chosen for further study as several studies suggest that this protein has a potential 
role in cell invasion and therefore may provide a target for the prevention of invasion and 
subsequent metastasis (Podgorski and Sloane, 2003, Mai et al., 2000b, Diaz et al., 2004). 
The role of All in invasion is thought involve its function not only as a co-receptor for 
several endopeptidases (e.g. plasmin) (Diaz et al., 2004), ECM components and 
pathogens (Pietropaolo and Compton, 1997, Choi et al., 2000, Mai et al., 2000b), but also 
in its participation in the remodelling of the basement membrane by activation of 
extracellular proteases and/or by direct interactions with components of the ECM in 
tumour cells (Falcone et al., 2001).
The presence of annexins on the outer leaflet of the plasma membrane has historically 
been a contentious issue (Siever and Erickson, 1997). However, there are many 
indications that All is present on the outer leaflet of the plasma membrane lipid bilayer 
and may contribute to the invasive potential of the cell (Emoto et al., 2001). In the 
clinical setting, All over expression on the cell surface has been reported in a number of 
carcinomas including brain (Nygaard et al., 1998), breast (Schwartz-Albiez et al., 1993), 
lung (Cole et al., 1992, Brichory et al., 2001b), pancreas (Paciucci et al., 1998) and colon 
(Emoto et al., 2001). In such cancers, surface All over expression has been linked to a 
more aggressive tumour phenotype and concurrent poor prognosis (Mai et al., 2000c). 
The link between All expression and an invasive phenotype was recently explored in 
macrophages where it was found to regulate their invasive and degradative phenotype. In 
this study the ability of All to bind plasmin was inhibited by treatment with an antibody 
to All and this prevented migration of cells through a simulated ECM (Falcone et al., 
2001). Recent studies have provided further evidence for the role of All in cellular 
progression to a more invasive phenotype. These studies have focussed on the ability of
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All to bind to proteases such as pro-cathepsin B, tissue plasminogen activator and 
plasmin (Mai et al., 2000b). Binding to All activates these protease enzymes, initiating a 
proteolytic cascade resulting in the degradation of the ECM (Roshy et al., 2003, 
Podgorski and Sloane, 2003). The literature supports the hypothesis that All present on 
the cell surface has a role in movement of the cell through the ECM (Mai et al., 2000b). 
This study aims to examine the effect of IFNy stimulation on cell surface AH expression. 
The first part of this chapter focuses on the identification and cell surface localisation of 
All and the effect of IFNy stimulation on AII expression. No connection has previously 
been found between IFNy stimulation and All expression. Despite the fact that other 
cytokines, such as interleukins, have been shown to modulate the expression of All on 
the cell surface (Brichory et al., 2001a), the regulation of All by IFNy is previously 
unreported. IL-6 increases the cell surface expression of annexins I and II in lung cancer 
cells by 3 and 2 fold respectively, although no change was seen in cytosolic expression 
indicating a cytokine stimulated translocation of Al and II to the cell surface (Brichory et 
al., 2001a). A similar modulation was seen in leukaemia cells exposed to IL-3 
(Matsunaga et al., 2004). The function of All is explored in the subsequent section, to 
delineate the effect on invasive capacity of modulation by IFNy. Invasive capacity was 
chosen for analysis because of the potential role AII has in cell invasion and an anti-AII 
antibody was used to inhibit invasive potential. The final part of this chapter concentrates 
on the mechanism of the IFNy induced modulation of surface expressed All, based on 
recent research into the transport and cell surface expression of annexin I (Chapman et 
al., 2003). Both annexins I and II are transported to the cell surface by some unknown 
mechanism, as they are not processed or transported through the trans-golgi network 
(TGN) (Chapman et al., 2003). Annexin I and II lack a cleavable signal sequence at the 
amino terminus that is usually required for the externalisation of proteins via the TGN. 
The transport mechanism of such proteins to the cell surface is yet to be discovered, 
though there is mounting evidence that proteins lacking this signal sequence are 
transported to the extra cellular face of the plasma membrane by ABC transporters 
(Chapman et al., 2003, Kuchler and Thomer, 1992). Annexin I has recently been reported 
to be transported to the cell surface by the ATP binding cassette transporter ABCA1 
(Chapman et al., 2003).
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The ABC protein family contains over 100 hundred proteins with varied roles, including 
the transport of ions (Ardehali et al., 2005), peptides (Koch et al., 2004), cytokines 
(Marty et al., 2005) and steroid hormones (Qian et al., 2001). They are defined by the 
possession of two nucleotide binding folds and two transmembrane domains forming 
channel like structures in the membrane (Kuchler and Thomer, 1992). There has been 
debate as to whether such transporters can facilitate the movement of large molecular 
weight proteins to the cell surface, however studies have shown that ABCA1 transports 
IL-jil to the intracellular face of the plasma membrane (Fielding et al., 2000).
The most well characterised role of ABCA1 is the transport of lipids and free cholesterol 
to apo-1, this mechanism is severely impaired by mutation of the ABCA1 gene, as in 
Tangier disease, leading to a build up of cholesterol in organs including, tonsils, liver and 
spleen (Lawn et al., 1999). Recent research has shown that the ABCA1 transporter is 
localised to calveolae or lipid raft structures on the cell membrane and that this position is 
critical for its role in cholesterol transport (Fielding et al., 2000). In a recent study, 
immunofluorescence demonstrated that Al co-localises with the ABCA1 transporter in 
these lipid raft structures (Chapman et al., 2003). It was also discovered that exposure to 
an inhibitor of ABC transporters, glyburide, negates Al expression on the cell surface. 
Conversely stimulation with dexamethasone increased the surface expression of Al 
(Chapman et al., 2003). The possibility that this transporter may also be responsible for 
the translocation of All to the cell surface is explored in the last section of this chapter.
5.2 Methods and Results
5.2.1 All is down regulated on the cell surface in response to IFNy
As surface exposed All appeared to be down regulated by IFNy on normal and cancer 
cells (See Figure 4.7), the total level of All expression in these cells was explored. 1542 
NPX and CP3TX cells plus or minus 24 hr stimulation with IFNy were cultured, using
2.25 x 106 cells for each condition and lysed as per protocol (see section 2.2.4) in 500pl 
of 1% OGP lysis buffer. 50pg of these complete cell lysates representing 1542 NPX and 
CP3TX cells plus or minus IFNy stimulation were resolved on 12.5% gels in triplicate. 
The gels were then subject to western transfer and immunodetection was performed using
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an anti-AII antibody. Expression levels were normalised to p actin and quantitated by 
densitometry. See Figure 5.2.
Similar levels of All were found in the normal and cancer prostate cell lines (Figure 5.2) 
and IFNy exposure did not change the total cellular level of All. This was verified by 
two-way ANOVA statistical analysis where the amount of variation in All expression 
was found to be within the limits of random sample fluctuations for both cell line and 
IFNy treatment comparisons (P=0.34 in both cases) no significant interaction between 
these variables was noted. This experiment was repeated using a panel of prostate cell 
lines including the benign prostate cell line Pre 2.8 and three cell lines PC3, DU 145 and 
LNCaP derived from metastatic prostate cancers. The total level of All expression in the 
other normal and cancer prostate cell lines were also unaffected by gamma stimulation 
(Figure 5.3). This was confirmed by a two-way ANOVA analysis which found that the 
amount of variation in All expression on stimulation with IFNy in these cell lines was 
within the limits of random sample fluctuations (P=0.66). There was however a 
significant difference in the mean expression of All when the data was categorised by 
cell line in an ANOVA analysis (P=<0.0001). This finding was further analysed using the 
Tukey test, which performs a pair wise comparison to isolate the source of variation 
within the factor. The LNCaP cell line was isolated as displaying the most significant 
difference in mean All expression when subject to pair-wise comparison with the other 
prostate cell lines (mean difference of 38.7 at a 95% confidence interval). This was in 
agreement with the preliminary observation that All expression was absent in the 
metastatic prostate cancer cell line LNCaP and in accordance with findings by Chetcuti 
and colleagues (Chetcuti et al., 2001a) who suggest that the All gene is frequently hyper- 
methylated in prostate cancer.
To test this hypothesis a sample of LNCaP lysate from cells that had been exposed to the 
de-methylating agent 5-aza-deoxycytidine was obtained from Dr. A Birtle at the Prostate 
Cancer Research Centre, UCL. 30pg of this lysate was run alongside the same quantity of 
untreated LNCaP lysate in duplicate on a 12.5% gel, transferred to nitrocellulose and 
subject to immunoblotting with an antibody to All. The results of this study can be 
observed in Figure 5.4. In both replicates a faint band corresponding to the 36kD
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molecular weight of All, was present in the de-methylated sample. Due to the limited 
number of replicates statistical analysis was not performed.
5.2.2 Confirmation of surface localization of All
The lack of response in total cellular All expression when exposed to IFNy indicated that 
the down regulation of All expression by IFNy was cell surface specific. As the surface 
localization of All was controversial due to the lack of signal peptide, it was necessary to 
verify the cell surface localization of All via additional methods. Initially this was done 
through immunofluorescence on 1542 NPX cells fixed in 4% paraformaldehyde. 2,000 
1542 NPX cells were added to each well of a 24 well plate containing glass cover slips 
and cultured for 72 hrs. The cells were then fixed and immunofluorescence performed 
using an anti-AII antibody as per protocol (see section 2.2.15) and visualized using an 
inverted microscope attached to a cooled CCD camera.
Immunofluorescence staining indicated that All was present on the plasma membrane of 
1542 NPX cells, as a generalised pattern of diffuse staining of the membrane was 
observed (Figure 5.5). Despite the use of 4% paraformaldehyde and lack of 
permeabilization, there appeared to be some background staining inside the cells. It was 
therefore necessary to further confirm that this All expression was on the cell surface and 
not on the cytosolic face of the plasma membrane.
Surface All expression was additionally verified by the release of All from the plasma 
membrane by interference with its calcium dependent association with phospholipids. 
This was performed using two methods, by disruption of the extra cellular calcium level 
and by the addition a calcium chelator. These methods were performed in triplicate on
2.25 x 106 1542 NPX cells as per protocol (see section 2.2.8). To analyse the efficacy of 
these techniques 30pg of the resultant samples were run on 15% gels and subject to 
western transfer. The membranes were then probed with anti-AII antibody.
The results demonstrate that All can be eluted from the cell surface with minimal cell 
disruption by manipulating the extra cellular calcium levels by either of the two methods 
(Figure 5.6 A, B). The lowest concentration of CaCh gave the highest yield of All; this 
concentration is lower than that usually found in the medium. The observation that
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calcium concentration has a significant effect on the presence of All in the elution extract 
was confirmed as significant via a one-way ANOVA analysis (P=<0.0001). To assertain 
the concentration generating the most significant effect a Dunnett test was performed, 
which compares the experimental groups to the baseline in this case the OmM calcium 
concentration. All concentrations were found to have a significant effect on All 
expression with the largest effect seen in the comparison of 0.5mM to the baseline (a 
difference of 46.3 at a confidence interval, Cl, of 95%).
The extra cellular calcium concentration was also lowered by use of the calcium chelator 
EDTA, the effect of which can be observed in Figure 5.6B. The apparent increase in the 
presence of All in the extra cellular media following EDTA treatment was confirmed as 
significant by a one-way ANOVA analysis (P=<0.0001). To confirm the concentration 
generating the most significant effect a Dunnett test was performed. The optimal EDTA 
concentrations for All yield, those producing the most significant deviation from the 
baseline, were 0.5 to ImM with difference values of 49.6 and 48.6 respectively, at the 
95% confidence limit. The 0.5mM concentration has been used in other studies to liberate 
cell surface All (Wright et al., 1995, Pietropaolo and Compton, 1997) and was therefore 
the elutant of choice for further experiments. Elution of surface bound All with EDTA 
solutions above this concentration appeared to yield a second All band of a lower 
molecular weight.
5.2.3 Timescale of surface down regulation by IFNy
Time course experiments were conducted utilizing several techniques to specifically 
analyze surface bound All. The first of these techniques was immunoprecipitation with 
an anti-AII antibody. For this experiment, 1.5 x 106 1542 CP3TX cells were cultured and 
stimulated with IFNy for 0, 1, 2, 6 and 8 hours. These were then labelled with SS biotin, 
lysed in 1% OGP and a Lowry protein assay performed. 500pg of each of these lysates 
was pre-cleared as per protocol (see Appendix 8) with 50pl of Protein A:G beads 
(Amersham). The sample was then incubated with anti-AII antibody for 1 hr at 4°C and 
immunoprecipitation was then performed as per protocol (see Appendix 8) using 50pl of 
Protein A:G beads. The samples were then run on a 12.5% gel under non-denaturing 
conditions and subject to western transfer. The blot was then probed with streptavidin-
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HRP and subject to densitometry. As can be observed in Figure 5.7A, this process 
detected a band corresponding to the correct weight for All, which was down regulated 
by IFNy. The level of cell surface All expression decreased by approximately 2 fold (43 
± 3 decreasing to 23 ± 1) following 2 hrs and was absent after 8 hrs stimulation with 
IFNy. This was verified through statistical analysis using one-way ANOVA analysis that 
resulted in the identification of a significant difference in mean All expression with 
exposure to IFNy (P=<0.0001). To identify which time point contributed the most 
significant difference in All expression a Dunnett test was performed, with the exception 
of the 1 hour time point, all other data groups displayed a significant difference when 
compared to the baseline (2vs.O hrs = -19.3, 6vs.O hrs = -32.3). The most significant 
difference was at the 8 hr time point (-44.0 at 95% Cl) confirming the earlier observation 
that this represented the maximal decrease in All expression.
To analyze the effect of IFNy on the binding partner of All, pi 1, the membranes from the 
above experiment were stripped and probed with anti-pll antibody (See Figure 5.7B). 
The bands were then analysed via densitometry and the data subject to statistical analysis 
using one-way ANOVA, which indicated that there was a significant difference in pi 1 
expression over time, in cells exposed to IFNy (P=<0.0001). To identify the length of 
exposure with most effect on pi 1 expression a Dunnett test was performed. This 
indicated that data from all time points with the exception of 1 hour, displayed a 
significant difference (2vs.O hrs =-8.0, 6vs.O hrs =-11.3) to the baseline (0 time point), 
with the greatest difference seen at 8 hours (-37.0 at 95% Cl) where expression of both 
All and pi 1 appears to be lost.
In concurrence with the effect of IFNy on All, a band of approximately 65kD was seen to 
be fractionally down regulated at 2 hrs and lost at 8 hrs stimulation with IFNy. This band 
was the wrong molecular weight to be monomeric pi 1 or the AII/pl 1 heterotetramer and 
therefore may represent non-specificity of the antibody. The same antibody was, 
however, also able to detect a band of the correct monomeric weight for p ll in total 
lysate samples exposed to denaturing conditions (see Figure 5.7C). A 65kD band was 
additionally detected in a p ll immunoblot of cell surface proteins liberated by calcium 
treatment (Figure 5.7D), indicating that this may represent some other form of p ll
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complex possibly with All. Unfortunately, the images obtained from these blots had high 
background interference and consequently the bands were not able to be accurately 
quantified via densitometry, which made statistical analysis of the results impossible.
The timescale of surface All regulation by IFNy was also examined by timecourse 
studies utilizing the calcium depletion methods for the release of All. In the first instance 
750,000 1542 CP3TX cells were cultured and stimulated with IFNy for each 0, 1, 2, 4, 6 
and 8 hours. The surface All was then liberated using 0.5mM CaCl2 as per protocol (see 
section 2.2.8). 30pg of each of the samples was loaded onto a 15% gel, run and 
transferred as per protocol (see section 2.2.10). The membrane was then probed with anti- 
AII and anti-plasminogen antibodies, the results were analysed by densitometry a 
representative image of which can be observed in Figure 5.8A.
A one-way ANOVA analysis was performed on these data to elucidate whether exposure 
to IFNy had a significant effect on surface All expression, this analysis indicated that 
there was a significant difference in mean All expression following various lengths of 
exposure to the cytokine (P<0.0001). A further Dunnett test was used to identify those 
time points at which All expression deviated most significantly from the baseline. The 
results confirm that there is a significant reduction in surface All expression within 1-2 
hrs (a difference of -14 at both time points when compared to the base line) and a loss of 
expression within 4-6 hrs of IFNy stimulation (with differences of 41 and 44.3 from the 
base line respectively at 95% confidence limits). Immunoblotting for pro-cathepsin B, an 
endoproteinase requiring All to bind to the cell surface, revealed a decrease in the level 
of surface associated pro-cathepsin B at the same time point as the majority of All is lost. 
This was analysed via densitometry and confirmed by statistical analysis using one-way 
ANOVA followed by a Dunnett test. Thee data disclosed that interferon gamma 
treatment had a significant effect on the amount of pro-cathepsin B present on the cell 
surface (P=<0.0001) and that all time points displayed a significant difference in 
expression of the protein when compared to the baseline (-13.3 for all time points at a 
95% Cl).
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To further confirm these results and clearly delineate the timescale of surface All 
modulation, a similar study was conducted using EDTA release of this protein. 750,000 
1542 CP3TX cells were grown to 70% confluence, stimulated with IFNy at a 
concentration of 500U/ml for 0, 20, 40, 60, 120, 240, 360 minutes and the cell surface 
All eluted with EDTA as per protocol (see section 2.2.8). 30pg of each sample was then 
run on a 15% gel, subject to standard electrophoresis and western transfer. This 
membrane was then probed with anti-AII and anti-plasminogen antibodies. This 
experiment was repeated in triplicate, a representative result can be seen in Figure 5.8B. 
These results were quantified by densitometry and analysed using one-way ANOVA, 
within which the data revealed that there was a significant difference in the mean 
expression of All on exposure to IFNy over a 360 minute timescale (P=<0.0001).
These results do not replicate the reduction in All surface expression after 1 hr seen in the 
CaCh release time course. However, the majority of surface expression is lost at 4 hrs 
with a complete loss at 6 hours of stimulation with IFNy. This was confirmed by the 
Dunnett test which indicated that there was no significant difference in mean All 
expression until 240 minutes of interferon exposure had elapsed (a difference of -24.8 
from the base line) and that the maximal difference was observed at 360 minutes (a 
difference of -41.8 at 95% Cl from the base line). The apparent retention of All 
expression seen in the results of this experiment may represent an increased efficiency of 
EDTA to elute All from the surface. Plasminogen immunoblotting however does suggest 
some change in surface All within this timescale, whether in expression or conformation, 
as after 20 minutes stimulation with IFNy, plasminogen which requires All to bind to the 
surface, is lost (Figure 5.8B). These results were analysed by densitometry and confirmed 
by one-way ANOVA statistical analysis. These data suggest not only a significant effect 
of interferon exposure on plasminogen present on the surface of cells (P=<0.0001) but 
that also all time points displayed significant mean differences when compared to the 
baseline, ranging from -6.8 for 20 vs. 0 minutes, to -15.5 for 360 vs. 0 minutes. This 
indicates that there is a two-stage loss of plasminogen from the cell surface with a portion 
lost at 20 minutes and the remaining protein lost at 360 minutes corresponding with the 
total loss of All from the cell surface at this time point.
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To explore the time dependent effect of IFNy on the cell surface expression of All in 
other prostate cell lines, an EDTA time course experiment was conducted using the other 
isogenic prostate cell lines 1532 NP/1532 CP3TX and 1535 NP/1535 CP3TX. 3 x T-80 
cell culture flasks of each cell line each containing 750,000 cells, were grown to 70% 
confluence and stimulated with IFNy for 0, 1, 2, 3, 4 and 6 hours. The surface All was 
eluted using the EDTA release method, 50fig of sample was loaded onto a 12.5% SDS 
PAGE, run and then transferred to a nitrocellulose membrane. This membrane was then 
probed with the anti-AII antibody and the expression of All analysed via densitometry. 
This experiment was performed in triplicate, representative results of which can be 
observed in Figure 5.9.
The results in Figure 5.9 suggest that both isogenic pairs of cell lines express All on the 
cell surface. Both 1535 NPX and CPT cells express high levels of All and appear 
unaffected by IFNy treatment. This was confirmed by two-way ANOVA analysis which 
found no significant difference in All expression when densitometry data was categorised 
by cell line (P=0.7) or time point (P=0.51), with no significant interaction between these 
factors (P=0.77). The other isogenic pair, 1532 NP and CPT however, did show a surface 
down regulation of All on stimulation with IFNy, similar to that observed in 1542 NPX 
and CP3TX cell lines. The 1532 CP3TX cell line appears to express less All on its cell 
surface than the normal cells in the resting state. On stimulation however, 1532 NP and 
CPT cell lines have the same pattern of expression, although down regulation was more 
marked in the cancer cell line. This was confirmed by statistical analysis using two-way 
ANOVA, which indicated that both cell line and exposure to IFNy factors had a 
significant effect on All expression (P<0.0001 for both factors), the enhanced down 
regulation in the cancer cell line was also indicated by the presence of significant 
interaction between the two factors (P=0.0037).
In these cell lines the level of surface All decreased significantly at 3 hrs, but appeared to 
become re-expressed at a lower level following 4-6 hrs stimulation with IFNy. The 
significance of this pattern of expression was analysed via one-way ANOVA followed by 
a Dunnett test to isolate the time point most different from the baseline. All time points, 
with the exception of 1 hour, displayed significant mean All expression differences, with
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the most significant difference at 3 hours (-17 at 3vs. 0 hrs, -14 at 4 and 6vs. 0 hrs). This 
pattern of expression, seen in all replicates, suggests that in 1532 cells surface All 
expression is lost at a point comparable to that seen in the 1542 lines, however, 
expression is regained by some unknown mechanism that does not occur in the 1542 cell 
lines.
5.2.4 Immunofluorescence analysis of the modulation of cell surface All by IFNy
The relationship between All, p ll  and the cell surface was examined further by 
immunofluorescence of these proteins in 1542 NPX and CP3TX cells. The two cell lines 
were seeded into a 24 well plate containing cover slips at a density of 2,000 cells per well 
and cultured for 48 hrs. IFNy was then added to half the cells and incubated for 24 hrs. 
Immunofluorescence was then performed as per the live cell protocol (see section 2.2.15) 
using All and pi 1 antibodies, in addition to phalloidin to stain actin and cholera toxin to 
stain GM1 gangliosides, which are a present in high abundance in lipid rafts. Following 
staining the cells were photographed under x40 magnification using a confocal 
microscope. Representative images can be observed in Figure 5.10.
The immunofluorescence staining indicated that All was indeed present on the surface of 
1542 NPX and CP3TX cells and that stimulation with IFNy reduced the level of All on 
the cell surface. A generalised pattern of All staining could be observed in both 1542 
CP3TX and NPX cells in their unstimulated state. The pattern of staining in these cells, 
however, differed greatly following 24 hour stimulation with IFNy. The staining in 1542 
NPX cells changed following stimulation from a generalized to focal staining of the 
membrane, to a pattern localised to areas corresponding to lipid raft structures. These 
lipid rafts appeared to congregate into large semi-circular structures polarised to one side 
of the cell. In IFNy stimulated 1542 CP3TX cells, however, All staining was vastly 
reduced and not localised to lipid raft structures. In these cancer cells lipid rafts appear to 
be more prevalent in the unstimulated state than in the corresponding normal cell line, on 
stimulation they appear remain at the same level or decrease in size and number.
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Cell surface staining for p ll in unstimulated 1542 NPX and CP3TX cells was more 
discrete than that observed with the All antibody. Unfortunately, it was impossible to use 
both antibodies in conjunction as both were derived from mice and of the same isotype. 
The cellular localisation of pi 1 in unstimulated cells closely mirrored that of the lipid raft 
structures in both cell lines. On stimulation, there was an accumulation of p ll in the 
hyper-enlarged lipid raft structures in the 1542 NPX cells, although the overall intensity 
of staining appeared to decrease. In stimulated 1542 CP3TX cells pi 1 staining was vastly 
reduced, possibly due to a reduction in lipid raft structures. When compared, All and pi 1 
proteins appear not to co-localise in unstimulated cells from either cell line (compare top 
images Figure 5.10 and Figure 5.11). However, under stimulation the proteins adopt a 
more similar pattern of staining (compare bottom images Figure 5.10 and Figure 5.11). 
This could possibly be due to a loss of monomeric All on the cell surface, leaving only 
the heterotetramer containing pi 1 bound to lipid rafts, when stimulated with IFNy.
5.2.5 The influence of IFNy on cell invasive capacity
The functional effect of All surface down regulation by IFNy on prostate epithelial cells 
was explored by means of cell invasion assays. 1.5 x 106 of each NP, 1542 CP3TX and 
LNCaP cells were cultured to 70% confluence at which point half of the flasks were 
stimulated with 500U/ml IFNy for 24 hrs. All cells were then removed from the growing 
surface and subject to the cell invasion assay protocol included in section 2.2.16. The 
migrants were then counted, these data pooled from six replicate experiments, tabulated 
and subject to the student’s t-test. A graph representing this data can be observed in 
Graph 5.1.
These cell invasion studies disclosed a statistically significant (to 95% confidence limits) 
correlation between IFNy stimulation and invasive capacity. Both 1542 NPX and CP3TX 
cells showed a reduction in invasive capacity when IFNy was present in the media, this 
reduction was statistically significant in both cell lines (p=0.0024 in NPX cells and 
P=0.029 in CP3TX cells). In LNCaP cells, that express no All, there was reduced 
invasive capacity and no reduction on stimulation with IFNy.
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The above experiment demonstrated that IFNy affects the invasive capacity of cells 
expressing All. The involvement of All in retarding cell invasion was confirmed by 
conducting an Anti-AII invasion assay. This assay followed a similar protocol to that 
featured above with the exception that only 1542 CP3TX cells were used and that an anti- 
AII antibody was added (see section 2.2.16). The data resulting from six replicate 
experiments can be observed in Graph 5.2.
The results of the anti-AII invasion assay indicated that there was a statistically 
significant reduction (p=0.021) in invasive capacity in 1542 CP3TX cells when anti-AII 
mAb was present in the media. A control assay following the same protocol but using 
mouse IgG confirmed that this result was not due to a non-specific antibody interaction 
(Graph 5.3). The functional effect of All expression on invasive capacity was explored 
further by re-expressing the protein in the LNCaP cell line. For this experiment, the 
LNCaP cells were seeded into a 24 well plate at a density of 71,250 cells per well then 
subject to transformation as per protocol (see section 2.2.17). GFP expression was then 
analysed and photographed (See Figure 5.12). Following a subsequent round of 
transformation, cell invasion assays were performed in six replicate experiments as per 
protocol (see section 2.2.16). The data from this experiment are represented in Graph 5.4. 
Figure 5.12can be observed in Figure 5.12.
The photograph in Figure 5.12 demonstrates that GFPAII expression in transfected 
LNCaP cells localises mainly to the perinuclear area. However, at higher magnification in 
the migrant cell pictured in Figure 5.13, cell borders can be observed which suggests a 
proportional membrane localisation for the GFPAII. This membrane expression of All 
may be responsible for the increased invasive potential of GFPAII transfected LNCaP 
cells observed in Graph 5.4. This graph demonstrates that there is a significant 
(P=0.0019) improvement in invasive capacity with GFP All transfection when compared 
to that of the vector only.
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5.2.6 Analysis of All membrane transport in prostate epithelial cells
The pathway by which All is transported to the cell surface is unknown; however, recent 
studies have suggested that Al is transported to the cell surface via ABCA1. To 
determine whether this transport pathway is also responsible for the externalisation of 
All, several studies were performed. Firstly following the protocol of Chapman et al 
2003, 1542 CP3TX cells were exposed to glyburide an agent known to inhibit ABC 
transporters and dexamethasone known to stimulate the external isation of Al. Six T-80 
flasks each containing 750,000 1542 CP3TX cells were cultured to 70% confluence and 
then treated with or without glyburide, in the presence or absence of dexamethasone. The 
stimulation of the cells was performed as follows; glyburide was added to the cell media 
24 hrs before lysis at a concentration of lOOpM, this agent is dissolved in DMSO the 
concentration of which was kept below 0.01% and a DMSO control included. 
Dexamethasone was added 3 hours before lysis at a concentration of 0.1 pM, this 
compound is soluble in EtOH, which was kept below 0.1% and an EtOH only control 
included.
Following culture and stimulation the cells were washed x3 with lx PBS and 1ml of 
0.5mM EDTA was added for 1 minute to liberate the surface bound All. The cells were 
then lysed in 1% OGP as protocol (see section 2.2.4). The samples were then vacuum 
dried where necessary and protein concentrations quantified using the Bradford assay 
protocol (see Appendix 2). The samples were then loaded at a concentration of 50pg of 
protein per well onto a 12.5% gel and subject to standard electrophoresis and western 
transfer. This was repeated in triplicate and the membranes were probed with anti-AII 
antibody, a representative result of which can be observed in Figure 5.14.
These results were quantified via densitometry and normalised against their respective 
controls i.e. DMSO or ETOF1 and analysed statistically using two-way ANOVA analysis. 
Both factors dexamethasone and glyburide, were found to have a significant effect on 
intracellular and extra cellular All expression (P<0.0001 in all cases) and there was a 
significant interaction between the two factors (PO.OOOl). Glyburide treatment
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decreased the proportion of All on the surface of 1542 CP3TX cells and increased that 
present in the total cell fraction, in comparison to the DMSO control. Dexamethasone 
slightly increased the amount of All on the cell surface but greatly reduced that found in 
the total cell lysate. When both agents were used together the same All pattern of 
expression as with dexamethasone alone was found in both surface fraction and cell 
lysate.
To observe the timescale of the effect of glyburide on surface All, a time course using 
this inhibitor was conducted. 12 T-80 cell culture flasks each containing 750,000 1542 
CP3TX cells were cultured to 70% confluence (1.5 x 106 cells for each time point) and 
exposed to lOOpM glyburide for 0 (DMSO only), 20, 40, 60, 120 and 240 mins. The cells 
were washed three times in lx PBS then 500pl of 0.5mM EDTA was used to liberate 
surface All from both flasks. The sample was then vacuum dried and the cells lysed in 
1% OGP. The EDTA and OGP samples were loaded onto a 12.5% gel at concentrations 
of 50fig and 30fig per well respectively and subject to western transfer as per protocol. 
All expression was quantitated by immunodetection and densitometry. This experiment 
was conducted in triplicate and a representative result can be observed in Figure 5.15A. 
Statistical analysis of these results, using one-way ANOVA, indicated that the reduction 
in All expression on the cell surface showed a significant correlation with time of 
exposure to glyburide (P<0.0001). The greatest lpss of expression was observed at the 
1 2 0 -minute time point and expression appeared to then remain at a low level for the 
duration of the time course (see 5.15A). This was further confirmed by the Dunnett test 
which indicated that the only significant difference in surface All expression was seen at 
time points 120 and 240 (a difference of -19.4 in both cases). A one-way ANOVA 
analysis also confirmed that glyburide had a significant effect on All expression within 
the cell (P<0.0001). All expression in the total lysate increased slightly at 40 mins, with 
total All expression remaining at this level for the remainder of the time course. This was 
also indicated by the Dunnett test which disclosed significant difference in mean All 
expression from the 40 minute time period onwards (average difference of 8.2 at all time 
points except 20 mins). The intra and extra cellular expression of All, measured by
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densitometry of immunodetected bands, appears to follow an inverse trend on exposure 
to glyburide as can be observed in Graph 5.5.
To confirm that glyburide treatment does negate All surface expression 1.5 x 106 1542 
CP3TX cells were cultured plus or minus lOOpM glyburide for 24 hours, then washed 
and the surface All EDTA liberated. These samples were run at a concentration of 50pg 
per well on a 12.5% gel. This was repeated in triplicate, a representative result can be 
seen in Figure 5.15B. In this figure, it can be observed that the expression of surface All 
is lost following 24 hr exposure to lOOpM glyburide (Figure 5.15B). These data were 
quantified and subject to statistical analysis via the students t-test which resulted in a 
significant difference (P=0.0005) in All expression between those cells exposed to 
glyburide and those exposed to the control DMSO.
In a previous experiment, it was noted that dexamethasone could increase the level of All 
expressed on the cell surface, to observe whether this effect could negate the suppressant 
effect of IFNy, the following experiment was conducted. 4 x T-80 cell culture flasks each 
containing 750,000 cells were cultured to 70% confluence and stimulated with or without 
0.1 pM dexamethasone, plus or minus IFNy for three hours. The cells were then washed 
and the surface All liberated by EDTA release, following which the cells were then lysed 
in 1% OGP. 20pg of each sample was run on a 10% gel and subject to western transfer. 
This was repeated in triplicate a representative result of which can be observed in Figure 
5.16.
These results were quantified and subject to two-way ANOVA statistical analysis. The 
results of this confirm that three hour exposure to IFNy decreases surface All 
significantly (PO.OOOl) and that dexamethasone significantly increases the level of this 
protein on the cell surface (P=0.002). When both agents are applied together however the 
effect appears similar to that of IFNy alone, however ANOVA analysis shows there is 
significant interaction between the two factors (P<0.0001).
141
To analyse whether the glyburide and IFNy dependent decrease in All expression was 
due to a down regulation in ABCA1 expression, the level of ABCA1 on exposure to these 
agents was analysed in a timecourse experiment. 750,000 1542 CP3TX cells were 
prepared and stimulated with IFNy for 0, 1, 2, 4, 6  hours. Two separate flasks each 
containing 750,000 cells were prepared for the glyburide exposure of 0 and 24 hours. The 
cells were washed three times, lysed in 500jil 2DLB and 40pg of each loaded onto a 10% 
gel, run and subject to western transfer as per protocol (see section 2.2.10). The 
membranes were then probed with anti-ABCAl antibody. This experiment was repeated 
in duplicate, an image of which can be seen in Figure 5.17. These results show that there 
is no change in ABCA1 expression either on stimulation with IFNy or inhibition with 
glyburide.
The activity of the ABCA1 transporter is known to be affected by phosphorylation of 
threonine residues in a PEST sequence, see Figure 5.18 (Wang et al., 2003). 
Phosphorylation of this site is thought to lead to targeted degradation by calpains. The 
hypothesis that phosphorylation could be a mechanism for down regulation of the activity 
of ABCA1, subsequently lowering the level of All, was tested via the following 
experiments. Firstly, isoelectric focussing (IEF) analysis was performed on 40pg of 1542 
CP3TX cell lysates from the above experiment, using Ampholine PAGplate gels pH 5.5- 
8.5 (Amersham). The samples were loaded onto two sample application strips placed on 
the negative edge of the gel and run as per manufacturer’s instructions (see Appendix 9). 
The gels were then transferred and probed with anti-ABCAl antibody. Unfortunately, the 
IEF separation time was not sufficient in this first experiment to resolve the protein 
sufficiently; however, the poorly resolved band did appear to migrate towards the 
negative terminal between 2 to 4 hrs, which could be suggestive of phosphorylation. A 
second replicate of the experiment, which was subject to IEF as listed in the 2DGE 
protocol, was sufficient to resolve bands. These results indicated that following 1 hr of 
stimulation with IFNy the band recognised by the ABCA1 antibody, shifts slightly 
towards the negative electrode and several additional bands appear. These additional 
bands are lost between 4-6hrs and may correspond to degradation products produced by
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labelled IFNy timecourse of 1542 CP3TX cells conducted by Dr S Naaby-Hansen (see 
Figure 5.19). Densitometry of these results revealed that ABCA1 expression decreased to 
70% following 1 hour and was further reduced to below 50% after 4 hour stimulation 
with IFNy in unlabelled cells and that this reduction was accompanied by an 
accumulation of lower molecular weight forms which may represent cleavage products. 
The results of the radio labelling experiment indicated that ABCA1 and the lower 
molecular weight forms became increasingly phosphorylated following 4 hrs of exposure 
to IFNy (see Fig.5.19B).
To delineate the involvement of calpain II in the modulation of ABCA1 activity and 
subsequent down regulation of All, calpain II inhibition studies were performed. 18 x T- 
80 flasks of 1542 CP3TX cells each containing 750,000 cells were cultured to 80% 
confluence, at which point 12 flasks were treated with 30pM calpain II inhibitor 
(Calbiochem) dissolved in DMSO, for two hours. The final concentration of DMSO was 
kept to 0.001% in the media. Following this, the untreated and calpain II inhibitor treated 
cells were stimulated for 0, 1, 2, 4, 6  hours with lOOU/ml IFNy. The cells were then 
washed three times in PBS, the surface All was eluted with 0.5mM EDTA and 50pg of 
this sample was run on a 12.5% gel and transferred to a nitrocellulose membrane. The 
membrane was probed with anti-AII. This was replicated in triplicate and analysed via 
densitometry, a representative result can be seen in Figure 5.20.
IFNy stimulation of cells without calpain II inhibition leads to a down regulation of 
surface All at 4 hrs. However, when cells were pre-treated with calpain II inhibitor the 
level of All surface expression remains the same even after 4 hour stimulation with IFNy. 
This can be observed in Graph 5.6. These results were analysed statistically by two-way 
ANOVA which indicated a significant difference in All expression with temporal 
exposure to IFNy and to the calpain inhibitor (P<0.0001 in both cases) and there was a 
significant interaction between the factors (P<0.0001). This suggests that there may be 
some calpain dependent regulation of surface expressed All.
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The calpain II inhibitor used in this study specifically acts on calpain I and II. The 
expression of calpain II was examined in the following study to observe any changes in 
expression pattern on stimulation with IFNy. The membranes created in the IFNy 
stimulated time course study of All expression in 1532/35 NP and CPT cell lines were 
stripped and re-probed with an anti-calpain II antibody. The results of this can be 
observed in Figure 5.21. The results of this study suggest that at least two forms of 
calpain are present in NP cells of both 1532 and 1535 lines. The corresponding cancer 
cell lines however, appear not to express both of these molecular weight forms. In 1532 
CPT cells the higher molecular weight form is expressed, whereas in 1535 the lower 
molecular weight form appears to predominate (Figure 5.21). In all cell lines calpain II 
expression appears to be induced following 1 hour of stimulation with IFNy. In the 
cancer cell lines, this expression shows an apparent decrease at 4 hours and is regained at 
6  hours. Due to the presence of different calpain isoforms and high background, possibly 
due to poor specificity of the antibody, statistical analysis of these data was not possible.
5.3 Discussion
This study aimed to examine the effect of IFNy on the cell surface expression pattern of 
one protein, All. The aim was addressed by focussing on three areas of study, firstly the 
modulation of All on the cell surface by IFNy, secondly the functional effect of this 
modulation and finally the transport of All to the cell surface.
5.3.1 The surface specific modulation of All by IFNy
Once the down regulation of All had been confirmed by immunoblotting, subsequent 
studies sought to examine whether this effect on All expression was observed on a total 
cellular expression level. No change was seen in the total level of All expression 
following 24 hr stimulation with IFNy, in any of the cell lines tested. These results 
suggest that All down regulation is surface specific involving either the regulation of the 
translocation of All to or its release from the plasma membrane. This was examined 
further in the third section on All transport.
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In the panel of prostate cell lines tested for All expression, LNCaP was the only cell line 
lacking expression of the protein. This had been found previously, in a study that 
suggested All was ubiquitously lost in PCa (Chetcuti et al., 2001a). The results of the 
present study however suggest the converse, that All is expressed in the majority of 
prostate cell lines. The reason for the lack of All expression in LNCaP has been 
postulated as being due to the methylation of the gene promoter. In this study, LNCaP 
lysate from cells that had been exposed to a de-methylating agent appeared to express a 
low level of a protein corresponding to the correct weight for All. Due to the nature of 
this result in both replicate experiments however, it is difficult to draw conclusions from 
this study. Although promoter methylation and subsequent silencing of the All gene in 
LNCaP is a parsimonious possibility, it is equally possible that the methylation status of 
the promoter is negligible and that the expression of the protein is due to a distal DNA 
demethylation leading to the reactivation of a protein upstream in the regulation pathway 
of All. This mechanism of gene activation was observed in a recent study of the cell 
cycle regulator protein p21WAF (Schmelz et al., 2005). To further investigate this 
possibility it would be necessary to characterize the other genes reactivated by 5-aza- 
deoxycytidine treatment and analyze their interaction with the All gene, transcript or 
protein. There are alternative hypotheses for the expression of All following 5-aza- 
cytidine treatment that require further exploration. 5-aza-deoxycytidine is a potent 
inhibitor of DNA Methyltransferase 3a and as such treatment with this drug does not 
have a specific effect on the All gene, it has been noted to have wide range 
demethylating and gene activating capabilities (Schneider-Stock et al., 2005). These 
include the activation of genes involved in cell cycle arrest (Schmelz et al., 2005, Lavelle 
et al., 2003), DNA repair (Arnold et al., 2003, Kim et al., 2002), apoptosis (Pulukuri and 
Rao, 2005) and transport (Worm et al., 2001). The activation of genes coding for 
transport proteins may particularly influence expression of All, as this protein is thought 
to be transported to the surface via a yet unknown protein chaperone. The most likely 
protein chaperone candidate is ABCA1, a protein which is part of a multi-drug resistant 
family, the expression of which is known to be affected by de-methylation with 5-aza- 
deoxycytidine (Worm et al., 2001). The effect of this drug on the transport of All could 
be further explored by the transfection of fluorescent All mutant constructs, with
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deletions in the protein binding domain (commonly the amino terminus), the location and 
expression of which could be followed post treatment with 5-aza-deoxycytidine. In 
conjunction, the expression of proteins likely to be involved in All transport, such as 
ABCA1, could be examined via immunoblotting pre and post treatment with 5-aza- 
deoxycytidine.
Due to the debate surrounding the surface localisation of All, it was necessary to confirm 
the cell surface expression of this protein. This was achieved by immunofluorescence and 
through the liberation of All by altering the level of extra cellular calcium. The initial 
immunofluorescence studies confirmed a plasma membrane localisation of All, there was 
however, background staining within the cells. This is not unexpected as the majority of 
All is expressed within the cell commonly localised to the cytoplasm and cytosolic face 
of the PM. Further evidence was required to support the surface expression of All and 
this was provided by All release through the modulation of the level of extra cellular 
calcium. Decreasing the level of calcium either by reducing the level of calcium in the 
extra cellular milieu or by the addition of the calcium chelator EDTA led to the release of 
All, proving that this protein was indeed present on the cell surface and bound in a 
calcium dependent fashion. EDTA extraction proved to be the more efficient method for 
providing a high yield of All. The concentration of EDTA most efficient at All release 
was 0.5- ImM. To ensure that the All released by either of these methods was solely from 
the cell surface and not due to protein leaking from the cell the nitrocellulose membranes 
could have been probed for an abundant intracellular protein such as (3-actin.
Treatment with EDTA at higher concentrations led to the release of an additional protein 
of approximately 34kD also recognised by the All antibody. The ability of this isoform to 
be liberated by higher EDTA concentrations, suggests that it is less sensitive to extra 
cellular calcium depletion. This protein may represent an isoform of All modified by 
cleavage, a phenomenon which has been reported previously (Babiychuk et al., 2002). In 
a recent study All was found to be subject to cleavage at the amino terminus yielding a 
34kD band, most likely to be facilitated by cathepsin, calpain or another metalloprotease 
(Babiychuk et al., 2002). The amino terminus of All is thought to be necessary for both
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heterotetramer formation and interaction with cholesterol in the plasma membrane (Gerke 
and Moss, 1997). It is possible therefore, that cleavage of All in this region yields an 
isoform, which cannot form the standard heterotetramer, but is still able to bind 
phospholipids in perhaps a monomeric confirmation. This cleavage would give two 
species of All on the cell surface, a full-length heterotetrameric form capable of binding 
cholesterol and phospholipids in a calcium dependent fashion and a truncated monomeric 
form capable of only binding phospholipids. In a previous study these different species of 
All were found to occupy different membrane locations, the lull length form present in 
lipid rafts, the truncated form in non-raft associated regions (Babiychuk et al., 2002). 
This result may suggest that All is present in a heterotetrameric form bound to 
cholesterol in the lipid rafts and a monomeric form more generally bound to 
phospholipids. The localisation of the All species on the cell surface is explored further 
in immunofluorescence studies, discussed later in this chapter.
Once the cell surface localisation of All had been confirmed, further studies sought to 
characterise the action of IFNy on surface All expression in 1542 NPX and CP3TX cells. 
Initially this was achieved through immunoprecipitation using the All antibody, which 
revealed that surface All is down regulated following 2 and lost after 6  hours stimulation 
with IFNy. Immunoblotting of the same membranes with an anti-pl 1 antibody indicated 
that the expression of this binding partner of All followed the same pattern of down 
regulation by IFNy as All. This result was inconclusive however as the band detected 
with the p ll antibody was of the incorrect molecular weight for monomeric pi 1. This 
band can also be detected in eluate from calcium-dependent extractions of All, when 
probed with the pi 1 antibody. This may be the result of a non-specific interaction of the 
antibody with some other protein, or a p ll complex resolved in the non-denaturing 
conditions. This complex may involve All as the two co-immunoprecipitate, however 
this band cannot correspond to the full heterotetramer, as the molecular weight is 
incorrect for this complex. Further research would require identification of the 
constituents of this band via mass spectroscopy.
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The elution of All by manipulating external calcium levels was also used to confirm the 
timescale of IFNy action. The studies using the CaCh method of extraction, demonstrated 
that surface All expression was down regulated between 1-2 hours and lost between 4-6 
hours. This confirmed the timescale of regulation seen in the previous 
immunoprecipitation experiment. The membranes for this experiment were also probed 
with pro-cathepsin B, a protease that requires surface expressed All as a binding site for 
its activation. Immunoblotting with this antibody resulted in the detection of a band 
corresponding to the correct weight for pro-cathepsin B that followed the same pattern of 
down regulation and loss as All. The timecourse study employing EDTA release of All 
showed no reduction in surface expression at the earlier time point, but replicated the loss 
of expression at 4-6 hours. The explanation for this differing result may be that EDTA is 
more efficient at eluting surface bound All and therefore masks a partial reduction in All 
after 1-2 hrs. There must be, however some change in the expression or conformation of 
All in the first hour as when the membranes were probed for plasminogen, expression of 
this All binding protein is lost after a 20 minute stimulation with IFNy.
In summary these studies suggest that All is down regulated on the surface of 1542 
CP3TX cells following 2 hours and lost after 6  hours stimulation with IFNy. The cell 
surface down regulation of All by this cytokine is therefore, extremely fast and likely to 
be the result of post-translational modification of All or of proteins in its transport 
pathway. The concurrent loss of plasminogen and pro-cathepsin B would be expected of 
a protein using surface All as a binding site, as this protein would lose its association 
with the membrane following the loss of All. The loss of All as a platform for 
interaction/activation of proteases and ECM components may explain some of the 
functional effects on cell invasive capacity seen on stimulation with IFNy, these effects 
are discussed later in this study.
The down regulation of surface All by IFNy was explored in two other pairs of isogenic 
cell lines to examine whether this response was a common feature amongst prostate cell 
lines. The 1535 NP and CPT cell lines appeared to express higher levels of surface All 
than the 1542 NPX and CP3TX cells and this expression was unaffected by IFNy. The
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1532 NP and CPT cell lines, however, did appear to show a reduction in expression of 
All at a time point comparable to that of the 1542 cell lines, with the exception that 1532 
cells regain expression of this protein. This response is possibly due to the activation of a 
redundant pathway, that the 1542 cells are unable to activate. A similar pattern of 
reactivation was also observed in recent studies of the highly invasive head and neck 
squamous cell carcinoma cell line HN5. This research, conducted at the proteomics lab at 
the Ludwig Institute, focussed on the cell surface expression of All following exposure to 
IFNy. The results of this study indicated that surface All was lost at 1 hr and regained at 
2 hrs following treatment with this cytokine. It appears from these results that IFNy has a 
rapid reductive effect on surface All in a number of cell lines including those known to 
be from highly invasive cancers. This may be therapeutically advantageous, given the 
potential role of All in cell invasion, in limiting the invasive and metastatic potential of 
such cancers. However, as several of the cell lines show a re-expression of All further 
research is required to delineate the response of other cancer cell lines to IFNy and the 
signalling pathways involved.
The final part of the study into cell surface All modulation by IFNy sought to examine 
the spatial relationship between All, pl l ,  lipid rafts and the cell surface, using 
immunofluorescence. The results of this study suggest that the surface specific down 
regulation of All by IFNy appears also to involve a change in localisation of both 
proteins. In unstimulated cells from both 1542 NPX and CP3TX cell lines, generalised 
All staining can be observed on the surface of the cells, which is reduced when both cell 
lines are exposed to IFNy for 24 hrs, confirming previous immunoblotting results. A 
similar response, in terms of surface All expression, of these isogenic cell lines to IFNy 
was noted in earlier studies. However, differences in the pattern of All expression were 
observed when the localisation of All and lipid raft structures was examined. In the 
normal cell line, on stimulation with IFNy, large semicircular structures that co-stain with 
cholera toxin, actin and anti-AII appear polarised towards the edge of the cell. This 
enlargement and fusion of lipid raft structures in normal cells following exposure to 
IFNy has been previously reported and denoted a “signalosome” containing many IFNy 
signalling factors such as IFNyR, STAT’s and JAK proteins (Sehgal et al., 2002).
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Formation of such a signalling platform could enhance the normal cell’s sensitivity to 
cytokines and therefore heighten immunosurveillance. In 1542 CP3TX, no enlargement 
or fusion of lipid raft structures is observed. In fact, the cancer cells appear to have a 
higher number of lipid rafts in the unstimulated state this however, does not increase on 
stimulation with IFNy. As lipid rafts are reported to contain a number of signalling 
factors including EGFR, an increased number of lipid rafts in the unstimulated state could 
be a selective advantage in the cancer cell, as it may increase the cell’s sensitivity to 
ambient levels of growth factors, increasing the mitogenic potential. However, such 
structures would become disadvantageous when the cell was exposed to cytokines as they 
contain all the molecules required for transduction of the growth inhibitory and motility 
reducing effects of IFNy. Therefore, suppression of the formation of such signalosomes 
on induction by IFNy would be a selective advantage for the cancer cell in avoiding 
immune surveillance.
In comparison to All, the staining of its heterotetrameric partner pi 1 in both 1542 NPX 
and CP3TX unstimulated cells was more localised, showing discrete co-localisation with 
lipid raft structures. On stimulation the level of expression of pi 1 is reduced in both cell 
lines, more markedly in 1542 CP3TX cells. In 1542 NPX cells pi 1 appears to accumulate 
in the enlarged lipid raft structures in a similar pattern to All, as 1542 CP3TX cells do not 
possess this structure pi 1 may be present at low levels in the cytoplasm. The difference 
in staining between the All and pi 1 proteins in unstimulated cells supports the theory that 
several All conformations are present on the surface of these prostate epithelial cells. As 
the only known function of pi 1 is to bind All in a heterotetrameric formation and in the 
above study p ll is only found associated with lipid rafts, it follows that the 
heterotetrameric form of All is found in the lipid raft structures. The generalised All 
staining seen in unstimulated cells may correspond to monomeric binding of the 
truncated All protein to the cell surface. On stimulation with IFNy this generalised 
membrane staining of All disappears, remaining only in the enlarged lipid raft structures 
in 1542 NPX cells. This could correspond to a loss of the monomeric form from the cell 
surface either by regulation of the release or translocation of All to the cell surface. 
Retention of the All tetramer on the cell surface may be due to its association with the
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lipid raft structures, or its heterotetrameric conformation. 1542 CP3TX cells do not 
appear to induce the formation of enlarged lipid raft structures on stimulation with IFNy 
and therefore may not retain the All heterotetramer. This may be the cause of the greater 
reduction in surface All seen in the earlier All immunoblotting of cell surface fractions 
from 1542 CP3TX cells in the presence of IFNy stimulation, in comparison to their 
normal counterpart.
5.3.2 The functional effect of surface AII down regulation by IFNy
As All has been widely reported to play a role in cell invasion, the functional effect of 
cell surface specific down regulation of All by IFNy was examined using cell invasion 
assays. The results of these studies disclosed a correlation between IFNy stimulation and 
invasive capacity. In all cell lines tested that express All, a reduced invasive capacity was 
observed following 24 hour treatment with IFNy. This reduction was statistically 
significant in both 1542 NPX and CP3TX cells. The finding that the greatest reduction in 
invasive capacity is seen in normal cells appears anomalous, however normal cells can be 
extremely invasive (Mareel and Leroy, 2003). The only cell line not to show a decrease 
in invasive capacity when stimulated with IFNy was LNCaP, a cell line that does not 
express All. This may suggest that All is responsible for the effect IFNy has on invasive 
capacity. To confirm this theory invasion assays in the presence of an anti-AII antibody 
were performed. The results of this study indicated that All has a role in the invasive 
capacity of the cell, as there was a significant decrease in the invasive capacity of 1542 
CP3TX cells when the anti-AII antibody was present. No change in invasive capacity was 
observed when an alternative mouse IgG was used. This effect has been observed 
previously in macrophages (Falcone et al., 2001) and suggests that All does play a key 
role in cell invasion and that invasive capacity can be reduced by treatment with the 
cytokine IFNy.
The ability of surface expressed All to influence the cell’s invasive capacity was 
examined further by transfecting this protein into LNCaP cells, which express no 
endogenous All. All was transfected into LNCaP via a GFP expression vector so that 
expression could be easily observed. The majority of GFPAII expression in LNCaP was
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located in the nuclear and cytoplasmic regions of the cell. However, GFPAII expression 
was observed on the surface of LNCaP cells. This concurs in part with the findings of a 
study using the same All construct in rat basophilic leukaemia (RBL) cells, which found 
that GFPAII was located in the cell cytoplasm, membranes, but excluded from the 
nucleus (Hayes et al., 2004). This study also found that All played a significant role 
vesicle transport especially macropinosome rocketing in response to stress, where it was 
found to mediate the interaction between the macropinosome and F-actin (Hayes et al., 
2004). In another study using the same All construct GFPAII was found to localise 
within the cytoplasm, nucleus and plasma membrane of PC 12 cells. All was found to be 
enriched at the plasma membrane in a calcium dependant manner, as expression of a
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mutant construct lacking the type II Ca binding sites led to exclusively cytosolic 
expression of All (Merrifield et al., 2001).
Although the use of a GFP construct to simulate the endogenous expression of All has 
provided interesting data with regard to the possible location and function of the protein 
there are various problems with this model that must be considered. Firstly fusion of the 
GFP to the All gene may interfere with transcription or translation of the nucleic acid 
decreasing expression. Secondly the GFP tag considerably increases the size of the 
resulting protein this often leads to misfolding, which may have subsequent effects on not 
only the function of All but also its interaction with other proteins and its transport within 
the cell. The GFP tag could therefore affect both the localisation and function of the All 
protein. In addition the GFPAII was expressed in LNCaP cells, which normally do not 
express the protein and therefore may not possess the transport pathway and/or 
interacting proteins necessary for All to be localised and function as it would in its 
normal state. However, the studies considered above have localised both the GFPAII 
(Hayes et al., 2004, Merrifield et al., 2001) and endogenous All (Zobiack et al., 2002, 
Deora et al., 2004) to both the intracellular and membrane localities suggested in this 
study. In addition the immunofluorescence analysis of All in 1542 NPTX and CP3TX 
cells also suggested that the protein was localised to the cytoplasm and plasma membrane 
of the cells. In light of this, the results of GFPAII expression in LNCaP cells appear to be 
an accurate reflection of localisation of All within prostate cells.
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The localisation of the GFPAII construct in LNCaP cells is unsurprising as in cells with 
endogenous All expression, the majority of All protein is observed within the cell. The 
observation of All on the surface of LNCaP cells, however, suggests that the transport 
systems and binding partners required for surface All expression are present despite the 
lack of endogenous expression. Once expression of the All construct had been confirmed, 
the transfected LNCaP cells were subject to an invasion assay to examine the effect of re­
introducing All on invasive capacity. The results of this assay further verify that All has 
a role in invasive capacity, as there was a significant increase in invasive capacity in All 
transfected cells when compared to those containing the GFP vector only.
Further studies may require the use of an All construct with a ‘super folder’ GFP tag 
which has been shown to be less prone to misfolding in vitro (Pedelacq et al., 2005). This 
could be used to further investigate the invasive capacity of All transfected cells under 
IFNy stimulation, or in the presence of anti-AII antibody. Such studies would be required 
to ascertain whether IFNy could modulate the level of surface All and therefore invasive 
capacity, in LNCaP cells. Other cell lines could also be used to negate any possible 
problems caused by lack of endogenous All expression in LNCaP cells, however this 
would lead to potential problems with All over expression masking the true function of 
this protein.
5.3.3 IFNy regulation of AII transport to the cell surface
The transport pathway responsible for the surface expression of All is unknown, due to 
the lack of signal peptide it is unlikely that All is transported via the trans golgi network 
(Chapman et al., 2003). As recent research has indicated that Al, a protein closely related 
to All in structure and function, is transported to the cell surface via the ABCA1 
transporter, the possibility that this transporter could also be responsible for the 
externalisation of All was explored (Chapman et al., 2003). Treatment with glyburide, an 
inhibitor of ABCA transporters, was seen to decrease the amount of All on the surface of 
1542 CP3TX cells, whilst increasing the amount of this protein present in the cell extract. 
The opposite effect was observed when cells were treated with dexamethasone, a protein 
known to increase cell surface expression of Al, possibly by stimulating the ABCA1
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transporter. These results may indicate that glyburide inhibits the ABCA1 transporter, 
leading to an accumulation of All within the cell and a depletion of All present on the 
outer leaflet of the PM. This effect can be reversed by dexamethasone treatment, which 
may stimulate the transporter, increasing surface All levels. Glyburide treatment of cells 
lead to loss of surface All following 24 hour exposure, a timecourse of All expression 
revealed that glyburide starts to decrease surface levels of All after 120 minutes and the 
All within the cell begins to accumulate at 40 minutes. This could provide further 
evidence that ABCA transporter activity is required for localisation of All to the cell 
surface. A similar time course study was conducted to elucidate whether stimulation of 
the ABCA transporter with dexamethasone could negate the suppressive effects of IFNy 
on All cell surface expression. The results of this study confirmed that dexamethasone 
increases the level of surface All and that treatment with IFNy alone led to a decrease in 
surface expressed All at around 3-4 hours. However, when dexamethasone and IFNy 
were applied together there was no prevention of the suppressive effect of IFNy. This 
suggests that the mechanism of action of IFNy on surface All expression via the ABCA 
transporter, is different to the action of glyburide or dexamethasone, as the down 
regulatory effect of glyburide can be negated by dexamethasone whereas that affected by 
IFNy cannot.
IFNy has been reported to regulate ABCA1 expression by transcriptional inactivation 
(Panousis and Zuckerman, 2000). The possibility that this may be the method of 
regulation of ABCA1 and subsequently All expression in 1542 CP3TX cells was 
examined by analysing the total cellular expression of ABCA1 throughout an IFNy 
timecourse. The results of this study indicated that there was no change in ABCA1 
expression on stimulation with IFNy or on exposure to glyburide. This suggests that any 
regulatory effect IFNy may have on ABCA1 must be posttranslational. Posttranslational 
modification of ABCA1 on stimulation by IFNy was examined by isoelectric focussing; 
this technique separates proteins according to their isoelectric point and therefore is able 
to resolve proteins differing in charge due to post translation modifications. The results of 
this IEF analysis were inconclusive, due to problems with reproducibly transferring 
proteins from the IEF gel to the nitrocellulose membrane. 2DGE proved ineffective also
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as ABCA1 could not be resolved in the second dimension due to its size and 
hydrophobicity. Though inconclusive, the IEF results did appear to exhibit a pattern 
suggestive of phosphorylation following 1 hour of stimulation. In addition to this, novel 
bands appear at this time point and are lost at 6  hours. ABCA1 is known to be 
phosphorylated on threonine residues within a PEST sequence; this post translational 
modification leads to targeted inactivation of ABCA1 by calpain cleavage (Wang et al., 
2003). The pattern of IEF bands mentioned above may reflect the initial phosphorylation 
of ABCA1, followed by targeted degradation causing the detection of further bands 
corresponding to cleavage products. This timescale of phosphorylation by IFNy was also 
found in radio-labelled samples subject to immunoprecipitation with the anti-ABCAl 
antibody. This study also detected a decrease in ABCA1 expression and a gradual 
increase of low molecular weight proteins recognised by the ABCA1 antibody. Although 
this is contradictory to the previous finding that ABCA1 levels are unaltered by IFNy 
treated, the finding that both the 220kD and low molecular weight forms of ABCA1 
become increasingly phosphorylated following exposure to IFNy suggests that the 
decrease in ABCA1 expression is due to degradation and not to transcriptional regulation. 
The phosphorylation and potential degradation of ABCA 1 on exposure to IFNy exhibits 
the same timescale of effect as loss of All cell surface expression. It is possible that down 
regulation of the ABCA1 transporter via phosphorylation and subsequent calpain 
degradation following IFNy stimulation is responsible for the reduction and eventual loss 
of All from the cell surface. Further studies of the posttranslational modification of 
ABCA1 by IFNy and the subsequent effect on All expression are required before this 
mode of All transport to the cell surface can be confirmed. Analysis of the expression of 
ABCA 1 in response to IFNy at the mRNA level is required to confirm that degradation is 
the cause of the reduction in expression seen in Dr. Naaby-Hansen’s experiments.
The effect of calpain activity on cell surface All expression was observed by blocking the 
action of calpain II in 1542 CP3TX cells. Inhibiting the action of calpain II by pre­
treatment with IFNy prevented the down regulation of surface All seen at 4 hours with 
IFNy treatment alone. These results indicate that regulation of cell surface All by IFNy is 
in some way calpain II dependent. The retention of All on the cell surface in the presence
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of IFNy may be due to a lack of calpain II cleavage of the ABCA1 transporter, allowing 
the transport of All to continue despite post-translational modification by IFNy. An 
alternative hypothesis could be that IFNy is directly regulating calpain II. This was 
explored by observing the expression of calpain II in the other isogenic cell lines 1535 
NP/CPT and 1532 NP/CPT over a timecourse of stimulation by IFNy. The normal cell 
lines appear to express two forms of calpain II, whereas the cancer cell lines appear to 
express a majority of one form or the other. This may indicate yet another IFNy 
signalling pathway that is deregulated in the cancer cell lines in comparison their normal 
counterparts. In all cell lines calpain II expression appears to be induced by 1 hour 
exposure to IFNy. In cancer cell lines however a reduction in calpain II expression is 
apparant at 4 hours. In 1532 CPT cells the cell surface expression of All is reduced at 4 
hours but regained at 6  hours, indicating that a fall in calpain II activity at the former time 
point may lead to a rise in cell surface All levels at the latter.
The results discussed above, suggest that both ABCA1 and calpain II have a role in the 
regulation of cell surface All expression by IFNy either directly or indirectly. Figure 5.1 
featured below, outlines the possible signalling pathways involved in the cause and effect 
relationship between IFNy and cell surface All expression. The model proposed is that 
activation of the IFNyR leads to the activation of an unknown kinase, which 
phosphorylates the threonine residues within the PEST sequence of ABCA1. This 
posttranslational modification leads to the inactivation of ABCA1 and the cessation of 
All transport to the cell surface. It is likely that All would be transported by ABCA1 in 
association with cholesterol containing endosomes, which then fuse into the outer leaflet 
of the plasma membrane.
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Figure 5.1. A model of cell surface All transport and regulation by IFNy.
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Figure 5.2. Total cellular expression o f AH in 1542 NPX and CP3TX cells with or without 24 hour 
stimulation with IFNy. 0 Actin expression is included as a loading control. It appears that total cellular 
expression o f All is unaffected by IFNy, suggesting that the reduction is solely cell surface specific.
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Figure 5.3. Total cellular expression of All in a panel o f prostate cell lines with or without IFNy 
stimulation. A Total cellular expression of all cell lines expressing All is unaffected by IFNy stimulation. B 
Expression o f the loading control P-actin. LNCaP appears not to express the All protein.
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Figure 5.4 An All immunoblot on LNCaP cells in normal state (N) and after treatment with the de- 
methylating agent 5-aza-deoxycytidine. At 36 kD, the correct weight for All, a faint band is present in the 
de-methylated sample suggesting methylation may be responsible for the lack o f All in LNCaP cells.
Figure 5.5. Annexin II staining in unstimulated 1542 NPX cells. Inlay shows enhanced image o f 
characteristic staining. This image demonstrates that All is present on the plasma membrane, although 
some background staining is also seen in the cell cytoplasm.
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Figure 5.6. Anti-AII immunoblot o f protein samples obtained by washing with different concentrations of 
A CaCl2, B EDTA. A manipulation of external CaCl2 levels either by addition o f calcium or by chelation 
with EDTA, leads to the release o f surface bound All. High concentrations, above lOmM, o f EDTA lead to 
the release of two All isoforms.
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Figure 5.7. Periodic regulation of surface All and pi 1 by EFNy A Avidin blot o f anti-AII BP timecourse B 
p ll  immunoblot o f the same membrane C p l l  expression in total cell lysate D p l l  expression in CaCl2 
liberated protein extract. A loss of cell surface Ail expression occurs between two and six hours stimulation 
with IFNy. pi 1 expression is lost following 8 hours stimulation with the same cytokine.
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Figure 5.8. Verification of cell surface AD modulation by IFNy by time courses using A CaCl2 release B 
EDTA release. All cell surface expression is lost between 4-6 hours stimulation with IFNy; All binding 
proteins are lost from the cell surface following 1 hour exposure to the cytokine.
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Figure 5.9, Time dependent modulation o f surface All by IFNy in two pairs o f isogenic cell lines. The 
1535 cell lines appear to express more surface A ll than 1542 cells and expression is unaffected by IFNy. In 
the 1532 cell lines, cell surface expression is reduced following 3 hour stimulation with IFNy, comparable 
to the timescale of down regulation seen in 1542 cell lines.
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Figure 5.10. Anti-AII, cholera toxin and actin staining in live 1542 NPX and CP3TX cells plus or minus 24 
hr stimulation with IFNy. The separate colour channels representing each protein are shown in black and 
white for increased resolution, the colour picture is a merged image o f all three fluorophores. In the colour 
image All expression is shown in green, cholera toxin corresponding to lipid raft regions in blue and actin 
in red. It can be observed that in unstimulated cells from both cell lines All staining is generalised on the 
cell surface. On stimulation, however, All expression is reduced and localised to enlarged lipid raft 
structure in the normal cells, which are not observed in the CPT cells.
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Figure 5.11. Anti-pl 1, cholera toxin and actin staining in live 1542 NPX and CP3TX cells plus or minus 
24 hr stimulation with IFNy. The separate colour channels representing each protein are shown in black and 
white for increased resolution, the colour picture is a merged image o f all three fluorophores. In the colour 
image p l l  expression is shown in green, cholera toxin corresponding to lipid raft regions in blue and actin 
in red. It can be observed that in unstimulated cells from both cell lines p i 1 staining co-localises with that 
o f the cholera toxin indicating pi 1 is present solely in lipid rafts. On stimulation p l l  expression is reduced 
and localised to the enlarged lipid raft structures in the normal cells and almost completely absent in the 
CPT cells.
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Graph 5.1. Graphical representation o f the number o f migrants resulting from invasion assays using 1542 
NPX, CP3TX and LNCaP cells plus or minus stimulation with IFNy. Asterisk indicates a result significant 
to P=0.05 confidence limits. It can be observed from this graph that IFNy reduces the invasive potential o f 
normal and cancerous prostate epithelial cells.
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Graph 5.2. Graphical representation of the number of migrants resulting from invasion assays using CPT 
cells plus or minus anti-AII antibody. Asterisk indicates a result significant to P=0.05 confidence limits.
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Graph 5.3. Graphical representation o f  the number o f migrants resulting from invasion assays using 1542 
CP3TX cells plus or minus anti-mouse IgG. The invasive capacity o f 1542 CP3TX cells is not affected by 
treatment with a non-specific antibody of the same isotype as anti-AII.
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Graph 5.4. Graphical representation o f the number o f migrants resulting from invasion assays using 
LNCaP transfected with GFP All or GFP vector alone. Transfection o f  All into LNCaP significantly 
increases the invasive potential o f these cells. Asterisk indicates a result significant to P=0.05 confidence 
limits.
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Figure 5.12. LNCaP GFP expression, cells are shown at x40 magnification under phase and fluorescent 
microscopy. GFP All expression appears localised mainly to the perinuclear and cytoplasmic regions o f the 
cell.
Figure 5.13. A migrant GFP All expressing LNCaP cell shown at x40 and x60 magnification in phase and 
fluorescent microscopy The majority o f GFP All expression is localized in the cytoplasm, however, cell 
surface expression can be observed at x60 magnification (see white arrows).
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Figure 5.14. AH expression on the cell surface and in 1542 CP3TX total lysate following exposure to 
glyburide and dexamethasone. A All expression analysis shows treatment with glyburide decreases the cell 
surface level o f All, whilst increasing the All level inside the cell. Dexamethasone has the opposite effect. 
Treatment with both agents results in the same pattern o f expression as with dexamethasone alone. B 
represents a p actin loading control for the total lysate samples.
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Figure 5.15. The effect of glyburide on surface All expression. A Time course All cell surface and total 
cell lysate expression in 1542 CP3TX cells exposed to glyburide. A loading control is shown for the total 
lysate samples. B Cell surface expression o f All following 24 hour exposure. Glyburide treatment 
decreases the cell surface level o f AH after 120 minutes o f  treatment; expression o f the protein is lost after 
24 hours. The level of AII inside the cell increases after 40 minutes o f glyburide treatment.
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Graph 5.5. The temporal effect o f glyburide treatment on the extra and intracellular expression o f AIL As 
duration o f drug exposure increases surface expression o f All decreases and intracellular expression 
increases.
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Figure 5.16. The effect o f dexamethasone on surface All plus or minus IFNy stimulation in 1542 CP3TX 
cells. Dexamethasone appears to slightly increase the surface expression o f AIL
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Figure 5.17. ABCA1 expression in total cell lysate from 1542 CP3TX cells exposed to IFNy and glyburide 
(Gly). A The expression of the ABCA1 transporter is unaffected by IFNy treatment. B A loading control (1 
actin.
mABCAl:1283 HPFTEDDAVDPNDSDIDPESRETD 1306 
hABCAl:1283 RPFTEDDAADPNDSDIDPESRETD 1306 
cABCAl:1283 RPFTEDDAFDPNDSDIDPESRETD 1306
Figure 5.18. The PEST sequence of ABCA1. (Wang et al., 2003)
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Figure 5.19. A ABCA1 expression in IFNy treated 1542-CP3TX cells demonstrated by immunostaining of 
whole cell detergent extracts. The expression o f the 220kD full-size ABC-transporter A l is down-regulated 
over 4 hours of stimulation, while the abundance o f low molecular weight (LMW) ABCA1 forms gradually 
increases over the same period. B 1542-CP3TX cells were grown to 70% confluence and metabolically 
labelled with [33P]-ortho-phosphate for six hours prior to stimulation. The isotope containing culture 
medium was then removed and exchanged with cold, phosphate-free medium and the cells treated with 500 
U/ml EFNy. After different stimulation periods the cells were lysed in RIP A buffer and ABCA1 isolated by 
immunoprecipitation. ABCA1 and co-precipitated proteins were then separated by SDS-PAGE, transferred 
to PVDF membranes, dried and visualized by phosphoimaging on a Molecular Imager FX scanner 
(Biorad). The two LMW phospho-proteins indicated by arrowheads are o f similar size as two o f the LMW 
ABCA1 antigens detected by immunoblotting o f whole cell extracts.
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Figure 5.20. Time course o f cell surface All expression in IFNy stimulated 1542 CP3TX cells plus or 
minus Calpain inhibitor. Calpain inhibition prevents the down regulatory effect o f IFNy stimulation surface 
All expression in these cells.
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Graph 5.6. The temporal effect o f calpain inhibitor on All expression in response to IFNy. Treatment with 
calpain inhibitor appears to prevent loss o f  surface expression o f All normally seen following 3-4 hours 
treatment with IFNy.
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Figure 5.21. Time course analysis o f calpain I expression on stimulation with, IFNy in 1532 and 1535 NP 
and CPT cell lines. In both cases A represents immunodetection o f calpain I and B the loading control P 
actin. Both normal cell lines appear to express two isoforms of calpain II, whereas the cancer lines express 
predominantly one form or the other calpain II expression is induced in all cell lines following 1 hour 
stimulation with IFNy.
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Chapter 6 
Discussion
The central aim of this study was to analyze the proteins differentially expressed on the 
surface of normal and cancer epithelial cells using a proteomic approach. This was 
addressed through the development of a reproducible and efficient method for analysing 
the cell surface proteome. In addition, application of this technique to a comparative 
analysis of 1542 NPX and CP3TX cell surface proteins in cells stimulated with 
interferons led to a comparative analysis of cytokine signalling in these cell lines and 
characterisation of several proteins of potential use in the management of prostate cancer.
6.1 Cell surface proteome analysis
In this study 39 cell surface proteins were identified in normal and cancer epithelial cells 
from an isogenic cell line pair. This represents a greater than 1 0 -fold enrichment, 
comparable to that achieved in other studies using gel separation (Zhao et al., 2004) and 
liquid based chromatography (HPLC) methods (Nielsen et al., 2005). However, despite 
this apparent level of enrichment there remained evidence of sample contamination from 
endogenous and exogenous proteins within the gel bands excised. This indicates that 
further optimisation of the cell surface protein separation protocol is required to 
efficiently analyse the cell surface proteome. Measures to reduce contamination could 
include conducting the experiment in a clean room environment, including further pre- 
fractionation steps to deplete non-membrane proteins using sequential addition of high- 
salt, carbonate and urea washes similar to those employed by (Nielsen et al., 2005) and 
separation using techniques offering better protein resolution such as HPLC and 2DGE.
The expression of calnexin and gp96, identified in the cell surface proteome analysis of 
the 1542 NPX and CPTX cell lines, was analysed through immunoblotting. Due to the 
lack of antibody availability and the degree of protein complexity in bands excised from 
ID SDS PAGE gels, the relative expression of the other 37 proteins could not be 
analysed. The remaining identified cell surface proteins therefore, require further 
quantitative analysis to examine their expression in these cell lines. Further analysis
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could involve 2DGE, to reduce band complexity and identify any post translational 
differences in the proteins expressed, immunoblotting with specific monoclonal 
antibodies and transcript expression analysis via quantitative polymerase chain reaction 
(QPCR).
Increases in expression of calnexin and gp96 in the cancer cell line were found to be 
statistically significant These proteins are molecular chaperones involved in the transport 
of peptides to MHC I molecules, most often localised to the endoplasmic reticulum. 
However, it appears that in the 1542 CP3TX cell line, gp96 and calnexin are found 
expressed at high levels on the cell surface. Calnexin has been found to be over expressed 
in breast cancer (Li et al., 2001, Yeates and Powis, 1997), multiple myeloma (Munshi et 
al., 2004), melanoma (Nielsen et al., 2005) and is known to associate with CAM’s such 
as integrin pi (Yeates and Powis, 1997, Ruoslahti and Reed, 1994). Over expression of 
calnexin in 1542 CP3TX cell line and its interaction with CAM’s suggests that this 
protein may be involved in cell invasion. A correlation with calnexin over expression and 
increasing breast cancer grade has been noted previously (Li et al., 2001). In a recent 
cDNA micro array analysis of prostate epithelial cells, androgens and growth factors 
were found to significantly up regulate calnexin expression. This may indicate that 
calnexin has a role in androgen induced proliferation in early tumourigenesis and also in 
the acquisition of androgen insensitivity through enhanced expression by other mitogenic 
factors (York et al., 2005). The possible role of this protein in early tumourigenesis and 
the correlation of expression with disease grade may suggest its utility as a potential 
diagnostic and/or prognostic marker. Further analysis of calnexin expression, via western 
blotting and immunohistochemical studies in other cell lines and prostate tissue, will be 
required before the diagnostic/prognostic potential of this protein in prostate cancer can 
be assessed.
Over expression of MHC 1 peptide chaperones, may appear disadvantageous to the cancer 
cell as it has been noted in several studies that surface expression of gp96 can elicit anti­
tumour immunity (Dai et al., 2003, Robert et al., 2003). However, gp96 over expression 
has also been associated with protection from cellular stressors such as chemotherapy
175
(Santin et al., 1998b), irradiation (Santin et al., 1998a), hypoxia, acidosis, nutrient 
depletion and the inflammatory response (Lee, 1992, Heike et al., 2000, Haverty et al., 
1997b). The main protective effect of gp96 is thought to be in the inhibition of apoptosis 
(Chen et al., 2002, Liu et al., 1998). Protection from such stressors via up regulation of 
gp96 may provide the cancer cell with a selective growth advantage. As such gp96 may 
be involved in the early stages of tumourigenesis and therefore of valuable diagnostic 
marker potential. To examine the broader clinical application of this protein, for example 
as a diagnostic marker, analysis of its expression in other cell line models and in prostate 
tissue is required. It would also be of interest to examine the response of prostate cells 
over expressing gp96 to stressors such as cytotoxic drugs to analyse the suggested 
protective effect.
6.2 Interferon signalling
This study also resulted in the identification of key constituents of the IFNy signalling 
pathway that appear to exhibit differential expression patterns between normal and 
neoplastic cells when stimulated with IFNy. In accordance with the published literature, 
these results suggest that 1542 CP3TX cells exhibit differential expression of certain 
molecules in the IFN signalling pathways in comparison to their normal counterpart, 
specifically the transcription factor p48 (Nagano et al., 2003). The pattern of induction of 
p48 expression following interferon stimulation observed in this study is in agreement 
with that seen in a recent study of transitional cell carcinoma of the bladder where 
interferon alpha treatment lead to a low level of p48 expression which could be restored 
by pre-treatment with IFNy (Matin et al., 2001). Combinatorial use of IFNy and alpha has 
also proven effective in increasing p48 and causing subsequent growth inhibition in renal 
cell carcinoma (Nanus et al., 2000). Defects in the activation of p48 have been noted in 
hepatocelluar carcinoma cell line MHCC97, where mutations possibly affecting the 
stability of the protein were shown to negate the anti-proliferative effect of interferon 
alpha (Wu et al., 2004b). This may suggest that cancer cells gain a selective advantage by 
suppression of the expression or activity of p48 and thereby decreasing sensitivity to the 
immunomodulatory effects of IFNs, which include growth inhibition, increased adhesion 
and heightened immunosurveillance. In clinical trials single cytokine therapy has been
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used for advanced prostate cancer, but its efficacy is limited and the toxic effects often 
severe (Kuratsukuri et al., 2000, van Haelst-Pisani et al., 1992). In general it has been 
noted that IFNy is capable of elevating p48 levels in cancer cells unresponsive to other 
cytokines and as a subsequent effect cancer cells become sensitive to the growth 
inhibitory effects of interferon alpha (Wong et al., 1998, Matin et al., 2001). In this 
capacity, the results of this study may suggest that IFNy could be used as an adjuvant to 
enhance the effects of IFNa in growth retardation of prostate tumours. Proof of this 
principle would require trial of the anti-proliferative effect of combinatorial therapy with 
these cytokines in vitro through MTT assays and in vivo using the TRAMP mouse 
model. In addition, it would be of interest to verify the results of this study in other 
prostate cell lines and determine the activity and phosphorylation status of key proteins 
such as p48 and STATs in normal and cancer prostate cell lines under stimulation with 
interferons.
6.3 Characterisation of gp96
The alteration in interferon signalling in cancer cell lines was found to include the 
modulation of proteins on the cell surface, of these gp96 and All were chosen for further 
study. It was observed that over expression of gp96 in the 1542 CP3TX cells, could be 
decreased significantly by treatment with IFNy. An opposite pattern of gp96 expression 
was observed in 1542 NPX cells, as in this cell line, stimulation with IFNy appeared to 
increase the expression level of gp96 and its isoforms. These results support the previous 
finding that gp96 is upregulated in the cancer cell line and add a novel dimension in the 
discovery of production of previously unreported gp96 isoforms in normal prostate cells 
following stimulation with IFNy. In their normal resting state, the prostate cancer cells 
appear to over express a single form of gp96, a feature known to be associated with 
avoidance of apoptosis (Chen et al., 2002, Liu et al., 1998). In these cancer cells, on 
stimulation with IFNy, there is an apparent decrease of the expression of this single gp96 
isoform and a failure to produce the multiple isoforms of gp96 observed in 
immunoblotting of normal cells. Although the immunologic activity of gp96 has yet to be 
characterized, gp96-associated peptides constitute the antigenic repertoire of the source 
tissue. As such the multiple isoforms may be required as part of the functional role of
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gp96 as a molecular chaperone involved in the transport of antigenic peptides to the 
MHC class 1 proteins on the cell surface. gp96 mediated antigen display has been 
demonstrated to elicit a CD8 -specific T cell response and therefore possible anti-tumour 
immunity (Blachere et al., 1997). The multiple isoforms of gp96 produced in response to 
IFNy in the normal cells could represent the result of glycosylation events, as a recent 
study observed differences in the gp96 monosaccharide composition between normal and 
cancer cells from rat and cell line prostate cancer models. Additionally a further decrease 
in gp96 glycosylation was observed in cells with more aggressive cell phenotypes 
(Suriano et al., 2005). Down regulation of gp96 glycosylation may be selectively 
advantageous for the cancer cells in avoidance of the immune response, a mechanism 
also observed in bacterial infection by Orientia tsutsugamushi (Cho et al., 2004).
Suppression of gp96 is a potential negative effect of IFNy treatment, as it is possible that 
MHCI display of tumour-associated antigens may be adversely affected. To further 
investigate the expression of gp96 in cancer cells and its regulation by IFNy, additional 
research is required. The potential anti-apoptotic effect of over expression of gp96 could 
be investigated through apoptosis assays comparing rates in the normal and cancer cell 
line, transfected cells over expressing the protein and in gp96 knockout cells. In addition, 
further characterisation of the gp96 isoforms in normal cells would be required as 
confirmation that the proteins observed represent variants of the gp96 protein and are not 
due to a non-specific effect of the antibody. This could be achieved by using 
immunodetection with antibody specific to a unique part of the protein. The use of 
specific antibodies, for example to the amino or carboxyl terminus, would also aid in the 
identification of whether variants are produced through cleavage of the full length protein 
and if so, possibly suggest the site of this modification. 2DGE followed by MS analysis 
to identify the isoforms via peptide sequencing, or by lectin overlays to detect 
glycosylation could also be used to further characterise gp96 isoforms. The effect of 
differences in gp96 expression on MHC presentation could be analysed by observation of 
MHC presentation in cells under/over expressing gp96 and in normal and cancer prostate 
cells stimulated with IFNy. The subsequent effect on cellular interaction with the host 
immune system could be examined by xenograft transplant into animal models. However,
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anti-sense mediated down regulation of gp96 has previously been reported as having no 
effect on MHCI presentation in PI3.1 cells (Lammert et al., 1996)
6.4 Characterisation of Annexin II
Other cell surface proteins found to be modulated by IFNy were identified as Selectin, 
IFN induced protein 53 and Annexin II. All was chosen for further study as it has been 
reported to have a potential role in cell invasion (Falcone et al., 2001, Emoto et al., 2001, 
Mai et al., 2000c, Wu et al., 2002, Brownstein et al., 2003, Mai et al., 2000b) and it is at 
the later stages of PCa where invasion often leads to incurable metastases, that 
interventions are needed. All was found to be expressed at the same level in both normal 
and cancer prostate cell lines. However, cell surface expression of All in 1542 CP3TX 
and NPX appears to be suppressed by IFNy in a surface specific manner, this was also 
observed in a second isogenic pair of cell lines 1532 NPX and CP3TX. The apparent 
surface specific suppression of All by IFNy also appeared to result in a decrease in the 
invasive capacity of cells expressing AIL This finding is in accordance with the research 
of Falcone et al, 2001, which demonstrated that matrix invasion and degradation was 
dependant on cell surface All expression in macrophages (Falcone et al., 2001). The role 
of All in invasion was further suggested by transfection of an All expression vector into 
LNCaP cells, which appeared increase in invasive capability. However, the vector was a 
dual construct also encoding GFP, which could interfere with the expression and normal 
biological function of AIL This study suggests that All may have a significant role in 
prostate epithelial cell invasion, possibly through interaction with endopeptidases and 
extra cellular matrix components (Kirshner et al., 2003, Chung and Erickson, 1994, Choi 
et al., 2000). The novel finding in this study is that IFNy down regulates All expression 
in a cell surface specific fashion. This finding has not been previously reported.
As the transport pathway of AII is unknown, the involvement of ABCA1, a protein 
known to transport the structurally similar Al (Chapman et al., 2003), was investigated as 
a potential candidate transporter. Treatment of cells with glyburide, a potent inhibitor of 
ABC transporters, appeared to decrease expression of All on the cell surface, whereas 
dexamethasone a promoter of ABC transporter activity appeared to increase expression.
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This finding suggested that the transport of All to the cell surface was influenced by the 
activity of an ABC transporter. ABCA1 has been shown to be transcriptionally regulated 
by IFNy (Wang et al., 2002b), however western blotting followed by immune detection 
showed that ABCA1 expression was apparently unaffected by IFNy treatment. This 
suggested that any effect on ABCA1 activity was post translational. Experiments 
conducted by Dr Naaby-Hansen contradicted this result by demonstrating that levels of 
ABCA1 did decrease, although data for ABCA1 expression were not available to be 
quantified or verified by statistical analysis and no loading controls were provided. This 
result therefore requires repeated demonstration and quantitative analysis. Dr Naaby- 
Hansen’s experiments did recognise the existence of low molecular weight proteins 
detected by the ABCA1 antibody. Radio labelling experiments indicated that ABCA1 and 
the low molecular weight forms became phosphorylated on exposure to IFNy. Once 
phosphorylated the PEST sequence of ABCA1 may act as a target for degradation by 
calpains (Wang et al., 2003). It is possible that the low molecular weight proteins 
recognised by the ABCA1 antibody may represent the degradation products of this 
process.
This theory was explored further by the inhibition of calpain, which appeared to maintain 
the expression of All in the presence of IFNy, indicating that IFNy may regulate the 
expression of All on the cell surface by a calpain-mediated process. The model proposed 
is that cell surface expressed All is regulated by IFNy via calpain-mediated inactivation 
of ABCA1 or a similar transporter. Further investigation of this mechanism is required to 
isolate the exact protein involved in the transport of All, as the inhibitors and promoters 
of activity used in these experiments have common effects in all ABC transporters. The 
results of a recent study suggest that treatment with the drug Probucol protects ABCA1 
from calpain-mediated degradation (Wu et al., 2004a), observation of cell surface All in 
cells exposed to this drug may further implicate ABCA1 involvement in the transport of 
All to the cell surface. Isolation of the exact ABC transporter responsible for the 
expression and localisation of All could also be examined through the use of ABC 
transporter knockout cells.
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IFNy has been shown to directly and indirectly regulate the expression of calpains 
causing effects such as down (Gollob et al., 2005, Shiraha et al., 2002) and up regulation 
(Gallardo et al., 2001, Deshpande et al., 1995). The latter findings concur with those of 
this study, which found that calpain II expression was apparently induced following one 
hour of IFNy stimulation in both normal and cancer isogenic cell lines. Due to the non- 
specificity of the calpain inhibitor used in this study, further analysis is required to isolate 
the calpain implicated in All transport. This could be achieved by observing the cell 
surface expression of All in response to IFNy in cells lacking different calpain isoforms. 
The mechanism of action of IFNy on calpain could be further investigated at the 
transcriptional level by expression analysis of calpain mRNA via QPCR and by protein 
immunodetection at the translational level, by 2DGE and analysis of the phosphorylation 
status of the protein by radiolabelling and/or detection by phosphorylation specific 
antibodies.
Immunofluorescence analysis indicated that All expression in the 1542 cell lines was 
similar to that described in other studies (Zobiack et al., 2002, Deora et al., 2004). 
However the presence of All expression in the cancer cell line is contradictory with 
recent research that indicated that All expression, although expressed in benign prostate 
epithelium (BPE), benign prostate hyperplasia (BPH) and prostatic intra-epithelial 
neoplasia (PIN), is lost in prostate cancer (Lehnigk et al., 2005). Similarly, it was found 
that All expression was reduced in prostate cancer cell lines and clinical samples 
(Chetcuti et al., 2001a). However, in this study a panel of prostate cell lines all, with the 
exception of LNCaP, expressed AIL This concurs with the findings of Bannerjee et al 
who also noted the expression of All in high grade PCa from American but not Indian 
patients (Banerjee et al., 2003). The discrepancy between the results of this study and that 
of cited literature indicate that several factors may influence the detection of All 
expression in prostate cancer cells. In PCa cell lines it appears that differences in cell 
culture methods or the specificity of the anti-AII antibody may affect detection of the 
protein, this could be tested by mimicking the culture and assay conditions used in 
previous studies. In immunohistochemical analyses it appears that racial factors and stage 
of disease may influence the detection of All in prostate sections, this may reflect true
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variation or an inability of the antibody used to detect variant All forms. This could be 
investigated via a large cohort study including specimens from various racial 
backgrounds and varying grade of disease. Initially an immunohistochemical trial of 
different All antibodies on a subset of specimens representative of the apparent racial and 
disease grade variation should be performed alongside immunodetection of All in cell 
lysates to test the efficacy of the antibodies in detecting All and any variant forms. This 
could be further confirmed at the molecular level by QPCR analysis of All expression in 
a large population cohort.
The apparent ability of IFNy to decrease All expression on the cell surface demonstrated 
in this study has a potentially therapeutic application, as it may decrease the invasive 
potential of prostate cancer cells. This could be further examined in the mouse model of 
prostate cancer, where TRAMP mice treated with IFNy could be monitored for time to 
metastasis and compared to untreated controls. In a study using prostate cancer 
xenografts in mice, Shou et al found that with interferon treatment the rate of progression 
to metastasis was decreased (Shou et al., 2002). In the present study however, it appears 
that the loss of surface expressed All is accompanied by a reduction in lipid raft 
structures in the cancer cells. These lipid raft structures are known to contain many of the 
signalling factors, receptors and MHC molecules required for interaction with the host 
immune system (Sehgal et al., 2002). In normal cells the response to IFNy treatment has 
been shown to involve the formation of signalosomes, as was seen in this study. In cancer 
cells, however, this cytokine appeared to decrease the quantity of lipid rafts and no 
signalsome formation was noted. Exogenous interferon treatment could therefore be 
potentially detrimental as it may impede detection of cancer cells by the host immune 
system. Further investigation into the formation of lipid rafts and the response to 
interferons in normal and cancer prostate cell lines is warranted. This could include co­
localisation of lipid raft structures with other molecules involved in interferon signalling 
such as the IFNGR and STAT proteins and molecules involved in immune detection e.g. 
MHCI. It would also be of benefit to confirm that the structures observed in this study are 
lipid rafts and not random collections of the GM1 ganglioside. This could be done be co- 
staining with fillipin, an auto-fluorescent molecule known to bind to cholesterol.
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6.5 Appraisal of the therapeutic benefit of IFNy
The results of this study suggest that IFNy treatment may prove beneficial as an adjuvant 
pre-treatment before exposure to further cytokine-based therapy, to limit proliferation and 
retard the invasive potential of cells in prostate cancer. However, it has also been 
demonstrated that this cytokine may affect proteins, i.e. gp96 and structures, i.e. lipid 
rafts, involved in cell-immune system interactions. Therefore, the potential benefits of 
IFNy treatment may be negated by the effect of the cytokine on immune system 
interactions. As such, treatment with IFNy may cause a lack of detection of cancer cells 
and potentially increase the disease load. However, as a result of examining the response 
of cells to IFNy this study has identified proteins that show apparent expression 
differences between normal and cancer cells from an isogenic pair of cell lines. These 
proteins could therefore become targets for therapeutic intervention in their own right. 
gp96, for example, has been used previously as an anti-tumour vaccine in a rat model of 
prostate cancer. The results of this study suggested that administration of host derived 
gp96 limits both the occurrence and growth of prostate tumours indicating treatment with 
this vaccine could be of prophylactic or therapeutic use in prostate cancer patients 
(Yedavelli et al., 1999b). The Yedavelli study could be repeated in TRAMP mice to 
assess whether administration of host-derived gp96 would lead to regression of prostate 
tumours and evaluate the longevity of the effect. Clinical trials would be required before 
this could be considered a viable treatment option. It may also be of interest to observe 
the effect of inducing the expression gp96 isoforms in cancer cells in a xenograft 
transplant model, as it is possible that this may increase MHC class I antigen presentation 
and the subsequent immune mediated destruction of cancer cells.
All expression could provide a potential drug target to limit remodelling of the basement 
membrane by cancer cells. This would require the design of a pharmacological agent, 
possibly mimicking the calpain-mediated regulation of All by IFNy, without causing the 
additional detrimental effects on lipid raft structures and gp96 expression. Evaluation of 
such an agent would require extensive trials in vivo and in vitro, before any assumptions 
could be made regarding its therapeutic potential. If effective, such treatment may be of
183
particular therapeutic use in mid to late stage prostate cancer in limiting further spread of 
the disease.
6.6 Conclusion
In conclusion, this study has led to the demonstration of a novel procedure capable of 
enriching membrane proteins in cell extract, which has subsequently led to the 
identification of proteins with apparent differential expression in normal and cancer cells 
and those exhibiting altered expression in response to IFNy in the cancer cell line. The 
outcomes of this study are primarily that proteins with the potential utility in the 
treatment of prostate cancer have been identified, though further characterisation of these 
proteins required before their clinical application can be realised. Secondly, this study has 
shown that IFNy may be of therapeutic benefit in the suppression of prostate cancer, but 
that the effects of this cytokine on cell-host immune system interactions may limit its 
clinical application. Finally, this study has uncovered several indicators that, in the case 
of 1542 NPX and CP3TX, the cancer cell line has acquired several features which could 
be selectively advantageous in avoidance of immune system detection. Further research 
of these mechanisms may indicate the molecular basis for the evasion of host responses 
necessary for tumourigenesis.
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Appendix 1
The TNM grading system for prostate cancer (Alliance, 2007)
T Stages (Tumor)
T1
The tumor cannot be felt or seen with imaging such as transrectal ultrasound.
Tla
The cancer is found incidentally during a transurethral resection (TURP) for benign 
prostatic enlargement and is present in less than 5 percent of the tissue removed.
Tib
The cancer is found through TURP and is present in more than 5 percent of the tissue 
removed.
Tic
The cancer is found by needle biopsy done because of an elevated PSA level.
T2
The cancer can be felt through a digital rectal exam (DRE).
T2a
The cancer is in one side of the prostate.
T2b
The cancer is in both sides of the prostate.
T3
The cancer has begun to spread outside the prostate and may involve the seminal vesicles. 
T3a
The cancer extends outside the prostate but not to the seminal vesicles.
T3b
The cancer has spread to the seminal vesicles.
T4
The cancer has spread to tissues next to the prostate (other than the seminal vesicles), 
such as the bladder's external sphincter (muscles that help control urination), the rectum 
and/or the wall of the pelvis.
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N Stages (Lymph nodes)
NO
The cancer has not spread to any lymph nodes.
N1
The cancer has spread to one or more regional (nearby) lymph nodes in the pelvis. 
M stages (Metastasis)
MO
The cancer has not spread beyond the regional nodes.
Ml
The cancer has spread to distant (outside of the pelvis) lymph nodes, bones or other 
organs such as the lungs, liver or brain.
Stage I
Tla, NO, MO, low grade or score 
Stage II
Tla, NO, MO, intermediate or high grade or score
Tib, NO, MO, any grade or score
Tic, NO, MO, any grade or score
Tl, NO, MO, any grade or score
T2, NO, MO, any grade or score
Stage III
T3, NO, MO, any grade or score 
Stage IV
T4, NO, MO, any grade or score 
Any T, N1, MO, any grade or score 
Any T, any N, M1, any grade or score
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Bradford protein concentration assay (Pierce Biotechnology, 2004a)
Test tube procedure
1. Pipette 0.03ml of each standard or sample into labeled test tubes.
2. Add 1.5ml Coomassie reagent and mix well.
3. Incubate sample for lOmins at room temperature.
4. Set spectrophotometer to 595nm and zero the instrument using water only blank.
5. Prepare a calibration curve by plotting standard concentration against absorbance, 
use this to determine the protein concentration of the unknown sample.
Lowry protein concentration assay (Bio-rad, 2007a)
Standard Assay Protocol
1. Prepare working reagent by adding 20pl of reagent S to each ml of reagent A 
required, (stable for 1 week, although precipitate may be present following 24hrs 
which can be dissipated by mixing)
2. Prepare dilutions of a protein standard from 0.2mg/ml to 1.5mg/ml.
3. Pipette 100pl of standards and samples into clean, dry test tubes.
4. Add 500pl of working reagent A and vortex.
5. Add 4ml of reagent B and vortex.
6. Incubate at room temperature for 15mins and read absorbance at 750nm.
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Procedure for packing avidin columns (Pierce Biotechnology, 2004b)
1. Equilibrate column, 50% gel slurry and buffer solution to room temperature
2. Secure bottom cap on column tip and secure column upright.
3. Add sufficient buffer to the column to fill up to the reservoir portion, tap to 
dislodge air bubbles.
4. Float porous disc of correct diameter on the buffer, then push to the bottom of the 
column using the open end of a serum separator.
5. Decant the column, return bottom cap.
6. Add a sufficient volume of gel slurry to obtain desired bed volume.
7. Allow gel to settle for 30mins.
8. Position a second porous disc on the settled gel bed using the serum separator, 
leaving a gap of 1 -2mm from top of column bed.
9. Wash the inner top of the column with buffer, the column is now ready for use or 
storage.
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Biosafe Coomassie staining (Bio-rad, 2007b)
SDS-PAGE Gels:
1) Wash gel 3 times for 5 minutes each in 200ml of ddH20 per gel.
2) Remove all water from the container and add 50ml Bio-Safe Coomassie Stain (or 
enough to completely cover gel).
3) Gently shake for lhr.
4) Protein bands will be visible within 20 minutes and reach maximum intensity 
within lhr.
5) Rinse gel in 200ml of ddH20 for at least 30 minutes.
6) Store gel in water.
Note: Residual SDS in the gel may cause background staining and interfere with 
band intensity. Rinsing the gel extensively after staining will decrease background.
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Silver stain protocol adapted from (Shevchenko et ah, 1996).
1. After electrophoresis, fix gel in 50% methanol, 5% acetic acid in water for 20min.
2. Wash gel for lOmin with 50% methanol in water and additionally for lOmin with 
water to remove the remaining acid.
3. Sensitized gel by lmin incubation in 0.02% sodium thiosulfate.
4. Rinse with two changes of distilled water for lmin each.
5. Submerge gel in chilled 0.1% silver nitrate solution and incubate for 20min at 4°C.
6. After incubation, discard the silver nitrate and rinse gel twice with water for lmin.
7. Develop the gel in 0.04% formalin [35% formaldehyde in water (Merck, 
Darmstadt)] in 2% sodium carbonate with intensive shaking.
8. After the developer turns yellow, discard and replace with a fresh solution.
9. After the desired intensity of staining is achieved, terminate development by 
discarding the reagent and washing the gel slab with 5% acetic acid.
10. Silver-stained gels can be stored in a solution of 1% acetic acid at 4°C until 
analyzed.
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Protocol for isolation of plasmid PNA (Oiagen, 2005b)
1. Pick a single colony from a freshly streaked selective plate and inoculate a starter 
culture of 2-5ml LB medium containing the appropriate selective antibiotic. Use a 
tube or flask with a volume of at least 4 times the volume of the culture. Incubate 
for ~8 h at 37°C with vigorous shaking (~300 rpm).
2. Dilute the starter culture 1/500 to 1/1000 into selective LB medium. For high- 
copy plasmids, inoculate 25ml or 100ml medium. Use a flask or vessel with a 
volume of at least 4 times the volume of the culture. For low-copy plasmids, 
inoculate 100ml or 500ml medium. Grow at 37°C for 12-16hrs with vigorous 
shaking (-300 rpm). The culture should reach a cell density of approximately 3-4 
x 109 cells per ml, which typically corresponds to a pellet wet weight of 
approximately 3g/litre medium
3. Harvest the bacterial cells by centrifugation at 6000 x g for 15min at 4°C. 
Remove all traces of supernatant by inverting the open centrifuge tube until all 
medium has been drained. Pellets can be stored at -20°C for later processing.
4. Resuspend the bacterial pellet in 4ml or 10ml Buffer P 1. For efficient lysis, it is 
important to use a vessel that is large enough to allow complete mixing of the 
lysis buffers. Ensure that RNase A has been added to Buffer PI. The bacteria 
should be resuspended completely by vortexing or pipetting up and down until no 
cell clumps remain.
5. Add 4ml or 10ml Buffer P2, mix gently but thoroughly by inverting 4-6 times and
incubate at room temperature for 5min. Do not vortex, as this will result in
shearing of genomic DNA. The lysate should appear viscous. Do not allow the
lysis reaction to proceed for more than 5min. After use, the bottle containing
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Buffer P2 should be closed immediately to avoid acidification from CO2 in the 
air.
6. Add 4ml or 10ml of chilled Buffer P3, mix immediately but gently by inverting 4- 
6 times and incubate on ice for 15min or 20min. Precipitation is enhanced by 
using chilled Buffer P3 and incubating on ice. After addition of Buffer P3, a fluffy 
white material forms and the lysate becomes less viscous. The precipitated 
material contains genomic DNA, proteins, cell debris and SOS. The lysate should 
be mixed thoroughly to ensure even potassium dodecyl sulfate precipitation. If the 
mixture still appears viscous and brownish, more mixing is required to completely 
neutralize the solution.
7. Centrifuge at >20,000 x g for 30min at 4 °C. Remove supernatant containing 
plasmid DNA promptly. Before loading the centrifuge, the sample should be 
mixed again. Centrifugation should be performed in non-glass tubes (e.g., 
polypropylene). After centrifugation, the supernatant should be clear. Centrifuge 
the supernatant again at > 20,000 x g for 15min at 4°C. Remove super-natant 
containing plasmid DNA promptly. Remove a 240pl or 120pl sample from the 
cleared lysate supernatant and save for an analytical gel (sample 1) in order to 
determine whether growth and lysis conditions were optimal.
8. Equilibrate a QIAGEN-tip 100 or QIAGEN-tip 500 by applying 4ml or 10ml 
Buffer QBT and allow the column to empty by gravity flow. Allow the QIAGEN- 
tip to drain completely. QLAGEN-tips can be left unattended, since the flow of 
buffer will stop when the meniscus reaches the upper frit in the column.
9. Apply the supernatant from step 8 to the QIAGEN-tip and allow it to enter the 
resin by gravity flow. The supernatant should be loaded onto the QIAGEN-tip 
promptly. If it is left too long and becomes cloudy due to further precipitation of
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protein, it must be centrifuged again or filtered before loading to prevent clogging 
of the QIAGEN-tip. Remove a 240pl or 120pl sample from the cleared lysate 
supernatant and save for an analytical gel (sample 2) in order to determine the 
efficiency of DNA binding to the QIAGEN Resin.
10. Wash the QIAGEN-tip with 2 x 10ml or 2 x 30ml Buffer QC. Allow Buffer QC to 
move through the QIAGEN-tip by gravity flow. The first wash is sufficient to 
remove all contaminants in the majority of plasmid DNA preparations. The 
second wash is especially necessary when large culture volumes or bacterial 
strains producing large amounts of carbohydrates are used. Remove a 400pl or 
240pl sample from the combined wash fractions and save for an analytical gel 
(sample 3).
11. Elute DNA with 5ml or 15ml Buffer QF. Collect the eluate in a 10ml or 30ml 
tube. Use of polycarbonate centrifuge tubes is not recommended, as 
polycarbonate is not resistant to the alcohol used in subsequent steps. Remove a 
lOOpl or 60pl sample of the eluate and save for an analytical gel (sample 4).The 
protocol can be stopped here and continued later, store the eluate at 4°C. Storage 
periods longer than overnight are not recommended.
12. Precipitate DNA by adding 3.5ml or 10.5ml (0.7 volumes) room-temperature 
isopropanol to the eluted DNA. Mix and centrifuge immediately at ~ 15,000 x 9 
for 30 min at 4°C. Carefully decant the supernatant. All solutions should be at 
room temperature in order to minimize salt precipitation, although centrifugation 
is carried out at 4°C to prevent overheating of the sample. Isopropanol pellets 
have a glassy appearance and may be more difficult to see than the fluffy, salt- 
containing pellets that result from ethanol precipitation. Marking the outside of 
the tube before centrifugation allows the pellet to be more easily located.
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Isopropanol pellets are also more loosely attached to the side of the tube and care 
should be taken when removing the supernatant.
13. Wash DNA pellet with 2ml or 5ml of room-temperature 70% ethanol and 
centrifuge at > 15,000 x g for 10 min. Carefully decant the supernatant without 
disturbing the pellet. The 70% ethanol removes precipitated salt and replaces 
isopropanol with the more volatile ethanol, making the DNA easier to re-dissolve.
14. Air-dry the pellet for 5-10 min and re-dissolve the DNA in a suitable volume of 
buffer (e.g., TE buffer, pH 8.0, or 10 mM TrisCl, pH 8.5). Re-dissolve the DNA 
pellet by rinsing the walls to recover the entire DNA, especially if glass tubes 
have been used. Pipetting the DNA up and down to promote resuspension may 
cause shearing and should be avoided. Over drying the pellet will make the DNA 
difficult to re-dissolve. DNA dissolves best under slightly alkaline conditions; it 
does not easily dissolve in acidic buffers.
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Protocol for transfection of cells using FuGENE 6 reagent (Roche, 2005a).
1. Prepare the cells the day before transfection.
2. Ensure the cells are growing well and are in log phase. Occasionally cells slow 
down when they reach confluence and it can take a day or two to recover.
3. For monolayers, plate the cells so they will only be 50-80% confluent the 
following day.
4. Plate the cells in medium that does not contain antibiotics.
5. For most adherent cell lines, plate 100,000-300,000 cells in 2 ml medium (50,000 
to 150,000 cells/ml) in one well of a 6-well plate Plan to test at least 3 ratios of
reagent to DNA See the table below for a suggested layout of a 6-well plate
Cell control Reagent control DNA control 3:1 ratio 3:2 ratio 6:1 ratio
No reagent 
No DNA
6pl reagent 
No DNA
No reagent 
1 pg DNA
3pi reagent 
1 pg DNA
3pl reagent 
2pg DNA
6pl reagent 
1 pg DNA
6. Select a plasmid that you know transfects your cell line and make sure you are 
able to measure the expression of reporter gene or transfected protein
7. Handle the DNA as aseptically as possible to avoid contaminating your cell 
cultures during the transfection.
8. Determine the concentration of the DNA with a spectrophotometer. Transfection- 
grade DNA should have a 260/280 ratio of 1.8.
9. Check the stock DNA concentration, if you need to dilute the DNA, use sterile 
DNase-free water or sterile DNase-free TE buffer as the diluent
10. Calculate accordingly for your DNA concentrations.
11. Prepare the FuGENE 6 Transfection Reagent and allow it to warm to room 
temperature.
12. Meanwhile, ensure cells look healthy and are 50-80% confluent.
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13. Warm serum-free DMEM (no additives) to room temperature and aliquot 94-100 
pi into each of 6 tubes as indicated below. Use sterile Eppendorf tubes or small 
sterile polystyrene tubes labelled;
•  A  ( l O O p l )
• B (94pl)
•  C  ( l O O p l )
• D (97pl)
• E (97pl)
• F (94pl), corresponding to the plate layout above.
14. Mix the room-temperature FuGENE 6 Reagent by tapping or briefly vortexing (1 
sec).
15. Carefully add the FuGENE 6 Reagent to the serum-free medium as follows;
• 6pl toTube B
• 3pl to Tube D (3:1 ratio)
• 3pi to Tube E (3:2 ratio)
• 6pl to Tube F (6:1 ratio)
16. Ensure the entire amount of reagent is delivered directly from the pipette tip into 
the serum-free medium. Avoid contact of the FuGENE 6 Transfection Reagent 
with the walls of the tube containing the serum-free medium. To avoid a FuGENE 
6 Reagent layer on top of the serum-free medium as soon as the FuGENE 6 
Reagent is added, immediately tap, flick, or vortex for 1 second to ensure 
adequate mixing of the components.
17. Incubate at room temperature for 5 minutes.
18. Add the DNA to each tube (see table above) the amount added will depend on the 
starting concentration of DNA.
19. Mix by tapping or vortexing the tube for 1 second
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20. Incubate for at least 15 minutes at room temperature. Longer complex incubation 
times of 30-60 minutes may enhance transfection efficacy.
21. Add 30pl FuGENE 6 Reagent to 970pl serum-free medium. Mix, then incubate 
for 5 minutes.
22. Add lOpg DNA to the diluted FuGENE 6 reagent mix, incubate for 15 minutes 
and then start adding lOOpl aliquots to cells at 15-minute intervals.
23. A slight haze may be visible if the transfection complex is in clear tubes
24. Remove the cells from the incubator.
25. Add lOOpl of complex drop-wise to its designated well as in the plate outline 
above swirl the plate to ensure mixing of the complex in all of the wells.
26. Return the cells to the incubator.
27. Incubate the cells for 1-3 days prior to measuring gene expression the incubation 
period is dependent on the reporter gene in
28. The plasmid if the plasmid contains a selectable marker, do not add the selection 
antibiotic until the first post-transfection passage.
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Immunoprecipitation With Soluble Antibodies (BD Biosciences. 2004)
PREPARATION OF THE CELL LYSATE
Denaturing Conditions
1. Rinse a 60mm culture dish of confluent cells with lx phosphate-buffered saline 
(PBS).
2. Lyse the cells with 0.5ml boiling lysis buffer (1% SDS, l.OmM sodium ortho­
vanadate, lOmM Tris pH 7.4).
3. Scrape the cells from the dish, transfer lysate to a 1.5ml microcentrifuge tube, and 
boil for an additional 5 minutes.
4. Pass several times through a 26 gauge needle; centrifuge (16,000 x g) for 15 
minutes. The supernatant is the total cell lysate (denatured).
Native Conditions
1. Rinse a 60mm culture dish of confluent cells with PBS.
2. Lyse the cells with 0.5ml cold immunoprecipitation buffer (1% Triton X-l 00, 
150mM NaCl, lOmM Tris pH 7.4, ImM EDTA, ImM EGTA pH 8.0, 0.2mM 
sodium ortho-vanadate, protease inhibitor cocktail (Boehringer Mannheim), 0.5% 
IGEPAL CA-630).
3. Maintain constant agitation for 30 minutes at 4°C.
4. Scrape the cells from the dish and pass several times through a 26 gauge needle to 
disperse any large aggregates. Centrifuge (16,000 x g, 4°C). for 15 minutes; keep 
on ice. The supernatant is the "total cell lysate (native).
Pre-clearing
It is important to pre-clear the lysate immediately before immunoprecipitation.
1. Centrifuge the cell lysates (16,000 x g, 4°C) for 15 minutes. Remove the 
supernatant.
2. For the denatured lysates, boil the supernatant for 5 minutes.
3. To 750-1000pl of supernatant, add 5pg of rabbit anti-mouse IgG antibody, 
vortex, then add 75-lOOpl of Protein A: Agarose (Life Technologies). Incubate at 
4°C for 30 minutes with agitation.
4. Centrifuge lysate (9000 x g, 4°C). for 2 minutes to pellet the agarose beads. The 
supernatant is the "total cell lysate".
IMMUNOPRECIPITATION
1. To a microcentrifuge tube, add 1-5 pg of antibody, 400pl of water, 200-500pg of 
total lysate and 500pl of 2X immunoprecipitation buffer (2% Triton X-l00, 
300mM NaCl, 20mM Tris pH 7.4, 2mM EDTA, 2mM EGTA pH 8.0, 0.4mM
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sodium ortho-vanadate, protease inhibitor cocktail (Boehringer Mannheim), 1.0%
IGEPAL CA-630).
2. Vortex and incubate for one hour with agitation at 4°C. If monoclonal antibodies 
are used, add 5pg rabbit anti-mouse IgG antibody, vortex, and continue the 
incubation for an additional 30 minutes at 4°C.
3. Add 50pl of 50% Protein A:Agarose (Life Technologies). Vortex and incubate for 
30 minutes with agitation at 4°C.
4. Wash with cold IX immunoprecipitation buffer (1% Triton X-l00, 150mM NaCl, 
lOmM Tris pH 7.4, ImM EDTA, ImM EGTA pH 8.0, 0.2mM sodium ortho­
vanadate, protease inhibitor cocktail, 0.5% IGEPAL CA-630). by centrifuging 2 
minutes (8000 x g, 4°C). Decant supernatant and repeat wash twice.
5. Resuspend pellet in 50pl of 0.1 Glycine pH 2.5 vortex and incubate with agitation 
for 10 minutes at 4°C.
6. Centrifuge (9000 x g, 4°C) for 2 minutes. Remove supernatant, this is your IP 
sample.
7. Add 5 pi of 1M Tris pH 8.0 to each tube to neutralize the pH. Add approximately 
lOpl of 5X concentrated electrophoresis sample buffer (125mM Tris pH 6.8, 4% 
SDS, 10% glycerol, 0.006% bromophenol blue, 2% B-mercaptoethanol) to each 
sample, and boil for 5 minutes.
8. Load the supernatant onto an SDS-PAGE gel and electrophorese.
9. Transfer to PVDF and probe with appropriate antibodies.
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Appendix 9
Manufacturers protocol for the running of Immobiline IEF gels (Amersham. 2005a)
Typical running condition for a whole Ampholine PAGplate pH 3.5-9.5 at 7°C:
Max. 1700 V 50 mA 30 W 2 hours 15 min
For narrower gradients, e.g. pH 4.0 to 6.5, the separation time must be prolonged, since 
the proteins with a low net charge must migrate long distances. Hydrophobic proteins 
need the presence of 8M urea to stay in solution. Because of the buffering capacity of 
urea, there is a light increase in the pH in the acid part of the gel. High urea contents in 
the gel lead to structural changes in many proteins and disruption of the quaternary 
structure. The solubility of very hydrophobic proteins, such as membrane proteins for 
example, can be increased by the addition of non-ionic detergents (e.g. Nonidet NP-40, 
Triton X-l00) or zwitterionic detergents (e.g. CHAPS, Zwittergent). Because the gels do 
not co-polymerize with the support films in the presence of non-ionic detergents, it is 
recommended to rehydrate a pre-pol ymerized, washed and dried gel in the relevant 
solution (see below).
Electrode solutions for IEF in polyacrylamide gels:
pH Gradient Anode Cathode
3.5-9.5 0.5 mol/L H3P04 0.5 mol/L NaOH
2.5-4.S 0.5 mol/L H3P04 2% Ampholine pH
2.5-4.5 0.5 mol/L H3P04 0.4 mol/L HEPES
3.5-5.0 0.5 mol/L H3P04 2% Ampholine pH
4.0-5.0 0.5 mol/L H3P04 1 mol/L glycine
4.0-6.5 0.5 mol/L acetic acid 0.5 mol/L NaOH
4.5-7.0 0.5 mol/L acetic acid 0.5 mol/L NaOH
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List of publications resulting from this thesis
Differential protein synthesis and expression levels in normal and neoplastic human 
prostate cells and their regulation by type I and II interferons.
Nagano, K., Masters, J. R., Akpan, A., Yang, A., Corless, S., Wood, C., Hastie, C., 
Zvelebil, M., Cramer, R. and Naaby-Hansen, S. (2003) Oncogene.
Abstract
Protein expression and de novo synthesis in normal and prostate cancer cell lines derived 
from the same patient were compared by proteomic analysis and the effects of IFN alpha 
and IFN gamma (IFN=interferon) determined. The expressions of several IFN-inducible 
proteins, including MxA, Nmi, PA28a and IFP53, were downregulated in the cancer cells. 
IFN gamma induced a more than twofold increase or decrease in the synthesis rates of 
almost twice as many proteins in the cancer cell line. The positive regulator of IFN- 
induced transcription ISGF3gamma was upregulated in the cancer cells and inversely 
regulated by IFN alpha and IFN gamma in the normal and cancer cells. Moreover, 
ISGF3gamma's induction by IFN gamma in the cancer cells was more enhanced by 
simultaneous stimulation with EGF, than its induction in the normal cells. In all, 31 
differentially regulated proteins were identified by mass spectrometry analysis, several of 
which are involved in chaperone-assisted protein folding in the endoplasmic reticulum 
(ER) or in regulated protein degradation. Our results suggest that the exclusion of 
proteins by the ER quality control system, crosstalk between the EGF- and IFN-induced 
signalling pathways and the regulation of IFN-inducible genes are all altered in the 
prostate cancer cells. The combination of upregulated activity in the growth-promoting 
PI3K/Akt pathway, suppression of Nmi and overexpression of hnRNP-K and c-myc 
proteins may explain why the prostate cancer cells were found to be more resistant to the 
growth inhibitory effects of IFNgamma.
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Combined affinity labelling and mass spectrometry analysis of differential cell
surface protein expression in normal and prostate cancer cells
Hastie, C., Saxton, M., Akpan, A., Cramer, R., Masters, J. R., Naaby-Hansen, S. 
(2005) Oncogene.
Abstract
Differences in the expression of cell surface proteins between a normal prostate epithelial 
(1542-NP2TX) and a prostate cancer cell line (1542-CP3TX) derived from the same 
patient were investigated. A combination of affinity chromatographic purification of 
biotin-tagged surface proteins with mass spectrometry analysis identified 26 integral 
membrane proteins and 14 peripheral surface proteins. The findings confirm earlier 
reports of altered expression in prostate cancer for several cell surface proteins, including 
ALCAM/CD166, the Ephrin type A receptor, EGFR and the prostaglandin F2 receptor 
regulatory protein. In addition, several novel findings of differential expression were 
made, including the voltage-dependent anion selective channel proteins Porin 1 and 2, 
ecto-5-nucIeotidase (CD73) and Scavenger receptor Bl. Cell surface protein expression 
changed both qualitatively and quantitatively when the cells were grown in the presence 
of either or both interferon IFN alpha and IFN gamma. Co stimulation with type I and II 
interferons had additive or synergistic effects on the membrane density of several, mainly 
peripherally attached surface proteins. Concerted upregulation of surface exposed 
antigens may be of benefit in immuno-adjuvant-based treatment of interferon-responsive 
prostate cancer. In conclusion, this study demonstrates that differences in the expression 
of membrane proteins between normal and prostate cancer cells are reproducibly 
detectable following vectorial labelling with biotin and that detailed analysis of 
extracellular-induced surface changes can be achieved by combining surface-specific 
labelling with high-resolution two-dimensional gel electrophoresis and mass 
spectrometry.
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IFNgamma reduces cell surface expression of annexin 2 and suppresses the invasive
capacity of prostate cancer cells 
Hastie, C., Masters, J. R., Moss, S.E., Naaby-Hansen, S. (2006) Submitted JBC. 
Abstract
The effect of interferon-y (IFNy) treatment on cell surface protein expression was 
compared in a benign epithelial (1542-NP2TX) and prostate cancer (1542-CP3TX) cell 
line derived from the same patient. While IFNy increased both the number and abundance 
of proteins in membrane fractions, the expression of annexin 2 and its binding partner 
pi 1 decreased. After 24 h exposure to IFNy, the surface density of the annexin 2 / pi 1 
complex was reduced four-fold and the remaining proteins localized to lipid rafts. The 
cytoplasmic expression of annexin 2 was unaffected by cytokine treatment. In the same 
time scale, IFNy reduced the abundance of the peripherally attached proteases 
procathepsin B and plasminogen. The invasiveness of the cancer cells was strongly 
reduced both following IFNy treatment and after exposure to an antibody against annexin
2. In contrast, the invasiveness of the annexin 2 negative prostate cancer cells LNCaP 
was unaffected by IFNy treatment and up-regulation of annexin 2 expression by 
transfection increased the invasiveness of LNCaP cells. IFNy induced calpain expression 
and activation and increased the phosphorylation and degradation of ABCA1 in 1542- 
CP3TX cancer cells. Surface expression of annexin 2 was reduced in cells treated with 
glyburide, an ABCA1 inhibitor, while inhibition of calpain abrogated the IFNy-induced 
annexin 2 down-regulation. These data indicate that IFNy reduces invasiveness by 
suppressing annexin 2 / pi 1 -associated pericellular protease activity via down-regulation 
of lipid transporter activity and that this effect is facilitated by calpain-dependent 
inactivation of ABCA1 in the 1542-CP3TX cells. The study identifies a new mode-of- 
action which enables IFNy to control the activity of cell surface associated hydrolases by 
regulating the peripheral membrane density and localization of the heterotetrameric 
annexin 2 / pi 1 complex.
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